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ABSTRACT
Caveolae are integral part of the smooth muscle membrane and caveolins, the defining
proteins of caveolae, act as scaffolding proteins for several G protein-coupled receptor signaling
molecules and regulate cellular signaling through direct and indirect interactions with signaling
proteins. Caveolin-1 is the predominant isoform in the smooth muscle and drives the formation
of caveolae. However, little is known about the role of caveolin-1 in the regulation of excitationcontraction and excitation-transcription coupling in gastrointestinal smooth muscle. In the
present study we have characterized muscarinic m2 and m3 receptor signaling in gastric smooth
muscle and tested the hypothesis that caveolin-1 positively regulates muscarinic receptor
signaling and contractile protein expression in smooth muscle. The role of caveolae/caveolin-1 in
the regulation of muscarinic signaling was examined using complementary approaches: a)
methyl β-cyclodextrin (MβCD) to deplete cholesterol in dispersed muscle cells, b) caveolin-1
siRNA to suppress caveolin-1 expression in cultured muscle cells, and c) caveolin-1 knockout
(KO) mice.
RT-PCR, western blot and radioligand binding studies demonstrated the selective
expression of m2 and m3 receptor in gastric smooth muscle cells. Carbachol (CCh), acting via
m3 receptors caused stimulation of phosphoinositide (PI) hydrolysis, Rho kinase and ZIP kinase
activity, and induced phosphorylation of MYPT1 (at Thr696) and MLC 20 (at Ser19), and muscle
contraction, and acting via m2 receptors caused inhibition of forskolin stimulated cAMP
formation. Stimulation of PI hydrolysis, Rho kinase and ZIP kinase activities, phosphorylation of
MYPT1 and MLC 20 phosphorylation and muscle contraction in response to CCh was attenuated
XV

in dispersed cells treated with MβCD or in cultured cells transfected with caveolin-1 siRNA.
Similar inhibition of all responses was obtained in gastric muscle cells from caveolin-1 KO mice
compared to gastric muscle cells to WT mice. Although, caveolin-1 had no effect on m2 receptor
signaling, agonist-induced internalization of m2, but not m3 receptors was blocked in dispersed
cells treated with MβCD or in cultured cells transfected with caveolin-1 siRNA. These results
suggest that caveolin-1 selectively and positively regulates G q/13 -coupled m3 receptor signaling,
G i -coupled m2 receptor internalization. The expression of contractile proteins, γ-actin and
caldesmone and the transcription factors SRF and myocardin that regulate the expression of
contractile proteins are down regulated, whereas EGF-stimulated EGF receptor phosphorylation
and ERK1/2 activity are up-regulated in cells transfected with caveolin-1 siRNA. These results
suggest using pharmacological, molecular and genetic approaches provide conclusive evidence
that caveolae and caveolin-1 play an important role in orchestrating G protein coupled receptor
signaling to have dual pro- excitation-contraction and excitation-transcription coupling, and antiproliferative role in gastric smooth muscle.
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CHAPTER I: INTRODUCTION
INTRODUCTION

The Gastrointestinal (GI) tract is a complex organ system with tissues that possesses
distinct structural and functional characteristics. It performs the important task of processing the
ingested food through digestion, absorption, expulsion of waste products and also protection
against ingested microbes. It accomplishes these critical functions by the concerted action of the
neuronal, muscular, immune and glandular tissue systems. The GI tract is highly innervated by
local intrinsic neurons (the enteric nervous system) and the extrinsic sympathetic and
parasympathetic nerves. This complex pattern of neural innervations control a variety of gut
functions ranging from controlling the complex motor activity and propel the intraluminal
content to the secretion of bioactive agents to facilitate digestion.
.
I. Structure of the Gastrointestinal Tract
The Gastrointestinal (GI) tract is a long tubular hollow structure with its wall divided into
four distinct layers that pocesses characteristic morphological and functional property. The
layering pattern of the gut from inside of the lumen to outside is as follows: mucosa, submucosa,
muscularis externa, and serosa (Gabella 1987). The enteric nervous system (ENS) is consists of
two ganglionated plexus within submucosa and muscularis externa. The ENS controls the GI
function through intrinsic and extrinsic neural reflexes that are mediated through an array of
messengers and neurotransmitters. The smooth muscle cells of the muscularis externa are aligned
into two layers: an outer thin longitudinal muscle layer and an inner thick circular muscle layer.
A large subpopulation of neurons, glial cells, fibroblasts, and interstitial cells of Cajal separates
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the muscle layers (Kunze and Furness 1999). Smooth muscle cells are responsible for
contractility of the GI tract.
I. 1. Enteric nervous system
The ENS consists of large number of nerve cell bodies that are found in the myenteric
plexus located between the two smooth muscle layers and between the circular muscle layer and
the submucosa (Gershon 1981). The ENS also contain glial cells that play an important role in
providing support and nutrition to the neurons and are also involved in neurotransmission (Ruhl,
Nasser et al. 2004). The enteric neural circuitry comprises of three functional classes of neurons
that form multicomponent neural reflexes, viz motor neurons, interneurons and sensory neurons
(Brookes 2001).
I. 1a. Motor neurons. Scientific investigation over the past decades has led to the
identification of both excitatory and inhibitory motor neurons innervating the muscle layers in
the gut. Commercial availability of selective receptor antagonist led to the identification of
acetylcholine as a co-transmitter of excitatory motor neurons in addition to tachykinins (Grider
1989). Excitatory cholinergic transmission is mediated through muscarinic m 2 and m 3 receptors
whereas; excitatory transmissions by tachykinin are mediated through NK 1 and NK 2 receptors
(Lecci, Altamura et al. 2008). Similar to the excitatory motor neurons, the inhibitory neurons
also encode for more than one transmitter (10) and include nitric oxide (NO), adenosine
triphosphate (ATP), vasoactive intestinal peptide (VIP), and pituitary adenylyl cyclase-activating
peptide (PACAP) (Harmar, Fahrenkrug et al. 2012).
Another subtype of motor neurons called the secretomotor neurons innervates the
mucosal layer of the gut and stimulates the secretion from glandular tissue. The secretomotor
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neurons have their cell bodies generally located in the sub-mucosal plexus and contain
acetylcholine and VIP as co-transmitters (Carey, Cooke et al. 1985; Reed and Vanner 2007).
I. 1b.

Interneurons. Physiological and pharmacological studies documented the

existence of interneurons in the ENS with their cells bodies localized in the myenteric and
submucosal plexus (Costa, Brookes et al. 1996). Based on structural evidences from guinea pig
intestine, the interneurons are classified as ascending and descending interneurons (Neal and
Bornstein 2008). Morphologically, the ascending reflex pathways represent a crosstalk between
interneurons and excitatory motor neurons that is purely cholinergic acting through nicotinic
receptors (Tonini and Costa 1990). However, the transmitters involved in the descending reflex
pathways to relay information between the descending interneurons and the inhibitory motor
neurons is clearly not elucidated, although, a possible involvement of ATP as a transmitter acting
through purinergic P 2 receptors has been proposed (LePard, Messori et al. 1997; Xue, Farrugia et
al. 1999).
I. 1c. Sensory neurons. Sensory neurons in the gut, acts as transducers to convey the
information pertaining to its physical state and chemical milieu including villi movement,
mucosal distortion, change in local distribution of blood flow, aberration in motility pattern and
the chemical contents of the lumen, and integrate to the ENS (Furness, Jones et al. 2004).
Morphologically, sensory neurons have been classified primarily as Dogiel type II neurons,
which are characterized with multiple processes that form complex neuronal network
establishing synaptic connections with other sensory neurons, interneurons, and motor neurons
(Pompolo

and

Furness

1988).

The

sensory

neurons

exhibits

well

characterized

electrophysiological properties, displaying broad action potential attributed to the presence of
voltage gated sodium, calcium and potassium currents (Sanders 2000). Data gathered from recent

3

studies also implicated the involvement of sensory neurons in nociception due to their ability to
trigger protective measures in response to noxious stimuli (Collins 1996; Lundgren 2002).

I. 1d. Neurotransmitters in the gastrointestinal tract
A variety of neurotransmitters that are expressed in the central nervous system are also
found in the enteric nervous system of the gut. Some of the most important neurotransmitters
involved in the gut function are briefly summarized below.
i) Acetylcholine. Acetylcholine (ACh) is one of the principal transmitters of the gut
controlling important functions like motility and secretion (Tobin, Giglio et al. 2009).
Acetylcholine is synthesized in neurons by the enzyme choline acetyl transferase (ChAT) and
stored in vesicles where it can be released from nerve terminals upon appropriate stimulation
(Schemann, Sann et al. 1993; Arvidsson, Riedl et al. 1997; Murthy, Zhou et al. 2003).
Acetylcholine receptors can be broadly classified into two types nicotinic and muscarinic. Since
the ENS contains more than 80% of cholinergic neurons, there must be other co-transmitters in
the gut. The most commonly expressed co transmitter in the gut are neuropeptides (Furness
2006).
ii) Neuropeptides. The residual contractile effect in response to cholinergic antagonist
paralleled the identification of the excitatory neuropeptide, tachykinins. The tachykinin family of
neuropeptides constitutes substance P and neurokinin A (NKA) and neurokinin B (NKB) that are
produced as preprotachykinins and undergo transcriptional and translational processing to form
mature polypeptides. To date the neuropeptide family has been shown to interact with three
receptors NK-1, NK-2 and NK-3 (Maggio 1988; Satake, Kawada et al. 2003). In contrast, the
inhibitory component is mediated by vasoactive intestinal polypeptide (VIP). VIP belongs to a
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structurally related family of peptides that includes secretin, PACAP and glucagon. On its
release from nerve terminals, when stimulated, VIP acts on its membrane spanning G-protein
coupled receptors and triggers the generation of the second messenger, cAMP. cAMP acts on its
downstream effectors to mediate the relaxant effects of VIP (Holst, Fahrenkrug et al. 1987). Like
other GI peptides, VIP is also secreted in its inactive precursor form that is processed to its active
form through proteolytic cleavage (Grider 1993).
iii) Gaseous neurotransmitters. Gaseous transmitters are released on demand and
diffuse across the cell membrane to act on specific intracellular targets. Nitric oxide (NO) is the
most well studied gasotransmitter in the ENS, however recently carbon monoxide (CO) and
hydrogen sulfide (H 2 S) are gaining importance in regulating some of the GI functions (Kasparek,
Linden et al. 2008).
The well defined characteristics of gaseous transmitters are as follows: a) they are
gaseous molecules with very small atomic radii; b) they are freely diffusible across cellular
membranes and do not activate cell surface receptors; c) they are synthesized denovo by
enzymatic action and released on demand in a regulated way; d) they exhibit specific cellular
functions at physiologically relevant concentrations; e) their cellular effects may or may not be
dependent on the generation of second messengers; f) they should have very short half-life and
efficient scavenging mechanisms to remove the transmitter following their action.
Nitric Oxide (NO). NO is generated as a gaseous product in the conversion of L-arginine
to L-citruline by the enzymatic action of nitric oxide synthase (NOS). In the GI tract, NO is
produced mainly by the action of constitutively expressed neuronal NOS (nNOS) and released
by the inhibitory nitrergic neurons of the enteric nervous system (ENS) (Boehning and Snyder
2003). Following release NO diffuses through cell membrane and acts on its intracellular targets,

5

such as soluble guanylyl cyclase (sGC) to trigger the formation of cGMP. The cGMP formed
then acts on several downstream effectors that collectively function to decrease the intracellular
Ca2+ concentration and leads to hyperpolarization and smooth muscle relaxation (Koh, Sanders
et al. 1996; Teng, Murthy et al. 1998). NO is the most prominent non-adrenergic, noncholinergic neurotransmitter in the gut. Abnormalities in NO production have been correlated
with many pathophysiological conditions such as achalasia, functional dyspepsia, delayed gastric
emptying, diabetic gastroperesis and other GI dysmotility disorders (Shah and Kamath 2003).
Carbon Monoxide (CO). CO is produced as a catabolite of heme synthesis by the
enzyme heme oxygenase (HO) along with other by-products such as biliverdin and iron. Release
of CO by enteric neurons causes smooth muscle relaxation. Apart from stimulating sGC to
produce cGMP, it also increases cAMP levels that lead to the activation of PKA (Xue, Farrugia
et al. 2000; Wu and Wang 2005). The activation of second messenger-mediated kinases induces
smooth muscle relaxation. Coexpression of HO and nNOS in myenteric neurons suggest a
possible interaction between CO and NO. NOS potentiate CO mediated activation of sGC and
enhance muscle relaxation. Defects in CO signaling are also associated with inflammatory and
immune responses (Snyder, Jaffrey et al. 1998; Miller, Reed et al. 2001).
Hydrogen Sulfide (H 2 S). H 2 S has recently been identified as a gasotransmitter (Li,
Bhatia et al. 2006). Endogenously, H 2 S is produced by the action of two enzymes, cystathione γlyase (CSE) and cystathione β-synthase, on L-cysteine. The expression of these enzymes has
been confirmed in ENS (Linden, Levitt et al. 2010). Following its release, H 2 S is metabolized by
several mechanisms including mitochondrial oxidation, cytosolic methylation, and glutathionemediated oxidation. H 2 S function of smooth muscle relaxation is primarily mediated by the
activation of ATP-sensitive K+ channels that lead to membrane hyperpolarization and subsequent
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closure of voltage gated Ca2+ channels and relaxation (Ebrahimkhani, Mani et al. 2005). Studies
have also shown that H 2 S is involved in inducing chloride secretion in guinea pig and human
colon (Schicho, Krueger et al. 2006; Pouokam and Diener 2012).
I. 2. Interstitial Cells of Cajal (ICCs)
The GI smooth muscle displays a distinct spontaneous electrical activity originating from
interstitial cells of Cajal (ICCs). The smooth muscle cells are electrically coupled to ICCs and
additionally integrate electrical inputs from ENS along with other endocrine and paracrine agents
to regulate gut motility (JH. 1987; Sanders, Koh et al. 2006). The continuous discharge of
electrical patterns by virtue of its pacemaker activity, ICCs enhances the open probability of
voltage gated Ca2+ to induce sustained mode of contraction at different regions of the GI tract
(Farrugia 1999; Bayguinov, Ward et al. 2007). This intrinsic rhythmic pattern of membrane
potential in response to excitatory and inhibitory neural inputs is called slow waves. Basically,
Slow waves function to shift the membrane potential of smooth muscle from a more negative
potential to a more positive value, that helps to enhance the open probability of the voltage gated
Ca2+ channels. The periodical influx of Ca2+ generating an inward current due to oscillatory
opening of voltage gated Ca2+ channels helps to organize the excitation-contraction coupling of
the muscle into a phasic pattern of contraction and relaxation (Morgan, Muir et al. 1981;
Camborova, Hubka et al. 2003; Bayguinov, Ward et al. 2007).
Based on morphological and physiological evidences it has been suggested that
interstitial cells of Cajal (ICC) are the pacemaker cells of the GI tract. Slow waves are initiated
from ICCs and conducted to the smooth muscle cells as confirmed by electrical and optical
recordings performed on ICCs and muscle cells simultaneously. In the absence of ICCs, muscle
cells no longer shows rhythmicity and do not propagate slow waves. Experimental studies on
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isolated and cultured ICCs have shown that ICCs express receptors for both excitatory and
inhibitory transmitter (Ward, Burns et al. 1994; Huizinga, Thuneberg et al. 1995; Iino and
Horiguchi 2006), the intracellular components and transmembrane ion channels necessary to
generate spontaneous slow waves (Koh, Sanders et al. 1998). ICCs has also been shown to
express different types of gap junction proteins including connexins, which help ICCs to form
well ordered network of electrical coupling with the adjacent smooth muscle cells (Schwentner,
Oswald et al. 2005). The cellular connectivity that ICC establishes with other ICCs and smooth
muscle cells are crucial for its pacemaker activity.

I. 3. Gastrointestinal smooth muscle and its contractile apparatus
The smooth muscle in the gut produces contractile force to propel food along the length
of the GI tract. Structurally, smooth muscle cells are about 200 to 300 µm in length and 5 to 15
µm wide. Unlike skeletal and cardiac muscles, smooth muscles are characterized by the lack of
cross-striations that gives a smoother appearance in contrast to other types of muscle.
Intracellular structural bodies such as dense bodies and contractile filaments populates in smooth
muscle cells (Bitar 2003). Smooth muscle filaments can be categorized into three subtypes: thin
actin filaments, thick myosin filaments and intermediate filaments. Actin is a 42-kDa protein that
is ubiquitously expressed in its globular form called G-actin and polymerizes into double helical
strands and forms filamentous actin or F-actin (Hodgkinson 2000; Rensen, Doevendans et al.
2007; Tang 2008). Thick filaments are hetero-multimeric proteins formed by the aggregation of
six different types of polypeptides: 1 pair of myosin heavy chains (MHC) and 2 pairs of myosin
light chains (MLCs) (Xu, Harder et al. 1996; Burgess, Yu et al. 2007). The MHCs forms a coiled
structure that terminates in a globular head like structure surrounded by two pair of MLCs, a 20-
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kDa regulatory light chain (MLC 20 ), and a 17-kDa essential light chain (ELC). The globular
head contains a binding site for actin and actin-activated magnesium-adenosine triphosphatase
(Mg-ATPase (Kamm and Stull 1989). Smooth muscle also contains thin filament associated
proteins such as calponin, caldesmon, and smoothelin (Morgan and Gangopadhyay 2001).

I. 4. Signaling Mechanism Involved in Smooth Muscle Contraction
“Excitation-contraction coupling” in all muscle is initiated by increase in intracellular
Ca2+ leading to changes in the activity of, or interactions of, actin and myosin. Actomyosin
interaction is dependent on phosphorylation of MLC 20 , which is both necessary and sufficient for
smooth muscle contraction. Phosphorylation of MLC 20 leads to muscle contraction, whereas
dephosphorylation leads to muscle relaxation. The levels of MLC 20 phosphorylation are
regulated by MLC kinase (MLCK) and MLC phosphatase (MLCP) activity (Horowitz, Menice et
al. 1996; Webb 2003; Huang, Zhou et al. 2005; Murthy 2006).
The signaling mechanisms for contraction in visceral smooth muscle is primarily
mediated by G-protein coupled receptors (GPCRs). The GPCR apparatus consist of three tier
membrane bound components: i) a seven transmembrane receptor protein, ii) a GTP-binding
heterotrimeric G protein tethered to the receptor, and iii) membrane bound precursors that
triggers the generation of one or more cellular signals that initiate cascades leading to activation
of downstream effectors (Puetz, Lubomirov et al. 2009; Wright, Tripathi et al. 2012). Several
subtypes of receptor were found to mediate the contractile response in smooth muscle cells and
include receptors for acetylcholine, peptides (tachykinins, endothelin, motilin), amines
(histamine, 5-hydoxytryptamine), pyrimidines/purines (UTP, ATP), and lipids (SIP, LPA)
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(Morini, Kuemmerle et al. 1993; Hellstrom, Murthy et al. 1994; Murthy and Makhlouf 1998;
Sarna 1999; Zhou and Murthy 2004).

I. 4.1. Regulation of myosin light chain kinase (MLCK).
In circular smooth muscle, activation of the receptor by the contractile agonist activates
G αq that leads to the activation of phosphoinositide (PI)-specific phospholipase C (PLCβ1).
Stimulation of membrane bound PLCβ1 triggers the turnover of membrane embedded
phosphatidylinositol 4,5-bisphosphate (PIP 2 ) that generates two important intracellular second
messengers; the soluble calcium mobilizing agent IP 3 and the surface bound DAG. Soluble
messenger, IP 3 binds to its high affinity receptors IP 3 R-I on the sarcoplasmic reticulum and
drives the release of Ca2+ into the intracellular milieu (Murthy, Grider et al. 1991). When Ca2+
gets released, it associates with calmodulin to form an active Ca2+-calmodulin complex which
then binds to and activates MLCK. The activation of MLCK causes phosphorylation of MLC 20 ,
an obligatory step in smooth muscle contraction. Additionally, Ca2+ influx through voltage-gated
Ca2+ channels also leads to activation of MLCK, phosphorylation of MLC 20 and muscle
contraction (Makhlouf and Murthy 1997). The initial Ca2+ surge responsible for initiating actomyosin interaction is very transient due to the operation of active Ca2+ extrusion and intracellular
Ca2+ uptake mechanisms. These processes that causes downregulation of cytosolic Ca2+ leads to
uncoupling of Ca2+-calmodulin complex from MLCK, and results in the inhibition of MLCK
activity and muscle contraction (Somlyo and Somlyo 1994; Murthy and Makhlouf 1997; Murthy
2006).
A number of studies have shown that MLCK itself is regulated by negative feedback
mechanism through phosphorylation by specific protein kinases. CAMKII is one such kinase that
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directly phosphorylates MLCK and inhibits its activity (Tansey, Luby-Phelps et al. 1994).
Recently, another protein kinase called AMP kinase (AMPK) was also shown to phosphorylate
MLCK at Ser815 that causes significant reduction in its catalytic activity (Horman, Morel et al.
2008).
Although, the increase in Ca2+ and MLCK activity is transient, MLC 20 phosphorylation
and muscle contraction are well maintained by Ca2+-independent mechanisms that exclusively
involve processes that target inhibition of MLC phosphatase (Murthy and Makhlouf 1997;
Ganitkevich, Hasse et al. 2002; Somlyo and Somlyo 2003).

I. 4.2. Regulation of myosin light chain phosphatase (MLCP)
In smooth muscle, regulated inhibition of MLCP is achieved by G-protein mediated
activation of RhoA. Stimulation of two subsets of G-protein; G q and G 13 in response to a
contraclite agonist leads to the activation of RhoA. RhoA belongs to a family of small G-proteins
and in inactive state it is associated with GDP to from RhoA-GDP and localized in the
cytoplasm. The GDP bound form of RhoA is stabilized by its interaction with another protein
called guaninine dissociation inhibitor (GDI). Signaling downstream of receptor activation
stimulates RhoA, a process mediated by several Rho-specific guanine nucleotide exchange
factors (RhoGEFs). When RhoGEFs is stimulated it promotes the release of GDP and exchange
GTP in its place (Murthy and Makhlouf 1997; Somlyo and Somlyo 2003; Siehler 2009). RhoAGTP is the activated form of RhoA, which then translocate from the cytoplasm and gets tethered
to the inner leaflet of the plasma membrane and subsequently activates the smooth muscle
specific isoform of Rho Kinase, Rho kinase II and also the membrane bound phospholipase D
(PLD) (Murthy, Zhou et al. 2001).
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When Rho kinase gets stimulated it act on MLCP to inhibit its activity. The MLCP
holoenzyme comprised of three distinct component; a 110 to 130- kDa regulatory subunit known
as the myosin phosphatase target subunit 1(MYPT1), a type 1 phosphatase (PP1cδ) of 37 kDa
which is the catalytic subunit and, finally a 20 kDa subunit whose function is still not known
(Hartshorne 1998). Rho kinase mediated phosphorylation of MYPT1 at Thr696 promotes
uncoupling of the catalytic and regulatory subunits of MLCP that ultimately leads to inhibition of
its catalytic activity (Fukata, Amano et al. 2001). Additionally, targeted phosphorylation of
Thr853 located within the myosin-binding domain of MYPT1 by Rho kinase, promotes
dissociation of MLCP from myosin and consequently decreases its efficiency to bind myosin
(Wooldridge, MacDonald et al. 2004). Zipper interacting protein (ZIP) kinase, also known as the
MYPT1-associated kinase, has a similar effect like Rho kinase on MYPT1 phosphorylation at
Thr696 promoting its dissociation from the catalytic subunit and decreasing MLCP activity
(MacDonald, Borman et al. 2001; Lincoln 2007).
As noted above, RhoA activation apart from stimulating Rho kinase also stimulates PLD
activity. PLD hydrolyses phosphatidylcholine to generate phosphatidic acid. The latter gets
subsequently dephosphorylated to yield DAG that causes prolonged activation of protein kinase
C (PKC). Smooth muscle typically expresses the ε and δ isoforms of PKC that function to
phosphorylate an endogenous MLCP inhibitor called CPI-17 (Murthy, Grider et al. 2000;
Woodsome, Eto et al. 2001). PKC mediated phosphorylation of CPI-17 at Thr38 greatly enhances
its ability to inhibit MLCP and potentiates muscle contraction (Kitazawa, Eto et al. 2000). This
dual role of RhoA to activate either Rho kinase or PKC is central to mediate the sustained phase
of smooth muscle contraction.
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Lack of inhibition of the sustained phase of smooth muscle contraction in the presence of
inhibitors specifically targeted to Ca2+/calmodulin dependent MLCK, suggests the involvement
of Ca2+-independent MLC Kinases during the sustained phase. Moreover, experimental
evidences demonstrated that contraction in arterial smooth muscle cell by phosphatase inhibitor,
microcystin-LR in Ca2+ free medium, is significantly abrogated by a non-specific kinase
inhibitor. All of the above findings exclusively implicate an involvement of Ca2+-independent
MLCK to phosphorylated MLC 20 and caused sustained contraction (MacDonald, Borman et al.
2001).
The most well characterized Ca2+-independent kinases in smooth muscle cells are ZIP
kinase and integrin-linked kinase (ILK). MLC 20 phosphorylation at both Ser19 and Thr18 leading
to contraction of permeabilized preparation of arterial smooth muscle in the presence of
endogenously purified ZIP kinase and phosphatase inhibitor in Ca2+ free environment confirmed
the involvement of ZIP kinase as a Ca2+-independent kinase responsible for sustained contraction
(Niiro and Ikebe 2001; Muranyi, MacDonald et al. 2002). ZIP kinase is a serine/threonine kinase
and a member of death-associated protein (DAP) kinase family. ZIP kinase has also been shown
to colocalize with MYPT1 and phosphorylate the MLCP subunit at Thr696 in conjunction with
Rho kinase (Borman, MacDonald et al. 2002). ILK is also a serine/threonine kinase that operates
in a Ca2+ independent fashion and found to be associated with MLCP (Zhou, Das et al. 2003).
ILK causes smooth muscle contraction either by directly phosphorylating MLC 20 at Ser19 and
Thr18 or by working in combination with CPI-17 to inhibit MLCP (Kiss, Muranyi et al. 2002;
Zhou, Das et al. 2003; Huang, Mahavadi et al. 2006).
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I. 5. Signaling Pathways Involved in Smooth Muscle Relaxation
Relaxation of contracted smooth muscle is mediated by generation of second messengers
such as cAMP and cGMP, and activation of cAMP-dependent protein kinase (PKA) and cGMPdependent protein kinase (PKG), respectively. PKA and PKG, in turn, act on various targets, and
their action culminates in the reduction of intracellular Ca2+ and/or MLC 20 phosphorylation, a
prerequisite for muscle relaxation. The relaxant neurotransmitter in the gastrointestinal tract
includes neuronal NO synthase (nNOS) and the peptide neurotransmitter, vasoactive intestinal
peptide (VIP) and its homologue, pituitary adenylate cyclae-activating peptide (PACAP).
Activation of soluble guanylyl cyclase by nitric oxide and G s -coupled VPAC 2 receptors by VIP
or PACAP result in the generation of cGMP and cAMP, respectively. Signaling cascades
initiated downstream of cGMP and cAMP leads to efficient removal of Ca2+ transients causing
inactivation of MLCK and subsequent MLC 20 dephosphorylation. Muscle relaxation and MLC 20
dephosphorylation can also be achieved by the removal of MLC phosphatase inhibition and
successive augmentation of its dephosphorylating activity (Webb 2003; Murthy 2006).

I. 5.1. Regulation of Cyclic Nucleotide Levels
The titre of cAMP and cGMP in gastrointestinal smooth muscle is regulated by a balance
between their synthesis by cyclases and degradation by phosphodiesterases (PDEs) (Turko,
Francis et al. 1998). The cyclic AMP levels in smooth muscle are rapidly degraded by the action
of cAMP specific PDEs, PDE3 and PDE4, whereas cGMP levels are regulated by cGMPspecific PDE5. PKA and PKG exert feedback regulation to fine-tune cAMP and cGMP levels
via feedback regulation. PKA phosphorylates cAMP specific PDEs to stimulate their activity and
subsequently promote cAMP degradation. On the other hand PKA mediated inhibitory
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phosphorylation of adenylyl cyclase V/VI, the predominant isoforms in smooth muscle, also
reduces the formation of cAMP. Similarly, cGMP levels are regulated via PKG-mediated
stimulatory phosphorylation of PDE5 that promotes cGMP degradation, and inhibitory
phosphorylation of sGC that attenuates cGMP generation (Francis, Turko et al. 2001; Murthy
2001; Murthy, Zhou et al. 2002).

I. 5.2. Molecular targets of PKA and PKG
In the initial phase of smooth muscle contraction, PKA and PKG induce relaxation
primarily by terminating the Ca2+ transients and thereby decreasing the sensitivity of MLCK to
Ca2+. Both PKA and PKG in smooth muscle, inhibit IP 3 formation via downregulation of Gα q dependent PLCβ1 activity. However the inhibition is not direct via inhibitory phosphorylation of
Gα q and PLCβ1, but mediated by the combinatorial effect of PKA and PKG induced stimulatory
phosphorylation of RGS4 and PKA induced phosphorylation of GRK2 that concertedly act to
inhibit PLCβ1 activity (Huang, Zhou et al. 2007). Similarly, inhibitory phosphorylation of IP 3 R1 on sarcoplasmic reticulum by PKG but not PKA causes blockage of Ca2+ release into the
cytoplasm (Murthy and Zhou 2003). PKG also phosphorylates sarco-endoplasmic reticulum
Ca2+/ATPase (SERCA) and enhances Ca2+ uptake from the intracellular milieu into the
sarcoplasmic store. Furthermore, PKG mediated stimulatory phosphorylation of plasmalemmal
Ca2+/ATPase augments intracellular Ca2+ extrusion (Cornwell, Pryzwansky et al. 1991). Finally,
both PKA and PKG inhibit the conductance through membrane bound Ca2+ channels and
simultaneously activate K+ channels to induce hyperpolarization (Koh, Sanders et al. 1996).
Relaxation can also be induced by PKA and PKG in a Ca2+ independent manner during
the sustained phase of contraction. The inhibition of the catalytic activity of MLCP through
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RhoA pathway is released by PKA and PKG mediated phosphorylation of the molecular targets
upstream as well as downstream of RhoA. The upstream targets of RhoA by the cyclic
nucleotides include the G α13 , p115 RhoGEF and RhoA and the downstream targets include Rho
kinase, and MYPT1. Both PKA and PKG can phosphorylate RhoA at Ser188 and promote its
translocation from the plasma membrane to the cytosol. The movement of RhoA from membrane
to cytosol strictly inhibits Rho kinase activity by impeding its physical interaction with
membrane-bound molecular targets. Therefore, the inhibitory effect of Rho kinase on MLCP via
MYPT1 phosphoryation is withdrawn. Additionally, the inhibitory effect of CPI-17 on MLCP
activity is released via inhibition of Rho kinase/PLD activity and PKC mediated phosphorylation
of CPI-17 (an endogenous MLCP inhibitor) at Thr38 (Sauzeau, Le Jeune et al. 2000; Murthy,
Zhou et al. 2003; Murthy 2006). Lastly, relaxation mediated via RhoA independent pathway is
also enhanced by stimulatory phosphrylation and activation of telokin, an endogenous MLCP
activator (MacDonald, Walker et al. 2000). All of the above effects of cAMP/PKA and
cGMP/PKG converge to produce enhanced activity of MLCP and accelerated dephosphorylation
of MLC 20 , a hallmark for smooth muscle relaxation.

I. 6. Receptor Desensitization and Internalization
Over the last two decades multiple molecular mechanisms has been proposed to explain
the regulation of GPCR signaling. Primarily, following activation of the GPCRs by their cognate
ligands, specific signaling mechanism gets triggered to produce an appropriate cellular response.
The intensity of the signaling cascade is regulated by reducing the efficacy of the GPCRs to
transmit signal through a process called desensitization, or by the subsequent removal of the
activated receptors from the surface to blunt the signaling response through receptor
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internalization (Drake, Shenoy et al. 2006). Desensitization refers to the process that leads to
reduce ability of the receptor to get stimulated as a consequence of prior enhanced activation
(Hausdorff, Caron et al. 1990).
The term desensitization has traditionally been used to describe events that cause the
uncoupling of the activated receptors from heterotrimeric G-proteins. In contrast, sensitization
refers to the process that causes increased ability of the receptor to get stimulated due to low
activation (Gainetdinov, Premont et al. 2004). GPCRs exhibit desensitization in response to its
activating ligands to regulate the signaling intensity and promote signaling termination. GPCR
mediated signaling is regulated at the receptor level majorly by two mechanisms: i) by
modulating signaling efficacy of the receptors and ii) by upregulating or downregulating the
number of cell surface receptors. Desensitization process can be further categorized into two
types: homologous desensitization that is dependent on ligand-receptor interaction and the
heterologous desensitization that is independent of ligand-receptor interaction (Bohm, Grady et
al. 1997).

I. 6.1. Molecular mechanism of homologous desensitization
Ligand bound GPCRs not only activates G-proteins to initiate specific signaling cascades,
but also the interacting ligand-receptor complex forms a substrate for protein phosphorylation
(Delom and Fessart 2011). Following receptor activation by the ligand, G protein coupled
receptor kinase (GRK) gets recruited to the cytoplasmic domain of the activated receptor and
phosphorylate the receptor at specific sites (Shenoy and Lefkowitz 2003). The GRK family of
kinases comprised of seven members that has been categorized into three subfamilies, viz. GRK
1/7, GRK 2/3 and GRK 4/5/6 on the basis of significant overlap of the amino acid sequence and
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structural homology (Pitcher, Freedman et al. 1998; Willets, Challiss et al. 2003). GRK 2, 3, 5
and 6 were found to be widely expressed and has been implicated in regulating most of the
GPCR signaling. The other members of the GRK family GRK 1/7 are exclusively involved in
signal transduction in visual pathways, whereas GRK4 is only expressed in the testes
(Gainetdinov, Premont et al. 2000; Penela, Murga et al. 2006).
GRK mediated phosphorylation of the activated receptor is a prelude to the binding of a
scaffolding protein called β-arrestin. The driving force of arrestin recruitment comprises of both
the GRK phosphorylation sites on the receptors and the active ligand-receptor configuration
(Perry and Lefkowitz 2002). The primary role of arrestin interacting with the activated receptor
is to dampen the firing of the ligand-receptor complex. The inhibition in signal transmission by
the ligand-receptor complex is achieved by restricting the G α subunit from exchanging GTP for
GDP. Locking the Gα subunit in the GDP conformation prevents the transmission of cellular
signal to the downstream effectors (Luttrell and Lefkowitz 2002). Among the most well
characterized arrestins are the nonvisual arrestins called the β arrestins viz. βarrestins-1 and
βarrestins-2. They are widely expressed in a variety of tissue and play an important role in
regulating many GPCR signaling machineries.

I. 6.2. Molecular mechanisms of heterologous desensitization
Heterologous desensitization involves attenuation of the signaling downstream of the
receptor and precludes physical interaction between the receptor and the ligand (Chuang,
Iacovelli et al. 1996). An efficient way of receptor uncoupling from the heterotrimeric G-protein
involves covalent modifications in the structure as imposed by receptor phosphorylation. The
second messenger dependent kinases such as protein kinase A (PKA) and protein kinase C
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(PKC) catalyzes transfer of γ-phosphate group of ATP to serine and threonine residues of its
target proteins (Pierce, Premont et al. 2002). PKA and PKC are activated downstream of GPCR
signaling and causes generation of second messengers such as cAMP, increase in intracellular
Ca2+ and diacylglycerol. The second messengers generated activate the downstream kinases and
transduce signal by stimulating them through prosphorylation (Ferguson 2001). Apart from
phosphorylating their target effectors, these kinases by virtue of feedback regulation,
phosphorylates

the receptors.

Second

messenger activated

protein

kinase mediated

phosphorylation of the receptors leads to a marked loss of the receptor function. Unlike GRKs
that selectively phosphorylated agonist bound receptors, second messenger dependent protein
kinases in contrast, randomly phosphorylates receptors irrespective of the presence or absence of
the agonist. Moreover, the sites of receptor phosphorylation by these kinases are different from
those of GRKs (Lefkowitz, Hausdorff et al. 1990). In addition to negatively regulating the
receptors through phosphorylation, PKA and PKC phosphorylates several other targets such as
adenylyl cyclase, phospholipase C that collectively contribute to the desensitization process
(Hamm and Gilchrist 1996).

I. 6.3. Deactivation of G-protein by RGS proteins
RGS (regulators of G protein signaling) proteins form a distinct class of regulatory
proteins containing a conserved 120 amino acid sequence called RGS domain that act as GTPase
activating protein (GAPs). The RGS domain binds specifically to the activated G α subunit and
increases the rate of GTP hydrolysis and stabilizing the GDP-bound conformation of the Gprotein. Thus by enhancing the intrinsic GTPase activity of the G-protein, they dampen the
intensity of signaling pathways (Berman and Gilman 1998; Neubig 2002). Recently it has also
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been demonstrated that RGS proteins can directly interact with the receptors and modulate their
activity (Snow, Hall et al. 1998).

I. 7. GPCR internalization
Agonist-activated receptor internalization into intracellular pockets is an important aspect
of regulation of GPCR activity. GRK phosphorylation of the activated receptors generates high
affinity binding sites for β-arrestins (Delom and Fessart 2011). Binding of coat proteins clathrin
follows binding of β-arrestins to the receptor, which exhibits high affinity to β-arrestins and
interacts through their carboxy terminal region. Overall, the process involves translocation of βarrestins from the cytoplasm to the plasma membrane and bind to the receptor at the site of GRK
phosphorylation to mediate the process of receptor internalization via both clathrin-dependent
and clathrin-independent caveolar pathway (Traub 2003). The model pathway for internalization
is exemplified by β1-adrenergic receptors internalization, which is selectively mediated via
clathrin-dependent

pathway

when

phosphorylated

by

GRK,

and

by

clathrin-

independent/caveolar-dependent pathway when phosphorylated by PKA (Rapacciuolo, Suvarna
et al. 2003). Additionally, lipid modification such as palmitoylation/depalmitoylation of
receptors has also been shown to play a role in targeting the receptors to lipid rafts for
internalization (Papoucheva, Dumuis et al. 2004).

I. 8. Regulation of GPCR Signaling by Scaffolding Proteins
Higher degree of specificity in the molecular interaction among multitude of signaling
proteins forms the basic tenet of the signal transduction process. It is of primary importance to
study the mechanisms involved in bringing the molecular partners of a signaling cascade in close

20

proximity for accurate and efficient signaling events. Scaffolding proteins forms a special class
of regulatory proteins that essentially act as molecular glue to gather signaling molecules in close
proximity that accounts for the precise and efficient signaling mechanisms. Scaffolding proteins
provides the basic platform that helps in subcellular colocalization of signaling molecules by
associating with protein components of a signaling cascade and enhancing protein-protein
interaction for an efficient transmission of cellular signals (Faux and Scott 1996; Wrana and
Pawson 1997). The hallmark of interaction of a scaffolding protein is defined by the presence of
a unique signature motif that helps them to interact and bind with their target proteins. The
function of a scaffolding protein to facilitate signal transduction may not necessarily be restricted
to mere tethering of signaling molecules to promote the assembly of a signaling complex, but
also to modulate/regulate the activity of its protein partners. The major function ascribed to
scaffolding proteins can be broadly classified into two broad areas- firstly, isolating signaling
molecules of a cascade into a pre-signaling complex and secondly, regulating the activation and
or inhibition of components of a signaling pathway (Good, Zalatan et al. 2011). Some of the
important scaffolding proteins involved in the regulation of GPCR signaling are summarized
below with particular emphasis on caveolin proteins.

I. 8.1. A-Kinase Anchoring Proteins (AKAPs). AKAPs constitute the first family of proteins
that was recognized with a scaffolding function. AKAP associate with its main host protein,
PKA along with several other proteins of a signaling pathway and co-localizes them in a specific
sub-cellular location (Michel and Scott 2002; Pidoux and Tasken 2010). The role of AKAP
regulation of signaling pathways is exemplified by the activation of G s -coupled β-adrenergic
receptors (βAR) by its specific ligand epinephrine, in response to stress to regulate
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cardiovascular function. To date many AKAP isoforms has been reported in a range of species,
including yeast, fruitflies, mice and humans. All AKAPs share some common characteristic
features such as a PKA-binding motif, a localization signal that helps to tether the protein to the
plasma membrane and the ability to form presignaling protein complex with other components of
a signaling pathway (Diviani and Scott 2001; Gold, Lygren et al. 2006; Pidoux and Tasken
2010).

I. 8.2. PDZ-domain containing scaffolding proteins.

PDZ domains are protein-protein

interaction domains found in several proteins. The name is derived from the initial letters of the
PSD-95, Dlg, and a ZO-1 protein that contains the sequence repeats from which the initial
discovery was made. Generally, the interaction between the PDZ domain and its target protein
though the C-terminal region is constitutive, however, in some instances the interaction also
entails agonist-dependent receptors activation (Gomperts 1996; Ranganathan and Ross 1997;
Feng and Zhang 2009). Conclusive evidence exists to support that β2-adrenergic receptors
interact with proteins containing PDZ-domain that acts as scaffolds to link the receptor to its
downstream effectors (Hall and Lefkowitz 2002; Valentine and Haggie 2011). Interestingly,
GRK mediated phophorylation of β2-adrenergic receptors completely disrupt the association of
the receptor to its PDZ-containing binding partners that clearly shows that GPCRs interaction
with PDZ-domain containing proteins is critically dependent on GRK phosphorylation.
Similarly, phosphorylation of inwardly rectifying K+ channels by PKA also disrupts its
interaction with other PDZ-domain harboring proteins (Cohen, Brenman et al. 1996; Cao,
Deacon et al. 1999; Fanning and Anderson 1999; Hu, Chen et al. 2002).
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I. 8.3. Tetratricopeptide repeat (TPR)-bearing scaffolding proteins. This subclass of
scaffolding proteins have been found to interact with different subtypes of G α subunits including,
G αs and G αq . The TPR bearing scaffolding proteins been shown to preferentially interact with the
active conformation of HA-Ras in the absence of the G-protein, G α16 . Although, the
physiological relevance of this interaction has not been explored in detail (Marty, Browning et al.
2003; Andreeva, Kutuzov et al. 2007).

I. 8.4. β-arrestins. The aforementioned interactions of GPCR with scaffolding proteins strictly
entail the presence of specialized sequence motifs embedded either in the receptor or present in
the scaffolding proteins. The association of GPCRs with β-arrestins exhibits a variation to the
rule of specific GPCR/scaffold interaction. The family of β-arrestins exist in two isoforms: βarrestins1 and β-arrestins2 both are exclusively involved in the desensitization process of the βAR. However, recent studies has revealed that β-arrestins can associate with a broad variety of
GPCRs. G-protein receptor kinase (GRKs) mediated phosphorylation of the activated receptors,
promotes the receptor association with β-arrestins and causes uncoupling of the receptor from the
G-protein (Luttrell and Lefkowitz 2002; Lefkowitz and Whalen 2004). Several proteins involved
in endocytotic pathway such as clathrin are also known to interact with β-arrestins. The
interactions of β-arrestins with the endocytotic proteins facilitate ligand induced receptor
internalization. This qualifies β-arrestins as scaffolding protein linking GPCRs with the
endocytotic machinery to promote internalization. Additionally, β-arrestins are also known to
interact with tyrosine kinase Src and the interaction is important for activation of Src kinase to
mediate other signaling events. Thus, β-arrestins are not only proteins merely involved in GPCR
internalization but can also function as a protein scaffold to simultaneously stimulate parallel
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signaling processes (Luttrell, Ferguson et al. 1999; Imamura, Huang et al. 2001; Ma and Pei
2007).

I. 8.5. Caveolin proteins. Caveolae are 50 to 100 nm omega shaped, cell surface membrane
invaginations found in many cell types including vascular endothelial cells, muscle cells,
adipocytes and fibroblasts (Parton and Simons 2007; Volonte, McTiernan et al. 2008). Previous
studies demonstrated myriad signaling molecules populate in caveolar pits including different
type of receptors such as GPCRs coupled to heterotrimeric and monomeric G-proteins, receptor
tyrosine kinases and other growth factor receptors (Wu, Butz et al. 1997; Okamoto, Schlegel et
al. 1998; Chini and Parenti 2004). Caveolae have been implicated to regulate important cellular
processes like endocytosis, transcytosis, calcium signaling and several other signal transduction
events (Minshall, Sessa et al. 2003; Cohen, Hnasko et al. 2004). Caveolae forms a distinct subset
of lipid rafts that are formed by the dynamic aggregation of cholesterol, glycosphingolipids and
sphingomyelin (Ortegren, Karlsson et al. 2004). They are also highly enriched with several
resident proteins of the plasma membrane such as glycophosphatidylinositol (GPI-anchored) and
other phospholipids (Lisanti, Tang et al. 1993; Lisanti, Scherer et al. 1994).
The caveolae coat proteins, caveolins serves as markers for identification of the caveolar
domains and are critical for caveolae function. Caveolins are approximately 22-kDa proteins
consisting of 178 amino acids with multiple acetylation and phosphorylation sites. Three
isoforms of caveolin proteins: caveolin-1, caveolin-2 and caveolin-3, has been identified to date
(Williams and Lisanti 2004; Chidlow and Sessa 2010). Caveolin-1 also known as vesicular
integral membrane protein (VIP) was the first member of the caveolin gene family to be
identified (Razani, Woodman et al. 2002; Parton 2003). It displays a wide range of expression
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pattern in many tissue types including non-muscle and smooth muscle tissues. In smooth muscle,
the first member of the caveolin family, caveolin-1 alone drives the formation of caveolae and
forms the major structural components that preferentially interacts with different signaling
molecules and regulate their function. In contrast, caveolin-2 is nonessential for caveolae
formation and colocalizes with caveolin-1 for its stable expression. Although, caveolin-2 is not
essential for caveolae formation, however co-expression and hetero-oligomerization of caveolin1 and 2 forms a more deeper and abundant caveolae, indicating a modulatory role of caveolin-2
in caveolae formation. The last dominant isoform of the caveolin family, caveolin-3 is a muscle
specific isoform and share high structural and functional similarities with caveolin-1. Unlike
caveolin-2, caveolin-3 can form caveolar microdomain independent of caveolin-1 (Tang, Scherer
et al. 1996; Scherer, Lewis et al. 1997; Williams and Lisanti 2004; Mercier, Jasmin et al. 2009).
Sequence analysis studies have shown that caveolins interact with their binding partners
through a short stretch of amino acids known as the caveolin scaffolding domain (CSD)
embedded in the cytosolic N-terminal region spanning from amino acids 82 to 101 (Couet, Li et
al. 1997; Epand, Sayer et al. 2005). Additionally, the interactions are also guided by a defined
sequence of amino acids called the caveolin binding motifs (CBM) integrated within the binding
partners. The most well defined CBM that has been identified contains a short tandem protein
sequence with aromatic amino acids inserted in a specific pattern (Razani, Woodman et al. 2002;
Collins, Davis et al. 2012).

I. 8.5a. Regulation of endothelial nitric oxide synthase by caveolin. The interaction of
caveolin proteins with endothelial nitric oxide synthase (eNOS) has been explored extensively
(Garcia-Cardena, Fan et al. 1996). Studies demonstrated that interaction of eNOS with CSD of
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the caveolin protein leads to inhibition of its enzymatic activity. Both caveolin-1 and -3 were
shown responsible for suppressing the catalytic activity of eNOS. A number of studies also
supported the hypothesis that decreases in caveolin expression upregulates eNOS activity under
basal condition (Venema, Ju et al. 1997; Feron and Kelly 2001; Rath, Dessy et al. 2009).

I. 8.5b. Regulation of cAMP/cGMP signaling by caveolin.

The scaffolding domain of

caveolin-1 and -3 also interacts with specific isoforms of adenylyl cyclase (AC) and inhibit their
activity (Toya, Schwencke et al. 1998; Willoughby and Cooper 2007). Consequently, disruption
of caveolae or downregulation of caveolin proteins significantly promotes adenylyl cyclase
activity (Yamamoto, Okumura et al. 1999; Head, Patel et al. 2006). Additionally, cyclic
nucleotide phosphodiesterases (PDE), the enzyme responsible for hydrolyzing cAMP and cGMP
has also been reported to localize in caveolar microdomains (Abrahamsen, Baillie et al. 2004;
Baillie, Scott et al. 2005). Previous studies have shown that PDE3B isoform is
compartmentalized in caveolae and its expression was decreased considerably in caveolin-1
knockout mice (Nilsson, Ahmad et al. 2006). Similar association of PDE5 isoform with caveolae
was reported and its expression decreased with targeted suppression of caveolin proteins with
siRNA techniques and also in caveolin-1 knockout mice (Murray F 2006). Although, preliminary
studies claims that caveolin-1 inhibits the catalytic activity of protein kinase A (PKA), however
the localization of PKA in caveolae is not very well defined and remains inconclusive (Razani,
Rubin et al. 1999; Razani and Lisanti 2001).

I. 8.5c. Regulation of receptor tyrosine kinases by caveolins. Receptor tyrosine kinases
(RTK), another major class of transmembrane receptor was also reportedly associated with or
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directly localized in caveolae (Couet, Sargiacomo et al. 1997; Pike 2005). Studies from several
groups have shown that caveolin proteins regulate the MAP kinase cascade components, which
forms the downstream effectors of RTK. Studies involving overexpression of caveolin isoforms
leads to a marked downregulation of the signaling through the MAP kinase pathway (Engelman,
Chu et al. 1998). In airway and vascular smooth muscle the expression of caveolin-1 was
markedly reduced in proliferating muscle cells. Consistent with the antiproliferative role of
caveolins, expression of receptors for growth factors such as EGF and PDGF, and constituent of
growth factor signaling cascades such as Src, Shc, Grb2 and Ras are localized in caveolae. The
selective interaction between the caveolin proteins with the members of the MAP kinase cascade
significantly suppresses their activity (Gosens, Stelmack et al. 2006; Gosens, Stelmack et al.
2011). This shows a clear regulation of growth factor signaling by caveolae and its defining
protein caveolins.

I. 8.5d. Regulation of ion channels by caveolins. Ion channels and transporters play an
important role in a variety of cellular functions that contribute in maintaining the membrane
potential and cellular excitability to the release of neurotransmitters. Many groups have reported
the potential localization of different kinds of ion channels such as Ca2+, K+, Na+, and Cl- in
caveolar pits (Taggart 2001; Isshiki and Anderson 2003; Bergdahl and Sward 2004). Subcellular
localization of these transmembrane proteins in rafts and caveolar microdomain are critical for
their modulation by different cellular signals. The active components of the intracellular calcium
handling machinery such as Ca2+-ATPase, IP 3 receptor, voltage gated calcium channels,
calmodulin, calcium pumps and transient receptor potential (TRP) channels, are preferentially
harbored in cholesterol rich plasma membrane domains including caveolae in many cell types
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(Fujimoto, Miyawaki et al. 1995; Schnitzer, Oh et al. 1995; Darby, Kwan et al. 2000; Lohn,
Furstenau et al. 2000; Wang, Ye et al. 2005). Subcellular localization of these proteins in
caveolar domains clearly indicates that caveolae and caveolin proteins conclusively participate in
the process of intracellular calcium signaling.

I. 8.5e. Regulation of endocytosis by caveolin proteins. Caveolae has been proposed to
mediate the process of transcytosis in order to shuttle macromolecules across endothelial
membrane. This process of transcytosis involves GTP-dependent, dynamin-mediated
internalization of caveolar microdomains from the plasma membrane (Oh, McIntosh et al. 1998;
Shajahan, Timblin et al. 2004; Predescu, Predescu et al. 2007). Internalization of caveolae is also
triggered by other signals that include actin polymerization, presence of cholesterol, the presence
of membrane protruding GMI ganglioside and phosphorylation through kinases (Schnitzer, Liu
et al. 1995; Mukherjee, Tessema et al. 2006). The role of tyrosine kinase Src is remarkably well
elucidated to understand its role in the molecular mechanisms of caveolar endocytosis.
Downregulation of Src using small interfering RNA has resulted in enhanced accumulation of
caveolar structure at the cellular membrane. Following endocytosis, the caveolar structure is
maintained as a stable unit that ultimately fuses with other intacellular compartments such as
caveosome in a RAB5 dependent manner. These intracellular caveolar units can later be recycled
back to the plasma membrane to restore the caveolar topology on the membrane (Pelkmans,
Burli et al. 2004; Shajahan, Tiruppathi et al. 2004; Parton and Simons 2007).
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I. 9. Regulation of smooth muscle function by caveolins
Studies from several laboratories have reported a very crucial role of caveolae to organise and
regulate smooth muscle function by modulating cellular processes such as contraction, and
growth and proliferation. Although, caveolin knockout mice are viable, however, they are more
prone to develop pathophysiological complications such as cadiomyopathy, enhanced eNOS
activity and severe pulmonary dysfunction (Drab, Verkade et al. 2001; Zhao, Liu et al. 2002;
Cohen, Hnasko et al. 2004; Chidlow and Sessa 2010). All these have drawn scientific attention to
investigate any modulatory effect of caveolae and caveolins in smooth muscle function. Several
studies demonstrated caveolar colocalization of ion channels and signaling molecules involved in
contraction (Maguy, Hebert et al. 2006; Balijepalli and Kamp 2008). Recently, caveolae and its
coat proteins have been shown to play an important role in 5-HT 2A and endothelin-1 (ET-1)
receptor mediated smooth muscle contraction and disruption of caveolae severely compromised
smooth muscle contractility (Cristofaro, Peters et al. 2007). The involvement of caveolae in
regulation of L-type Ca2+ channel is controversial. Darby et al provided evidence of caveolar
enrichment of L-type Ca2+ channels and Ca2+ binding proteins and their direct modulation by
caveolae to control smooth muscle contractility (Darby, Kwan et al. 2000). However, Lohan et al
reported that caveolae downregulation has no effect on conductance through L-type Ca2+
channels. Caveolae has also been implicated to mediated Ca2+ sensitisation process through its
interaction with Rho kinase and several isoforms of PKC and regulate arterial smooth muscle
contraction. Targeted erosion of caveolar pits from arterial smooth muscle cells caused
significant impairment in muscarinic m2 and m3 receptor mediated airway smooth muscle
contraction (Schlenz, Kummer et al. 2010). Moreover, response of ileum longitudinal muscle to
endothelin-1, but not to carbachol or serotonin was reduced in caveolin-1 KO mice, whereas the
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response of femoral arterial muscle to α1-adrenergic agonist was increased (Shakirova,
Bonnevier et al. 2006). Thus, it appears that regulation of smooth muscle contraction by
caveolins is both tissue- and receptor-specific.
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I. 10. Novelty and Significance
Caveolae provide an essential platform for signal transduction by G protein-coupled
receptors in vascular and airway smooth muscle contractile function by integrating the
contractile signals and intracellular effector pathways. Recent studies using caveolin knockout
animals demonstrated that caveolae and caveolin-1 play an important role in several diseases
phenotypes such as diabetes, athresclerosis, cardiac hydpertrophy, pulmonary hypertension and
bladder dysfunction. Studies in vascular and airway muscle also demonstrated that the
expression of caveolin-1 was significantly reduced in proliferating muscle cells compared to
contractile phenotype. Caveolins, therefore, are also important for the maintenance of smooth
muscle contractile phenotype. Gastrointestinal motility depends on the integrated function of
enteric neurons, interstitial cells of Cajal and smooth muscle cells. Studies examining the
involvement of caveolae and caveolin-1 in the regulation of GI motility are limited and, often,
restricted to the intact tissue or organ. An obvious conclusion form these studies is the
importance of caveolae and caveolins in the regulation of contractile function. Undoubtedly, the
next step in the process of the understanding the mechanism by which caveolae and caveolins
regulate muscle contraction is to understand the regulation of signal transduction pathways
activated by contractile neurotransmitters in the smooth muscle. The signal transduction
pathways that regulate muscle contraction short-term also regulate smooth muscle phenotype
long-term. In this study we examined the hypothesis that caveolae and caveolin-1 provide a
critical regulatory environment for excitation-contraction and excitation-trascription coupling in
the smooth muscle cells. To test this hypothesis we investigated the role of caveolae in the
regulation of gastric smooth muscle function by the main excitatory neurotransmitter,
acetylcholine mimetic, carbachol using freshly dispersed muscle cells devoid of neurons and
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ICC. The role of caveolae and caveolin-1 in m2 and m3 receptor signaling was examined using
pharmacological, biochemical, molecular and genetic approaches. Our study provides important
biochemical basis by which caveolin-1 can regulate the integration of extracellular contractile
stimuli and the downstream intracellular effectors in smooth muscle. For perspective, as
demonstrated in the present study, caveolin-1 represents an important scaffolding protein in
orchestrating G protein-coupled receptor signaling to have a dual role in pro- excitationcontraction and excitation-transcription, and anti-proliferatiion in gastric smooth muscle. These
results may also help to establish caveolin-1 as a therapeutic target in the treatment of smooth
muscle complications in GI motility disorders.
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CHAPTER: II MATERIALS AND METHODS
II. 1. Materials
[125I]cAMP, [γ-32]ATP, [3H]myo-inositol, [3H]Scopolamine were obtained from PerkinElmer
Life Sciences (Boston, MA); methoctramine (muscarinic m2 receptor antagonist) Sigma-Aldrich
St. Louis, MO; 4-DAMP (muscarinic m3 receptor antagonist) Sigma-Aldrich, (St. Louis, MO);
Y27632 (Rho kinase inhibitor) Calbiochem, (La Jolla, CA); U73122 (PLC inhibitor) Enzo Life
Sciences, Inc., NY; PP2 (Src inhibitor) Enzo Life Sciences, Inc., NY; Antibodies: Caveolin-1,
caveolin-3, phospho-MYPTI, phospho-MLC 20 , α-actin, γ-actin, caldesmone, β-actin, Rho kinase
II, ZIP kinase, muscarinic m2 receptor, muscarinic m3 receptor, SRF, myocardin, phospho EGF
receptor, ERK1/2 were obtained from Santa Cruz biotechnology, Santa Cruz, CA;
RNAqueousTM kit was obtained from Ambion, Austin, TX; LipofectamineTM 2000 transfection
reagent, SuperScriptTM II Reverse Transcriptase kit, DH5-α competent cells, were obtained from
Invitrogen, Carlsbad, CA; Restriction enzymes were obtained from New England Biolabs
(Ipswich, MA); QIAprepR Spin Miniprep Kit was obtained from QIAGEN Sciences, Maryland;
PCR reagents were obtained from Applied Biosystems, Roche. Caveolin-1 SiRNA was obtained
from BD Biosciences, San Jose, CA. pSIREN-DNR-DsRed vector was obtained from Clontech
Laboratories, Inc. CA; EGF was obtained from BD Biosciences, San Jose, CA. Collagenase CLS
type II and soybean trypsin inhibitor for cell isolation were obtained from Worthington,
Freehold, NJ; Western botting materials, Dowex AG-1 X 8 resin (100-200 mesh in formate
form), chromatography materials and protein assay kit, Tris-HCl ready made gels were all
obtained from Bio-Rad Laboratories, Hercules, CA; Dulbecco’s modified Eagle’s medium for
primary cell culture was obtained from Fisher Scientific. All other chemicals were obtained from
Sigma, St. Louis, MO.
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Animals
New Zealand white rabbits (weight: 3-4 lbs) were purchased from RSI Biotechnology,
Clemmons, NC and killed by injection of euthasol (100 mg/Kg), and caveolin-1 knockout and
wild type mice (B6129SF2/J) were obtained from the Jackson Laboratory (Bar Harbor, ME) and
killed by suffocation with CO2. All the procedure was followed as approved by the Institutional
Animal Care and Use Committee of the Virginia Commonwealth University. The animals were
housed in the animal facility maintained by the Division of Animal Resources, Virginia
Commonwealth University. All procedures were conducted in accordance with the Institutional
Animal Care and Use Committee of the Virginia Commonwealth University.
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Table 1: Primers for qRT-PCR
Target

Forward Primer 5’-3’

Reverse Primer 5’-3’

m1 receptor

GGTGGCAGCAGCAGCAGCTCA

GCCTCTTGACTGTATTTGGGGAGC

m2 receptor

GTGACTGAAACCTGTGTT

GGAGGCTTCTTTTTGGCAGGCTG

m3 receptor

AGCTCCATCCTCAACTC

GGTTTTGGGTATGCAGCTGTCAC

m4 receptor

TGAGTCCAGCTCAGGCAGTGCC

GTTCCGATACTGGCACAGCA

m5 receptor

GAAAGGAATCAGGCCTCCTGG

CCACCAATCGGAACTTATAGGC

Caveolin-1

GACGCGCACACCAAGGAG

GTCACAGTGAAGGTGGTG

Caveolin-3

GTCTCCAAGTACTGGTGC

GGGTTGCAGAAGGTGCGG

γ-actin

ATCAGGCCCGCGACAACTCGT

GCCGCCAGTTGTGCTCTAAAAGGT

Caldesmon

CAGAAGGGAAGTCGGTAAATGAAA

GGGCAGCTGTCTGAAGTTTATCTTCTT

β-actin

CCCTCCATCGTGCACCGCAA

CTCGTCTCGTTTCTGCGCCGT

GAPDH

GCCTGGAGAAAGCTGCTAAGTATG

CCTCGGATGCCTGCTTCA

Myocardin

CGGATTCGAAGCTGTTGTCTT

AAACCAGGCCCCCTCCC

SRF

TCTCAGGCACCATCCACCAT

CCCAGCTTGCTGTCCTATCAC

SM-MHC

TGGACACCATGTCAGGGAAA

ATGGACACAAGTGCTAAGCAGTCT
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II. 1. METHODS

II. 2. 1. Tissue collection and processing
Rabbits were sacrificed by injecting euthasol at a concentration of 100mg/kg of body weight into
the ear vein. The stomach was rapidly isolated and removed of its content, washed and placed in
pre-chilled smooth muscle buffer (pH 7.4) with the following composition: 120 mM Nacl, 4 mM
KCl, 2.6 mM KH 2 PO 4, 2 mM CaCl 2 , 0.6 mM MgCl 2 , 25 mM HEPES (N-2hydroxyethylpiperazine-N’ 2-ethanesulfonic acid), 14 mM glucose, and 2.1% essential amino
mixture.

II. 2.2. Preparation of dispersed gastric smooth muscle cells
The stomach was separated into thin distal fundus and the thicker posterior antrum. Smooth
muscle cells were isolated by sequential enzymatic collagenase digestion from the circular
muscle layer followed by filtration and collection through Nitex mesh and centrifugation as
described previously (Bitar and Makhlouf 1982; Murthy, Zhou et al. 2001). After removal of the
mucous layer by sharp discussion from both regions, the fundus was chopped and minced
thoroughly with a pair of sharp scissors and the antrum was sliced into thin pieces using a StadieRiggs tissue slicer. Following tissue processing, they were incubated separately in a solution of
smooth muscle buffer containing 0.1% collagenase (300U/ml) and 0.001% soybean trypsin
inhibitor (w/v) for 30 min at 310C in a water bath with a constant supply of 100% oxygen. The
partially digested tissue was washed twice with collagenase free smooth muscle buffer and the
smooth muscle cells were allowed to disperse spontaneously for approximately 30 min in the
enzyme free medium. At the end of digestion and dispersion the cells were harvested by filtration
through 500µm Nitex mesh and centrifuged twice at 350 g for 10 min to eliminate broken cells
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and cellular organelles. With an estimated 95% of the cells excluded trypan blue staining after
counting in a hemocytometer, the experiments were conducted within 2-3 h of cell dispersion.

II. 2.3. Preparation of primary cultures of gastric smooth muscle cells
The smooth muscle cells dispersed and isolated from rabbit’s stomach were resuspended in
DMEM culture medium containing the following antibiotics; penicillin (200 U/ml), streptomycin
(200 U/ml), gentamycin (100mg/ml), amphotericin B (2.5 µg/ ml) along with 10% fetal bovine
serum (DMEM-10) added through a filtered flask. The muscle cells were then plated at a
concentration of 5 X 105 cells/ml and incubated at 37oC in a CO 2 water-jacketed incubator. The
cells were allowed to attach to the base of the culture dish and DMEM-10 medium was replaced
with fresh medium every three days for 2-3 weeks until confluence was attained. When the
primary cultures of smooth muscle cell were fully confluent, they were trypsinized (0.5 mg
trypsin/ml) and re-plated at a concentration of 2.5 X 105 cells/ml and further cultured under the
same conditions. All the experiments were conducted with muscle cells in their first passage.
Previous studies have confirmed the purity of the primary cultured cells with smooth muscle
specific marker γ- actin (Teng, Murthy et al. 1998). The cultured muscle cells were starved for
24 h in serum and antibiotic free medium prior conducting any experiments.
The project entails conducting experiments on both freshly dispersed gastric smooth muscle cells
and primary culture of gastric smooth muscle cells. Inspite of the limitations in interpreting the
experimental data obtained from cultured cells, their use was indispensable for conducting
molecular studies and introducing genetic manipulations.
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II. 2.1. Total RNA isolation
50-100 mg of gastric tissue was isolated from rabbit and mice stomach and transferred to a glassTeflon homogenizer with 1 ml of TRIzol (GIBCO BRL). The tissue was properly homogenized
for 1 min in the polytron. Following homogenization, the content was transferred into a 1.5 ml
centrifuge tube and 0.2 ml of chloroform was added. Sample tubes were capped securely and
mixed by inverting the tube for 15 sec. The tubes were incubated at room temperature for 3 min
and then centrifuged at 12,000 g for approximately 15 min. At the end of centrifugation the
mixture separates into two distinct layers, a lower red, phenol-chloroform phase and an upper
clear aqueous phase. Since RNA appears exclusively in the upper aqueous phase, the upper
phase was carefully transferred into a fresh tube. RNA was precipitated from the aqueous phase
by mixing with 0.5 ml of isopropyl alcohol followed by incubating the sample at room
temperature for 2 h. The mixture was then centrifuged at 12,000 g for 10 min at 4oC and the
precipitated RNA appeared to be a white pellet. The pellet was washed with 0.5 ml of 70%
ethanol and centrifuged at 7500 g for 10 min at 4oC (Zhang, Li et al. 2012) and completely
air/vacuum dried using an Integrated Speed-Vac System for 10 min. The dried RNA pellet was
dissolved in 50-100 µl of DEPC treated water and the concentration was measured with a
NanoDrop 1000.

II. 2.5. Real Time PCR
Real-time PCR was carried out on cDNA samples prepared from total RNA isolate from freshly
dispersed smooth muscle cells, whole gastric tissue and also primary cultures of gastric cells.
The experiment was performed using StepOne™ Real-Time PCR System (Applied Biosystem,
Foster city, CA) and the intercalating dye SYBR green. Optimum PCR conditions were
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determined on the gradient thermal cycler using the StepOne™ Real-Time PCR System. For
each cDNA sample, 20 µl by volume of the reaction was mixture was prepared with the
Quantitect TM SYBRgreen PCR Mastermix (Qiagen, Mississauga, ON). The time and
temperature profile used for each real-time PCR mixture is as follows: 95 ˚C for 5 min; 50 cycles
of a series consisting of 15 s at 94 ˚C, 30 s at 52 ˚C, 30 s at 72 ˚C; and a final extension of 5 min
at 72 ˚C. The optimal annealing temperature for each primer set was determined empirically. The
primary sequence of the primer sets used for the reactions are tabulated as follows:

Each real-time RCR reactions were performed in triplicate. Only one PCR product was generated
by each primer set and the correct molecular weight was confirmed by electrophoresis on 1.5%
agarose gel containing 0.1 μg/ml ethidium bromide followed by sequencing of the individual
bands to finally confirm the identity and integrity of the band. The fluorescent threshold value
for each data set was calculated using the StepOne™ Real-Time PCR System software. The
absence of signal in control wells containing water precluded the possibility of formation of
primer-dimer.

Quantification of gene expression- Usually, two types of data quantification methods are
applicable in quantitative RT-PCR (qRT-PCR). One, using an absolute quantification method
that directly measures the levels of expressed genes and the other by a more relative
quantification method. The absolute quantification approach uses a calibration curve that relates
the PCR signal to input copy number of the target gene. On the other hand in the relative
quantification method the PCR signal of the transcript of interest in a treatment group is
compared to the transcript level of another sample considered as an untreated or control group.
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Relative quantification of a target gene in reference to another gene also called the housekeeping
gene whose expression is absolutely unfluctuating under any condition (treatment or control) is
calculated on the basis of delta delta CT values (CT, also known as CP, is the cycle number at
which the fluorescence generated within a reaction crosses the threshold). CT is defined as the
point during the course of a reaction at which there is sufficient accumulation of amplicons.
There are several mathematical models to calculate the relative expression ratio (R), based on the
comparison of the diverse cycle differences. One of them includes the delta delta CT method and
the efficiency corrected calculation model. In these models, the target-gene expression is
normalized to the expression of one or more non-regulated housekeeping genes. The choice of an
internal control to normalize the expression of the gene of interest is critical to the interpretation
of experimental real-time PCR results. The housekeeping gene expression must not be
influenced by the applied treatment.

Delta delta CT method

ΔΔCT = (C T, Tag − C T, HKG )

Treatment

− (C T, Tag – C T, HKG ) Control

R = 2 −ΔΔCT
Where, HKG is the housekeeping gene and Tag, the evaluated gene.

Adhering to the criteria for choosing the reference genes in the delta delta method, GAPDH was
selected as the reference gene. After normalization, the data for one gene or control group were
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expressed as the fold-change in mRNA expression relative to that obtained for another gene or
treatment group.

II. 2.6. Western blot analysis
Smooth muscle cells isolated from rabbit stomach or harvested from primary cultures were
solubilized in Triton X-100-based lysis buffer containing 20 mM Tris-HCl (pH 8.0), 1 mM DTT,
100 mM NaCl, 0.5% sodium dodecyl sulphate, 0.75% deoxycholate, 1 mM PMSF, 10 µg/ml of
leupeptin and 100 µg/ml of aprotinin, in the presence of protease and phosphatase inhibitors. The
lysates obtained after solubilization was centrifuged at 20000 g for 10 min at 4 °C and the
supernatant was collected and its protein concentration was determined with a Dc protein assay
kit from Bio-Rad. Equal amount of protein was resolved by SDS/PAGE gel, followed by an
eletrophoretic transfer of the protein bands onto a nitrocellulose paper. The blots were then
blocked with 5% (w/v) non-fat dried milk/TBS-T [tris-buffered saline (pH 7.6) and 0.1% Tween20] for 1 h and then incubated overnight at 4 °C with the specific primary antibodies in TBS-T
and 1% (w/v) non-fat dried milk. Following overnight incubation with primary antibodies, the
blots were washed thrice with PBST and 0.1% tween and then incubated for 1 h with
horseradish-peroxidase-conjugated corresponding secondary antibody (1:2000; 10 μg/ml, Pierce)
in TBS-T /1% (w/v) non-fat dried milk. The immunoreactive proteins were visualized using
SuperSignal Femto maximum sensitivity substrate kit (Pierce). All washing steps were
performed with TBS-T. Enhanced chemiluminescence reagent identified the protein bands.
Quantification of protein bands obtained on western blot was subjected to densitometric analysis
by the Odyssey software using the median method for calculation of background. The average
intensity obtained for each band was normalized to that of β-actin for the same lane. The band
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intensity of each treatment was then calculated as a percent value normalized with the control.
The percent value of the control was used for statistical analysis.

II. 2.7. Radioligand binding studies
Dispersed gastric smooth muscle cells were isolated from rabbit stomach and radio-ligand
binding studies were performed using [3H] scopalamine as described previously (Murthy and
Makhlouf 1997). The muscle cells were suspended in HEPES medium (pH 7.4) containing 1%
fetal bovine serum. For total binding, 0.5 ml of cell suspension (106 cells/ml) were aliquot in
triplicates and incubated at room temperature for 15 min with 1 nM [3H] scopolamine alone. For
total binding with the specific receptor subtypes the cells were incubated with [3H] scopolamine
in the presence of methoctramine for total m3 receptor binding or in the presence of 4-DAMP for
total m2 receptor binding. Following treatment, the bound and free radio-ligand was separated by
rapid filtration under reduced pressure through 5-µm polycarbonate Nucleopore filters. The
filters were extensively washed for 4 times with 3 ml of ice-cold HEPES medium containing
0.2% of bovine serum albumin. Non-specific binding was measured by treating the cells with
carbachol at a concentration of 10 µM. Specific binding of the radio-ligand with the receptors
was obtained by subtracting the non-specific binding from total binging.

II. 2.8. Assay for Phosphoinositide (PI) hydrolysis
The total inositol phosphates pool from muscle cells was measured by the process of anion
exchange chromatography using the method of Berridge et al (Murthy and Makhlouf 1991;
Murthy, Zhou et al. 2003). A volume of 10 milliliters of cell suspension were labeled with myo2-[3H] inositol (15 µCi/ml) for 180 min at 31oC. Excess [3H] inositol was removed by
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centrifuging the muscle cells at 350 g for 10min. After incubating with DMSO and MβCD and
treatment with CCh (0.1µM) and methoctramine (0.1µM,) the cells was placed in a shaking
water bath for 1 min. Similar procedure was followed for the other two approaches, caveolin-1
siRNA targeted cultured smooth muscle cells and gastric tissue obtained from caveolin-1 KO
mice.

Following

treatment

the

reaction

was

terminated

by

the

addition

of

choloform:methanol:HCl in the ratio of 50:100:1 by volume. After adding equal volume of
chloroform and water (340 µl), the samples were vortexed and centrifuged at 1000 g for 15 min
to separate the phases. The upper clear aqueous phase was applied to a column containing 1 ml
of 1:1 slurry of Dowex AG-1 X8 resin (100-200 mesh in formate form) and distilled water. The
column was then washed with 10 ml of distilled water followed by 10 ml solution of 5 mM
sodium tetraborate and 60 mM ammonium formate to remove [3H] glycerophosphoinositol. Total
inositol phosphates were eluted by applying 6 ml of 0.8 M ammonium formate - 0.1 M formic
acid. The eluates were collected in scintillation vials and counted in gel phase after addition of
10 ml of scintillation fluid. The results were expressed as counts per minute per mg of protein.

II. 2.9. Assay for adenylyl cyclase activity
Adenylyl cyclase activity was measured by the formation of the second messenger cAMP in
response to the contractile agonist carbachol. Radioimmunoassay using radiolabeled [125I] cAMP
was performed to measure the level of cAMP production (Murthy and Makhlouf 1997; Murthy
and Makhlouf 1998; Teng, Grider et al. 2001). Carbachol stimulates muscarinic m2 receptor
acting via Gαi to inhibit adenylyl cyclase activity. Carbachol induced inhibition of adenylyl
cyclase activity was monitored as percent reduction of cAMP formation compared to forskolin
induced cAMP levels. The experiments were performed after the cells were treated with
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carbachol (CCh: 0.1µM) and the muscarinic m3 receptor antagonist 4-DAMP (0.1µM). One
milliliter of cell suspension containing approximately 3 x 106 cells/ml was treated with 10µM of
forskolin either alone or in combination with carbachol (0.1 µM). Following treatment the
reaction was terminated with cold 6% trichloroacetic acid (v/v) and vortexed vigorously. The
mixture was then centrifuged and the supernatant was collected and were extracted three times
with water-saturated diethyl ether to remove the trichloroacetic acid and then lyophilized and
frozen at -20oC. Before radioimmunoassay, the samples were reconstituted in 50 µl of 50mM
sodium acetate (pH 6.2) and acetylated with triethylamine/acetic anhydride (2:1 v/v) for 30 min.
Cyclic AMP was measured in triplicates using 100 µl aliquots and the results was analyzed and
derived from a standard curve using Prism

@

GraphPad program. The results were expressed as

pmol of cAMP/mg protein.

II. 2.10. Immunokinase assay for Rho kinase and ZIP kinase activity
Rho kinase and ZIP kinase activities were measured by immunokinase assay as previously
described (Murthy and Makhlouf 1998; Murthy, Zhou et al. 2001; Zhou and Murthy 2004).
Muscle cells were divided into two groups, control and experimental group. The control group
was incubated with DMSO and the experimental group was incubated with MβCD (10mM) each
for 30 min. After 30 min incubation cells were washed three times with smooth muscle buffer
and equal amount of cells (3x106 cells/ml) were treated with carbachol (0.1 µM) and Rho Kinase
inhibitor, Y27632 (1 µM) for 10 minutes and the reaction was terminated by rapid centrigugation
at 25000 g for 15 mins at 4oC. The same treatment process was followed for other two
approaches, caveolin-1 siRNA transfected cultured gastric muscle cells and cells obtained from
caveolin-1 knockout mice. Following treatment the cells were lysed with lysis buffer containing
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50mM Tris-HCl (pH 7.5), 150mM NaCl, 0.1% SDS, 0.5%sodium deoxycholate, 1%NP-40,
10mM sodium pyrophosphate, and protease inhibitor cocktail (2 µl/ml, BD Biosciences). The
homogenates were further centrifuged at 10,000 rpm for 10 min at 4oC. The supernatant
containing cytosolic protein after being transferred to a new 1.5 ml tube was mixed with 5 µl of
Rho Kinase antibody and incubated for 2 hrs at 4oC.
At the completion of two hours, protein A/G agarose beads were added to each tube and the
mixture was reincubated at 4oC for overnight and washed 3 times with lysis buffer. The pellet
was resuspended in 50 µl of kinase buffer containing 100mM Tris-HCl (pH7.4), 1M KCl, 50mM
MgCl 2 , 10mM EDTA, and 1mM DTT. Twenty microlitres of Rho kinase immunoprecipitates
were added to the reaction mixture containing 100 mM Tris- HCl (pH7.4), 1M KCl, 50 mM
MgCl 2, 1mM DTT, 1mM ATP, and 10 µCi of [γ-

32

P] ATP (3000 Ci/mol) along with 1µg of

myelin basic protein, followed by incubation for 15 mins at 37oC. Phosphorylation of myelin
basic protein was absorbed onto phosphocellulose disks, and free radioactivity was removed by
washing 3 times with 75mM H 3 PO 4 . The amount of radioactivity on the disks was measured by
liquid scintillation. The results are expressed as counts per minute per milligram protein (31).

II. 2.11. Transfection of caveolin-1 siRNA into cultured gastric smooth muscle cells
Primary culture of gastric smooth cells was grown at 80-90% confluence and serum starved for
overnight. The caveolin-1 specific siRNA was subcloned into the pSIREN-DNR-DsRed
expression vector. The recombinant vector was diluted with Opti-MEM

R

and mixed gently.

After dilution of the plasmid vector into Opti-MEM the mixture was incubated for 5 min at room
temperature. Similarly, the transfection agent LipofectamineTM 2000 was also diluted in optiMEM and mixed gently. The diluted recombinant plasmid and the diluted LipofectamineTM 2000
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reagent was mixed together and further incubated at room temperature for 20 min. After 20 min,
the mixture were added to cultured muscle cells and kept for 48 h for sucessful knockdown of
caveolin-1 protein. The transfection efficiency was monitored by the expression of the red
fluorescent protein integrated into the vector, by TRITC filters. The control cells were
transfected with vector alone. Imaging using fluorescent microscopy confirmed 80% transfection
efficiency. Following each transfection method, cell lysates were collected and the protein level
was confirmed by western blot analysis (Zhou, Das et al. 2003; Huang, Zhou et al. 2007).

II. 2.12. Sucrose Density Centrifugation of gastric cells
Rabbit gastric smooth muscle cells in their first passage were maintained in culture. Once the
cells attained 70-80 % confluence, the medium was aspirated and the plates were washed with
ice cold PBS. At the end of third wash, PBS was completely removed and 1 ml of 1% Triton-X
100 buffer was applied to each plate enough to cover the plates. The cells were then scrapped off
using a cell scraper and transferred into a prechilled Dounce (glass-glass) homogenizer.
Following homogenization, the cell lysate was subjected to sucrose density centrifugation to
separate caveolar and non- caveolar fraction. The principle of separation was based on the
unique lipid enrichment of the caveolar fraction such as sphingolipids and cholesterol, which
makes these fractions more buoyant compared to other cellular content.
After homogenization, 2 ml of the sample was mixed with 2 ml of 90 % MBS/Triton X-100
buffer in an ultracentrifuge tube to prepare a sucrose layer of 45%. 4 ml each of 35% and 5 %
sucrose prepared in MBS/Triton X-100 buffer was carefully layered on top of the 45% sucrose
layer. Following the preparation of the sucrose density layer, the tube was perfectly balanced and
centrifuged for 16-20 h at 39,000 rpm at 40C in a SW41Ti rotor (Beckman). After the
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centrifugation, the tubes were carefully removed from the bucket and the samples were collected
from top to bottom in 1 ml fractions. Each fraction collected was analyzed by SDS-PAGE. The
caveolar fractions were probed with a caveolin-1 specific antibody (Murthy and Makhlouf 2000;
Ostrom and Insel 2006).

II. 2.13. Receptor Internalization by radioligand binding studies
Dispersed gastric smooth muscle cells and cultured cells were used to study the effect of
caveolin-1 on muscarinic m2 and m3 receptor internalization. Receptor internalization was
measured by radio-ligand binding studies using [3H] scopolamine (Murthy, Grider et al. 2000).
The muscle cells were suspended in HEPES medium (pH 7.4) containing 1% fetal bovine serum.
For total binding, 0.5 ml of cell suspension (106 cells/ml) were aliquot in triplicates and
incubated at room temperature for 15 min with 1 nM [3H] scopolamine alone or with [3H]
scopolamine and 0.1 µM carbachol in the presence of muscarinic m2 and m3 receptor
antagonists, methoctramine and 4-DAMP respectively. Receptor internalization was induced by
pre-treating the cells with CCh (0.1 µM) for 20 min. Following incubation the bound and free
radio-ligand was separated by rapid filtration under reduced pressure through 5 µm
polycarbonate Nucleopore filters. The filters were extensively washed for 4 times with 3 ml of
ice-cold HEPES medium containing 0.2% of bovine serum albumin. Total binding was again
measured using similar protocol after receptor internalization. Non-specific binding was
calculated by treating the cells with CCh at a concentration of 10 µM (100 times). Specific
binding of the radio-ligand for the receptors was obtained by subtracting the non-specific binding
from total binging.
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II. 2.14. Measurement of smooth muscle cell contraction by scanning micrometry
Freshly dispersed gastric smooth muscle cells were incubated with DMSO and methyl βcyclodextrin (MβCD) (10 mM) separately each for 30 min. Dispersed cells was also isolated
from caveolin-1 KO and WT mice. Following incubation and cell isolation, aliquots of 0.4 ml of
cell suspension were treated with CCh (0.1µM) in the presence of m2 receptor antagonist
methoctramine (0.1µM). After treatment the reactions were terminated using 8% acrolein at a
final concentration 0.1% that helps to kill and fixed the cells without affecting the cell length.
The resting cell length was determined in control experiments with muscle cell suspension
treated with 100 µl of 0.1% bovine serum albumin without the agonists and antagonist. The peak
contraction was derived from the concentration response curve after various treatments. The
mean length of 50 smooth muscle cells treated with CCh and methoctramine were measured by
scanning micrometry as described previously (Murthy, Zhou et al. 2003) and compared to the
mean length of untreated cells. The contractile response was expressed as the percent decrease in
mean cell length compared to the control cell length.

II. 2.15. In-cell western
Culture of smooth muscle cells were grown in 96 well plate (0.1 X 106 cells/well) and treated
with carbachol (CCh: 0.1 µM) and methoctramine (0.1 µM). Following treatment the medium
was aspirated and washed three times with 1XPBS and immediately fixed by adding 150 µl of
fixing solution to each well. After 20 min of fixation at room temperature without shaking, the
solution was removed and 200 µl of Triton washing solution was added to each well and placed
on a shaker for 5 min. The washing step was repeated for 4 more times. Following extensive
washing 150 µl of Odyssey blocking buffer was added to each well and incubated for 2 h at
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room temperature on a shaker. After blocking, the primary antibody (1:200 dilution) was
dissolved in 50 µl of blocking buffer and added to each well. The plate was incubated with the
primary antibody on a shaker at a gentle speed at 40C for 2 h. Following incubation with primary
antibody the wells were washed with Tween washing solution for five times and 50 50 µl of the
specific secondary antibody containing Sapphire and DRAQ5 for background detection was
added for 1 h at room temperature. The plate was washed 5 times with 200 µl of Tween washing
solution and scanned under Licor-Odyssey imaging system using both 700 and 800 nm channels.
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Statistical Analysis

The results were expressed as means + S.E of n experiments and analysed for statistical
significance using Student t-test for paired and unpaired values. Each experiment was performed
on cells and tissues obtained from different animals. Difference of responses among different
groups were tested and confirmed for significance using Fisher’s protected least significance
difference test. The results were analysed using GraphPad software, San Diego, CA. A
probability of P< 0.05 was considered significance.
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CHAPTER III: RESULTS
III. 1. Signaling transduction by muscarinic receptors
Molecular, pharmacological and immunohistochemical studies demonstrated that at
least five different muscarinic acetylcholine (ACh) receptors (m1-m5) are expressed in
mammalian tissues and their expression is tissue- and species-specific. In vascular and visceral
smooth muscle ACh interacts mainly with m2 and m3 receptors; m3 receptors are coupled via
G q with phosphoinositide (PI) hydrolysis and inositol 1,4,5-trisphosphate (IP 3 )-dependent Ca2+
release, whereas m2 receptors are coupled via G i with inhibition of adenylyl cyclase (Migeon,
Thomas et al. 1995; Schramm, Arjona et al. 1995; Morel, Macrez et al. 1997; Murthy, Zhou et al.
2003; Tran, Matsui et al. 2006). Our initial studies characterized the expression of muscarinic
receptors and the receptor-specific signaling pathways activated by carbachol (acetylcholine
mimetic) in rabbit gastric smooth muscle cells.

III. 1a. Expression of muscarinic m2 and m3 receptors in gastric smooth muscle
Specific primers for muscarinic m1, m2, m3 and m4 receptors were designed based on the
conserved sequences in human, rabbit, rat, and mouse cDNAs and used for identification of
muscarinic receptor mRNA expression. Muscarinic m2 and m3, but not m1 and m4 receptors
were detected by RT-PCR on RNA extracted from cultures of gastric smooth muscle cells in first
passage (Fig. 1). When experiments were done in the absence of reverse transcriptase (RT), there
was no amplification of either m2 or m3 receptors. Use of m1, m2, m3 and m4 receptor cDNA’s
as positive control resulted in an amplification of mRNA with receptor specific primers. As
shown previously, the use of confluent cultures of smooth muscle in first passage ensured the
absence of neural, endothelial, or interstitial cell contaminants (Teng, Murthy et al. 1998) and the
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presence of PCR product in cultured muscle cells demonstrate the specific expression of m2 and
m3 mRNA in smooth muscle cells.
Further confirmation for the expression of m2 and m3 receptors was obtained by western
blot analysis using selective antibody to m2 and m3 receptors. The results demonstrated the
expression of both m2 and m3 receptors of predicted size 52 kDa and 66 kDa respectively in the
homogenates of isolated smooth muscle cells (Fig. 1). The results are consistent with the
selective expression of m2 and m3 receptors in vascular and other visceral smooth muscle (Lin,
Kajimura et al. 1997; Belmonte 2005; Gericke, Sniatecki et al. 2011).
Selective expression of m2 and m3 receptors in gastric smooth muscle cells was further
confirmed by radioligand binding studies using [3H]Scopolamine as muscarinic agonist. Specific
binding was calculated as the difference between the total binding in the absence of acetylcholine
(ACh) and non-specific binding in the presence of (10 µM) ACh. Total binding was 2,105±302
cpm/mg protein and the non-specific binding was 22±4% of the total binding (456±65 cpm/mg
protein). Incubation of cells with the selective m2 receptor antagonist, methoctramine (0.1 µM)
inhibited specific binding by 69±3%, whereas incubation of cells with the selective m3 receptor
antagonist 4-DAMP (0.1 µM) inhibited specific binding by 32±4%. Incubation of cells with both
methoctramine and 4-DAMP abolished the specific binding of [3H]Scopolamine (Fig. 2). The
results suggest that the gastric smooth muscle cells express only m2 and m3 receptors and the
expression of m2 receptors are more abundant than m3 receptors. The radioligand binding studies
are consistent with the selective expression of m2 and m3 receptor mRNA and proteins in these
cells.
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III. 2. Signaling pathways coupled to m2 and m3 receptors in gastric smooth muscle
Previous radioligand binding and pharmacological studies in gastrointestinal smooth
muscle cells had demonstrated a high selectivity of methoctramine for m2 receptors and 4DAMP for m3 receptors (Murthy and Makhlouf 2000). This made it possible to use these
antagonists to examine signaling pathways initiated by m2 and m3 receptors. The signaling
pathways activated by m2 receptors are examined in response to carbachol (CCh: 0.1 µM) in the
presence of 4-DAMP (0.1 µM), whereas the signaling pathways activated by m3 receptors are
examined in response to CCh in the presence of methoctramine (0.1 µM). The concentrations of
CCh and antagonists were selected based on our previous studies in isolated gastrointestinal
smooth muscle cells. Since previous studies have demonstrated that m3 receptors are coupled
with G q /G 13 and m2 receptors are coupled to pertussis toxin (PTx)-sensitive G i (Murthy 2008) ,
in the present study, PTx was also used as an additional tool to identify pathways initiated by m2
and m3 receptors.

III. 2a. Gq-coupled muscarinic m3 receptor signaling
Acetylcholine was shown previously to stimulate PI hydrolysis, IP 3 formation and Ca2+ release
via Gα q in dispersed intestinal smooth muscle cells (Murthy 2008). In the present study, CChstimulated PI-specific phospholipase C (PLC) activity (PI hydrolysis) in the presence of m2
receptor antagonist methoctramine (0.1 µM) was measured as readout of m3-coupled G q activity.
Incubation of freshly dispersed smooth muscle cells from rabbit stomach with CCh (0.1 µM) in
the presence of methoctramine (0.1 µM) caused a significant increase in PI hydrolysis
(3,075±532 cpm/mg protein) compared to the basal PI hydrolysis (400±83 cpm/mg protein). The
increase in PI hydrolysis was significantly inhibited in the presence of selective m3 receptor
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antagonist 4-DAMP (843±121 cpm/mg protein; 84±5% decrease compared to control CCh
response, p<0.001). Pretreatment of cells with U73122 (1 µM), a selective inhibitor of PI
hydrolysis blocked CCh-induced increase in PI hydrolysis (87±6% inhibition, p<0.001) (Fig. 3).

III. 2b. G 13 -coupled muscarinic m3 receptor signaling
Acetylcholine was shown previously to stimulate RhoA and RhoA-dependent Rho kinase
activity via Gα 13 in dispersed intestinal smooth-muscle cells (Murthy, Zhou et al. 2003). In the
present study, stimulation of Rho kinase and zipper interacting protein (ZIP) kinase activity in
response to CCh was measured as readout of m3-coupled G 13 activity.
Rho kinase. Incubation of freshly dispersed gastric smooth muscle cells with CCh (0.1
µM) for 10 min caused a significant stimulation of Rho kinase activity (33,582±2412 cpm/mg
protein) compared to basal activity (9,006±1683 cpm/mg protein). Pretreatment of cells with
Y27632 (1 µM), the specific inhibitor of Rho kinase blocked the increase in Rho kinase activity
(88±5% inhibition, p<0.001). Pretreatment of cells with 4-DAMP (0.1 µM) also blocked the
increase in Rho kinase activity in response to CCh (12,649±1443 cpm/mg protein; 85±7%
decrease compared to CCh response, p<0.001), whereas pretreatment of cells with
methoctramine (0.1 µM) had no significant effect on the increase in Rho kinase activity
(30,829±3406 cpm/mg protein; 9±6% inhibition) (Fig. 4). These results suggest that CChstimulated Rho kinase activity was mediated via m3 receptors.
ZIP kinase. Incubation of freshly dispersed smooth muscle cells with CCh (0.1 µM) for
10 min caused a significant stimulation of ZIP kinase activity (21,328±2757 cpm/mg protein)
compared to basal activity (4,446±1207 cpm/mg protein). Pretreatment of cells with Y27632 (1
µM), the specific inhibitor of Rho kinase significantly inhibited the increase in ZIP kinase
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activity (7,467±1397 cpm/mg protein; 83±6% inhibition, p<0.001). These results suggest that
ZIP kinase activity is downstream of Rho kinase activity. Pretreatment of cells with 4-DAMP
blocked the increase in ZIP kinase activity in response to CCh (7,610±1192 cpm/mg protein;
80±5% decrease compared to CCh response, p<0.001), whereas pretreatment of cells with
methoctramine (0.1 µM) had no significant effect on the increase in ZIP kinase activity
(21,549±2868 cpm/mg protein) (Fig. 5). These results suggest that CCh-stimulated ZIP kinase
activity was mediated via m3 receptors and is dependent on stimulation of Rho kinase activity.

III. 2c. G i -coupled muscarinic m2 receptor signaling
Previous studies in vascular and visceral smooth muscle have shown that ACh interacts
with Gi-coupled m2 receptors and inhibits adenylyl cyclase activity (Zhang, Horowitz et al.
1991; Murthy and Makhlouf 1997; Hakonarson and Grunstein 1998). In the present study,
inhibition of forskolin-stimulated cAMP formation was measured as readout of m2-coupled G i
activity. Forskolin (10 µM) caused an increase in cAMP formation in dispersed muscle cells
(24.0±2.3 pmol/mg protein) compared to basal levels of cAMP (2.5±0.5 pmol/mg protein). The
increase in cAMP by forskolin (10 µM) was significantly inhibited (8.0±1.7 pmol/mg protein;
74±3% inhibition, p<0.001) in the presence of CCh (0.1 µM), and the inhibition was
significantly reversed by pretreatment of cells with methoctramine (0.1 µM) (9±4% inhibition),
whereas pretreatment of cells with 4-DAMP had no significant effect on the inhibition of cAMP
formation (67±7% inhibition) (Fig. 6). Pretreatment of muscle cells with PTx (400 ng/ml)
abolished the inhibitory effect of CCh on cAMP formation consistent with the stimulation of G i
proteins by m2 receptor activation (23.5±3.2 pmol/mg protein; 4±2% inhibition, NS) (Fig. 6).
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III. 2d. m3 receptor-mediated muscle contraction
As shown previously in intestinal muscle, treatment of dispersed muscle cells with CCh (0.1
µM) for 30 s caused muscle contraction (28±3% decrease in muscle cell length from basal
muscle cell length of 112±4 µm) (Murthy, Zhou et al. 2003). Pretreatment of muscle cells with
4-DAMP (0.1 µM) abolished CCh-induced contraction (4±2% decrease in cell length), whereas
pretreatment of cells with methoctramine (0.1 µM) had no significant effect on muscle
contraction (25±3% decrease in cell length) (Fig. 7). These results are consistent with the
previous reports demonstrating selective involvement of m3 receptors in smooth muscle
contraction. More than 90% of the contraction in response to CCh was blocked in
gastrointestinal and urinary bladder muscle from m3 receptor knockout (KO) mice, whereas
contraction was minimally affected in m2 receptor KO mice (Stengel, Yamada et al. 2002).
In summary, gastric muscle cells express both m2 and m3 receptors: expression of m2
receptors was more abundant than m3 receptors. Carbachol, acting via m3 receptors caused
stimulation of PI hydrolysis, Rho kinase and ZIP kinase activity, and induced muscle
contraction, and acting via m2 receptors caused inhibition of forskolin-stimulated cAMP
formation (Fig. 8.).
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Fig. 1. Selective expression of muscarinic m2 and m3 receptors in gastric smooth muscle
cells.
Upper panel: mRNA Expression: Total RNA was isolated from cultured gastric smooth
muscle cells (first passage) and reverse transcribed using 2µg of total RNA. The cDNA was
amplified with specific primers for different muscarinic receptor subtypes m1 to m4.
Experiments were done in the presence or absence of reverse transcriptase (RT). PCR products
corresponding to m2 and m3 receptor were obtained with the specific primers and further
confirmed with control cDNAs. Primers corresponding to m1 and m4 receptors did not amplify
any specific bands from RNA isolated from muscle cells, but amplified a specific product from
control cDNA. Results show representative PCR products separated by electrophoresis in
agarose gel containing ethidium bromide and visualized under a chemiImager fluorescence
system.
Lower panel: Protein expression: Freshly dispersed mucle cells were homogenized in
lysis buffer and lysates containing equal amounts of total proteins were separated on SDS-PAGE
and the expression of muscarinic receptors was analysed using selective antibody to m2 (1:1000)
and m3 (1:1000) receptors and the band corresponding to 52 kDa and 66 kDa, respectively was
detected by chemiluminiscence. The representative western blot shows the presence of
muscarinic m2 and m3 receptors.
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Fig.2. Selective expression of muscarinic m2 and m3 receptors by radioligand binding
studies.
Freshly dispersed gastric smooth muscle cells were incubated with [3H]scopolamine for 15
minutes at room temperature and the amount of radioactive [3H]scopolamine bound to cells was
measured by liquid scintillation. Specific binding was measured as the difference between the
total binding (cpm/mg protein) measured in the absence of 10 µM carbachol (CCh) and nonspecific binding (cpm/mg protein) measured in the presence of 10 µM CCh. Cells were incubated
in the presence of 4-DAMP (0.1 µM) to measure binding to m2 receptors or in the presence of
methoctramine (0.1 µM) to measure binding to m3 receptors. Results are expressed as % specific
binding. Values are means ± S.E of 5 experiments.
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Fig. 3. m3 receptor-dependent stimulation of phosphoinositide (PI) hydrolysis in gastric
muscle
Freshly dispersed muscle cells labelled with myo-[3H]inositol were incubated with carbachol
(CCh; 0.1 µM) plus methoctramine (0.1 µM) for 60 seconds. In some experiments cells were
pretreated with 4-DAMP (0.1 µM) or the selective PI hydrolysis inhibitor U73122 (1 µM) for 10
min. Total [3H]inositol phosphates were separated by ion-exchange chromatography and
radioactivity counted by liquid scintillation. Results are expressed as total [3H]inositol phosphate
formation in cpm/mg protein. Values are means ± S.E. of 4 experiments. ** Significant increase
in response to CCh (P<0.001).
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Fig. 4. m3 receptor-dependent stimulation of Rho Kinase activity in gastric muscle.
Freshly dispersed gastric muscle cells were incubated with carbachol (CCh, 0.1 µM) for 10 min
in the presence or absence of 4-DAMP (0.1 µM), methoctramine (0.1 µM), or the selective Rho
kinase inhibitor Y27632 (1 µM). Rho kinase activity was measured using [γ-32P]ATP by
immunokinase assay. Rho kinase activity was stimulated by CCh and inhibited by 4-DAMP and
Y27632, but not by methoctramine. Results are expressed as cpm/mg protein. Values are means
± S.E of 5 experiments. ** Significant increase in response to CCh (P<0.001).

63

64

Fig. 5. m3 receptor-dependent stimulation of zipper interacting protein (ZIP) Kinase
activity in gastric muscle.
Freshly dispersed gastric muscle cells were incubated with carbachol (CCh, 0.1 µM) for 10 min
in the presence or absence of 4-DAMP (0.1 µM), methoctramine (0.1 µM), or the selective Rho
kinase inhibitor Y27632 (1 µM). ZIP kinase activity was measured using [γ-32P]ATP by
immunokinase assay. ZIP kinase activity was stimulated by CCh and inhibited by 4-DAMP and
Y27632, but not by methoctramine. Results are expressed as cpm/mg protein. Values are means
± S.E of 5 experiments. ** Significant increase in response to CCh (P<0.001).
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Fig. 6. m2 receptor-dependent inhibition of adenylyl cyclase activity in gastric muscle.
Adenylyl cyclase activity was measured as cAMP formation in freshly dispersed muscle cells in
the presence of 100 µM isobutylmethylxanthine (IBMX).

Muscle cells were treated with

forskolin (FSK, 10 µM) in the presence or absence of CCh (0.1 µM) for 60 s and cAMP was
measured by radioimmunoassay. In some experiments, cells were pre treated with 4-DAMP or
methoctramine for 10 min or pertussis toxin (400 ng/ml) for 60 min, and then treated with
forskolin (10 µM) and CCh for 60 s. Results are computed from a standard curve using Prizm@
and expressed as pmol cAMP/mg protein. Values are means ± S.E. of 4 experiments. **
Significant inhibition of forskolin-stimulated cAMP formation (P<0.001).
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Fig.7. m3 receptor-dependent muscle contraction in gastric muscle.
Freshly dispersed gastric smooth cells were treated separately with CCh (0.1 µM) for 30 s. The
mean length of 50 muscle cells was measured by scanning micrometry and was compared with
the length of untreated muscle cells. In some experiments, cells were pre treated with 4-DAMP or
methoctramine for 10 min or pertussis toxin (PTx, 400 ng/ml) for 60 min, and then treated with
CCh for 30 s. Results were expressed as percent decrease in cell length from control length
(112±4 µm). Values are means ± S.E of 6 experiments. ** Significant decrease in muscle cell
length in response to CCh (P<0.001).
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Fig 8: Signaling pathways activated by m2 and m3 receptors in gastric muscle cells.
Gastric muscle cells express m2 and m3 receptors. m2 receptors are coupled to inhibition of
adenylyl cyclase (AC) activity and cAMP formation via a pertussis toxin (PTx)-sensitive G
protein, whereas m3 receptors are coupled to stimulation of PI hydrolysis and Rho kinase and
ZIP kinase activity via PTx-insensitive G protein(s), and muscle contraction.
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III. 3. Regulation of G q -coupled muscarinic m3 receptor signaling by caveolae and
caveolin-1.
Mature contractile smooth muscle is characterized by the presence of abundant
caveolae. Recent in vitro and in vivo studies from several investigators suggest that caveolae and
caveolins modulate vascular and visceral smooth muscle function (Hardin and Vallejo 2006).
The role of caveolae/caveolin-1 in the regulation of muscarinic signaling was examined using
three complimentary approaches: a) methyl β-cyclodextrin (MβCD) treatment to deplete
cholesterol in dispersed muscle cells, b) caveolin-1 siRNA to suppress caveolin-1 expression in
cultured muscle cells, and c) caveolin-1 knockout (KO) mice.
Expression of caveolin-1 and caveolin-3 were examined by qRT-PCR using specific
primers. mRNA expression of caveolin-1 was nearly 13-fold higher than caveolin-3 in gastric
smooth muscle (Fig. 9). This is consistent with previous studies in both visceral and airway
smooth muscle showing that the relative mRNA expression levels were 15:1:1 for caveolin-1,
caveolin-2 and cavelolin-3, respectively (Shakirova, Bonnevier et al. 2006).

III. 3a. Inhibition of carbachol-stimulated PI hydrolysis by methyl β-cyclodextrin.
Freshly dispersed gastric smooth muscle cells labeled with [3H]myo-inositol were divided
into control and experimental group. The control group was incubated with DMSO and the
experimental group was incubated with methyl β-cyclodextrin (MβCD) (10 mM) each for 30
min. Previous studies have demonstrated that treatment of several types of cells with MβCD
depletes cholesterol and disrupts caveolae (Patel, Murray et al. 2008). After 30 min, cells were
treated with CCh (0.1 µM) for 1 min in the presence of the m2 receptor antagonist
methoctramine (0.1 µM) and PI hydrolysis was measured as described in Methods. The basal
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levels of PI hydrolysis in both groups are similar (366±88 cpm/mg protein in control cell vs.
305±62 cpm/mg protein in cells treated with MβCD). Treatment of control cells with CCh (0.1
µM) caused a significant increase in PI hydrolysis (2,566±394 cpm/mg protein; 603±54%
increase above basal). Carbachol (0.1 µM) also caused an increase in PI hydrolysis in cells
treated with MβCD (1,381±95 cpm/mg protein; 352±38% increase above basal); however, the
increase was significantly attenuated (42±3% inhibition, p<0.01) compared to CCh response in
control cells (Fig. 10). The selective PI-specific PLC inhibitor, U73122 (1 µM) blocked CChstimulated PI hydrolysis in both control cells and in cells treated with MβCD to a similar extent
(Fig. 10). These results suggest that caveolae positively regulates G q -mediated PI hydrolysis in
gastric smooth muscle.

III. 3b. Inhibition of carbachol-stimulated PI hydrolysis by caveolin-1 siRNA.
Primary culture of gastric smooth muscle cells were transfected with control pSIRENDNR-DsRed vector and pSIREN-DNR-DsRed vector containing caveolin-1 specific siRNA for
48 h. Suppression of caveolin-1 expression was verified by western blot analysis and
immunofluorescence. After plasmid transfection, cultured cells were labeled with [3H] myoinositol, and then treated with the contractile agonist CCh (0.1 µM) in the presence of m2
receptor antagonist methoctramine (0.1 µM) for 1 min to measure PI hydrolysis. The basal levels
of PI hydrolysis in both groups were similar (396±75 cpm/mg protein in control cell vs. 343±113
cpm/mg in cells treated with caveolin-1 siRNA). Treatment of control cells with CCh (0.1 µM)
caused a significant increase in PI hydrolysis (2,813±288 cpm/mg protein; 610±8% increase
above basal, p<0.001). Carbachol also caused an increase in PI hydrolysis in cells transfected
with caveolin-1 siRNA (1,470±243 cpm/mg protein; 328±5% increase above basal); however,
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the increase was significantly attenuated (46±4% inhibition, p<0.01) compared to CCh response
in control cells (Fig. 11). The selective PI-specific PLC inhibitor, U73122 (1 µM) blocked CChstimulated PI hydrolysis in both control cells and in cells transfected with caveolin-1 siRNA
(Fig. 11). These results suggest that caveolin-1 positively regulates G q -mediated PI hydrolysis in
gastric smooth muscle.

III. 3c. Inhibition of carbachol-stimulated PI hydrolysis by caveolin-1 KO.
Gastric muscle was isolated from wild type and caveolin-1 KO mice and labeled with
[3H] myo-inositol for 4 h and then treated with CCh (0.1 µM) in the presence of m2 receptor
antagonist methoctramine (0.1 µM) for 1 min to measure PI hydrolysis. The basal levels of PI
hydrolysis in gastric muscle from wild type (WT) and caveolin-1 KO mice were similar
(457±104 cpm/mg protein in WT mice vs. 384±97 cpm/mg protein in caveolin-1 KO mice).
Treatment of muscle from wild type mice with CCh caused a significant increase in PI
hydrolysis (2,714±191cpm/mg protein: 500±15% increase above basal, p<0.001). Carbachol also
caused an increase in PI hydrolysis in muscle from caveolin-1 KO mice (1,577±218 cpm/mg
protein; 310±18% increase above basal, p<0.001), however, the increase was significantly
attenuated (38±7% inhibition, p<0.01) compared to CCh response in wild type mice (Fig. 12).
U73122 (1 µM) blocked CCh-stimulated PI hydrolysis in both wild type and caveolin-1 KO
mice. These results provide conclusive evidence that caveolin-1 positively regulates G q mediated PI hydrolysis in gastric muscle.
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III. 3d. Inhibition of carbachol-stimulated initial MLC 20 phosphorylation and muscle
contraction by MβCD and caveolin-1 KO.
Previous studies in gastrointestinal muscle have shown that initial contraction is mediated
by stimulation of PI hydrolysis, generation of IP 3 , IP 3 -dependnet Ca2+ release, and
Ca2+/calmodulin-dependent activation of MLCK and phosphorylation of MLC 20 at Ser19 (Murthy
2006). Since there is decrease in PI hydrolysis by disruption of caveolae with MβCD, we tested
the effect of MβCD on CCh-induced MLC 20 phosphorylation and contraction in freshly
dispersed muscle cells. MLC 20 phosphorylation was measured by in-cell western using phosphospecific (Ser19) antibody. Treatment of cells with CCh (0.1 µM) significantly increased MLC 20
phosphorylation (210±36% increase, p<0.001). Carbachol also caused an increase in MLC 20
phosphorylation in cells treated with MβCD (114±35% increase, p<0.001); however, the increase
was significantly attenuated (46±9% inhibition, p<0.01) compared to CCh response in control
cells (Fig. 13).
Treatment of cells with MβCD (10 mM) had no significant effect on basal muscle cell
length (control: 115±4 µm vs. MβCD treated: 111±5 µm). Consistent with the increase in PI
hydrolysis and MLC 20 phosphorylation, treatment of freshly dispersed muscle cell with CCh (0.1
µM) induced muscle contraction (29±3% decrease in muscle cell length). Carbachol also caused
muscle contraction in cells treated with MβCD (14±1% decrease in cell length); however,
contraction was significantly attenuated (51±4±% inhibition, p<0.01) compared to CCh response
in control cells (Fig. 14). MβCD induced decrease in muscle contraction is consistent with its
inhibitory effect on CCh-induced PI hydrolysis and MLC 20 phosphorylation in dispersed muscle
cells. The specific involvement of caveolin-1 in CCh-induced muscle contraction was examined
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using caveolin-1 KO mice. Basal lengths of gastric muscle cells isolated from WT mice were
similar to that of caveolin-1 KO mice (WT: 92±5 µm; KO: 98±4 µm). Carbachol (0.1 µM)
caused a significant contraction (29±2% decrease in muscle cell length) in gastric muscle cells
isolated from WT mice that was similar to contraction in isolated rabbit gastric muscle cells
(29±3% decrease in cell length). Carbachol (0.1 µM) also caused muscle contraction in muscle
cells isolated from caveolin-1 KO mice (16±2% decrease in muscle cell length), however,
contraction was significantly attenuated (44±4% inhibition, p<0.01) compared to CCh response
in WT mice, and the attenuation was similar to that obtained in rabbit gastric muscle cells treated
with MβCD, suggesting that caveolin-1 positively regulates initial Ca2+-dependent muscle
contraction (Fig. 14).
In summary, stimulation of PI hydrolysis, MLC 20 phosphorylation and muscle
contraction in response to CCh was attenuated in dispersed cells treated with MβCD or in
cultured cells transfected with caveolin-1 siRNA. Similar inhibition of PI hydrolysis and muscle
contraction was obtained in gastric muscle cells from caveolin-1 KO mice compared to gastric
muscle cells of WT mice. These results suggest that caveolin-1 positively regulates G q -coupled
m3 receptor signaling.
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Fig. 9. Expression of caveolin-1 and -3 in gastric smooth muscle.
Total RNA was isolated from cultured gastric smooth muscle cells (first passage) using
RNAqueous kit (Ambion, Austin, TX). The RNA was subsequently treated with DNAase and
reverse transcribed using 2µg of total RNA by qScript cDNA prep kits (Quanta, Gaithersburg,
MD). The cDNA prepared was used for quantitative real-time PCR (qRT-PCR) to measure realtime expression levels of caveolin-1 and 3 transcripts. For each cDNA sample, a 20 µl reaction
volume was prepared using QuantitectTM SYBRgreen PCR mastermix (Qiagen, Mississauga,
ON). Real-time PCR reaction mixtures were prepared in triplicates. Each primer set yielded only
one PCR product whose identity and integrity was confirmed by sequence analysis of the
individual bands. Standard curves were generated from a dilution series of cDNA and the data
was quantified using 2∆∆Ct method based on GAPDH amplification. The GAPDH thresholds
remain constant. Relative quantification of a target gene in relation to a reference gene was
calculated on the basis of delta delta CT values. Results demonstrated that caveolin-1 expression
was 15 folds higher than caveolin-3 isoform. Values are means ± S.E of three experiments.
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Fig.10. Inhibition of carbachol-stimulated PI hydrolysis by methyl β-cyclodextrin.
Freshly dispersed gastric smooth muscle cells were labelled with [3H]myo-inositol and divided
into control and experimental group. The control group was incubated with DMSO and the
experimental group was incubated with methyl β-cyclodextrin (MβCD) (10 mM) each for 30
min. After 30 min, cells were treated with CCh (0.1 µM) plus methoctramine (0.1 µM) for 60 s.
In some experiments cells were pretreated with a selective PI hydrolysis inhibitor U73122 (1
µM) for 10 min and then with CCh plus methoctramine. PI hydrolysis (formation of water
soluble [3H]inositols) was measured as formation of water soluble [3H]inositol phosphates by
ion exchange chromatography and the radioactivity counted by liquid scintillation. Results are
expressed as cpm/mg protein. Values are means ± S.E of three experiments. ## Significant
inhibition of CCh response in MβCD treated cells compared to CCh response in control cells
(P<0.01).
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Fig. 11. Inhibition of carbachol-stimulated PI hydrolysis by caveolin-1 siRNA.
Primary culture of gastric smooth muscle cells were transfected with control pSIREN-DNRDsRed vector and pSIREN-DNR-DsRed vector containing caveolin-1 specific siRNA for 48 h.
After plasmid transfection, cultured cells were labeled with [3H]myo-inositol, and then treated
with CCh (0.1 µM) plus methoctramine (0.1 µM) for 60 s. In some experiments, cell were
pretreated with a selective PI hydrolysis inhibitor U73122 (1 µM) for 10 min and then treated
with CCh plus methoctramine. PI hydrolysis (formation of water soluble [3H] inositols) was
measured as formation of water soluble [3H]inositol phosphates by ion exchange
chromatography and the radioactivity counted by liquid scintillation. Results are expressed as
cpm/mg protein. Values are means ± S.E of three experiments. ## Significant inhibition of CCh
response in cells trasnfected with caveolin-1 siRNA compared to CCh response in cells
transfected with vector alone (P<0.01). Inset showing transfection of siRNA verified by
immunofluorescence and knockdown of caveolin-1 expression by caveolin-1 siRNA verified by
western blot analysis.
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Fig.12. Inhibition of carbachol-stimulated PI hydrolysis by caveolin-1 KO.
Gastric muscle isolated from wild type and caveolin-1 KO mice were labelled with [3H]myoinositol and then treated with CCh (0.1 µM) plus methoctramine (0.1 µM) for 60 s. In some
experiments cell were pretreated with a selective PI hydrolysis inhibitor U73122 (1µM) for 10
min and then treated with CCh plus methoctramine. PI hydrolysis (formation of water soluble
[3H] inositols) was measured as formation of water soluble [3H]inositol phosphates by ion
exchange chromatography and the radioactivity counted by liquid scintillation. Results are
expressed as cpm/mg protein. Values are means ± S.E of three experiments. ## Significant
inhibition of CCh response in caveolin-1 KO mice compared to CCh response in wild type mice
(P<0.01).
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Fig. 13. Inhibition of carbachol-stimulated initial MLC 20 phosphorylation by MβCD
Primary culture of gastric smooth muscle cells was grown on a 96 well plate and divided into
control and experimental group. The control group was incubated with DMSO and the
experimental group was incubated with methyl β-cyclodextrin (MβCD) (10 mM) each for 30
min. After 30 min, wells in each group were treated with CCh (0.1µM) plus methoctramine
(0.1µM) for 30s. MLC 20 phosphorylation was measured by in-cell western using phosphospecific (Ser19) antibody. Results are expressed as percent phosphorylation. Values are means ±
S.E of three experiments. ** Significant inhibition of CCh response in MβCD treated cells
compared to CCh response in control cells (P<0.05).
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Fig. 14. Inhibition of carbachol-stimulated initial muscle contraction by MβCD and
caveolin-1 KO.
Left panel: Freshly dispersed smooth muscle cells from rabbit stomach were divided into
control and experimental group. The control group was incubated with DMSO and the
experimental group was incubated with methyl β-cyclodextrin (MβCD) (10 mM) each for 30
min. After 30 min, cells were treated with CCh (0.1 µM) plus methoctramine (0.1 µM) for 30 s.
Right panel: Gastric muscle cells were isolated from caveolin-1 KO mice and WT mice were
separately treated with CCh (0.1 µM) plus methoctramine (0.1 µM) for 30 s.
The mean length of 50 muscle cells was measured by scanning micrometry and compared
with the length of untreated muscle cells. Results were expressed as percent decrease in cell
length from control length (rabbit stomach: control (115±4 mm) and MβCD treated (111±5 µm);
mouse stomach: wild type (92±5 µm) and caveolin-1 KO (98±4 µm)). Values are means ± S.E of
5-6 experiments. ** Significant inhibition of CCh response in MβCD treated cells and in muscle
cells isolated from caveolin-1 KO mice compared to CCh response in DMSO treated cells and
muscle cells isolated from wild type mice (P<0.05).
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III. 4. Regulation of G 13 -coupled m3 receptor signaling by caveolae and caveolin-1.
Previous studies have demonstrated that muscarinic m3 receptors are coupled to
stimulation of Rho kinase and ZIP kinase activity via G 13 /RhoA (Murthy, Zhou et al. 2003).
Stimulation of Rho kinase and ZIP kinase activity in response to m3 receptor activation was
confirmed in gastric muscle cells in the present study. To examine whether caveolae and
caveolin-1 also regulated G 13 /RhoA pathway, stimulation of Rho kinase and ZIP kinase activity
in response to CCh was measured in freshly dispersed muscle cells treated in the presence or
absence of MβCD, cultured muscle cells transfected with control siRNA and caveolin-1 siRNA,
and in gastric muscle from WT and caveolin-1 KO mice.

III. 4a. Inhibition of carbachol-stimulated Rho kinase activity by methyl β-cyclodextrin.
Freshly dispersed gastric smooth muscle cells were divided into control and experimental
group. The control group was incubated with DMSO and the experimental group was incubated
with methyl β-cyclodextrin (MβCD) (10 mM) each for 30 min. After 30 min, cells were treated
with CCh (0.1 µM) for 10 min, and Rho kinase activity was measured by immunokinase assay as
described in Methods. The basal levels of Rho kinase activity in both groups are similar
(8,411±1584 cpm/mg protein in control cells vs. 8,431±1600 cpm/mg protein in cells treated
with MβCD). Treatment of control cells with CCh (0.1 µM) caused a significant increase in Rho
kinase activity (33,505 cpm/mg protein; 298±18% increase above basal, p<0.001). Carbachol
also caused an increase in Rho kinase activity in cells treated with MβCD (19,570±2039 cpm/mg
protein; 132±6% increase above basal, p<0.001), however, the increase was significantly
attenuated (54±6% inhibition, p<0.001) compared to CCh response in control cells (Fig. 15). The
selective Rho kinase inhibitor, Y27632 (1 µM) blocked CCh-stimulated Rho kinase activity in
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both control cells and in cells treated with MβCD (Fig. 15). These results suggest that caveolae
positively regulates G 13 /RhoA-mediated Rho kinase activity in gastric muscle cells.

III . 4b. Inhibition of carbachol-stimulated Rho kinase activity by caveolin-1 siRNA.
Primary culture of gastric smooth muscle cells were transfected with control pSIRENDNR-DsRed vector and pSIREN-DNR-DsRed vector containing caveolin-1 specific siRNA for
48 h. Suppression of caveolin-1 expression was verified by western blot analysis and
immunofluoresence. Muscle cells were treated with CCh (0.1 µM) for 10 min, and Rho kinase
activity was measured by immunokinase assay as descried in Methods. The basal levels of Rho
kinase activity in both groups are similar (7,582±1217 cpm/mg protein in control cells vs.
8,126±1906 cpm/mg protein in cells transfected with caveolin-1 siRNA). Treatment of control
cells with CCh caused a significant increase in Rho kinase activity (33,288±4549 cpm/mg
protein; 239±8% increase above basal, p<0.001). Carbachol (0.1 µM) also caused an increase in
Rho kinase activity in cells transfected with caveolin-1 siRNA (21,579±3842 cpm/mg protein;
165±6% increase above basal, p<0.001); however, the increase was significantly attenuated
(31±4 % inhibition, p<0.01) compared to CCh response in control cells (Fig. 16). The selective
Rho kinase inhibitor, Y27632 (1 µM), blocked CCh-stimulated Rho kinase activity in both
control cells and in cells transfected with caveolin-1 siRNA (Fig. 16). These results suggest that
caveolin-1 positively regulates G 13 /RhoA-mediated Rho kinase activity in gastric muscle cells.

III . 4c. Inhibition of carbachol-stimulated Rho kinase activity by caveolin-1 KO.
Gastric muscle was isolated from wild type and caveolin-1 knockout mice and Rho
kinase activity in response to CCh (0.1 µM) was measured by immunokinase assay. The basal
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levels of Rho kinase activity in gastric muscle from control and caveolin-1 KO mice were similar
(7460±1895 cpm/mg protein in WT mice vs. 7,150±1338 cpm/mg protein in caveolin-1 KO
mice). Treatment of muscle from WT mice with CCh (0.1 µM) caused a significant increase in
Rho kinase activity (30,033 cpm/mg protein: 302±10% increase above basal, p<0.001).
Carbachol (0.1 µM) also caused an increase in Rho kinase activity in muscle from caveolin-1
KO mice (19,090±2049 cpm/mg protein; 166 ± 5% increase above basal, p<0.001); however, the
increase was significantly attenuated (45±8% inhibition, p<0.01) compared to CCh response in
WT mice (Fig. 17). The selective Rho kinase inhibitor, Y27632 (1 µM), blocked CCh-stimulated
Rho kinase activity in both WT and caveolin-1 KO mice (Fig.17). These results provide
conclusive evidence that caveolin-1 positively regulates G 13 /RhoA-mediated Rho kinase activity
in gastric muscle.

III . 4d. Inhibition of carbachol-stimulated ZIP kinase activity by methyl β-cyclodextrin.
Freshly dispersed muscle cells incubated in the presence or absence of MβCD (10 mM)
for 30 min were treated with CCh (0.1 µM) for 10 min, and ZIP kinase activity was measured by
immunokinase assay as descried in Methods. The basal level of ZIP kinase activity was similar
in the presence or absence of MβCD (4,058±921cpm/mg protein in control cells vs. 4,039±975
cpm/mg protein in cells treated with MβCD). Treatment of control cells with CCh (0.1 µM)
caused a significant increase in ZIP kinase activity (19,726±2213 cpm/mg protein; 386±11%
increase above basal, p<0.001). Carbachol (0.1 µM) also caused an increase in ZIP kinase
activity in cells treated with MβCD (12,028±2013 cpm/mg protein; 197±12% increase above
basal, p<0.001), however, the increase was significantly attenuated (48±6% inhibition, p<0.01)
compared to CCh response in control cells (Fig. 18). The selective Rho kinase inhibitor, Y27632
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(0.1 µM) blocked CCh-stimulated ZIP kinase activity in both control cells and in cells treated
with MβCD, suggesting that ZIP kinase activity is downstream of Rho kinase activity (Fig. 18).
These results suggest that caveolae positively regulates G 13 /RhoA-mediated ZIP kinase activity
in gastric muscle cells.

III . 4e. Inhibition of carbachol-stimulated ZIP kinase activity by caveolin-1 siRNA.
Muscle cells transfected with control siRNA or caveolin-1 siRNA were treated with CCh
(0.1 µM) for 10 min, and ZIP kinase activity was measured by immunokinase assay as described
in Methods. The basal level of ZIP kinase activity was not affected by the transfection of
caveolin-1 siRNA (3,609±1016 cpm/mg protein in control cell vs. 4,206±1127 cpm/mg protein
in cells transfected with caveolin-1 siRNA). Treatment of control cells with CCh (0.1 µM)
caused a significant increase in ZIP kinase activity (21,414±3043 cpm/mg protein; 493±25%
increase above basal, p<0.001). Carbachol (0.1 µM) also caused an increase in ZIP kinase
activity in cells treated with caveolin-1 siRNA (12,507±2201 cpm/mg protein; 194±21%
increase above basal, p<0.001), however, the increase was significantly attenuated (59±6%
inhibition, p<0.01) compared to CCh response in control cells (Fig. 19). Y27632 (1 µM) blocked
CCh-stimulated ZIP kinase activity in both control cells and in cells transfected with caveolin-1
siRNA. These results suggest that caveolin-1 positively regulates G 13 /RhoA-mediated ZIP
kinase activity in gastric muscle cells.

III. 4f. Inhibition of carbachol-stimulated ZIP kinase activity by caveolin-1 KO.
Gastric muscle was isolated from wild type and caveolin-1 KO mice and ZIP kinase
activity in response to CCh (0.1 µM) was measured by immunokinase assay. The basal levels of
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ZIP kinase activity in gastric muscle from control and caveolin-1 KO mice were similar
(3,136±644 cpm/mg protein in WT mice vs. 3,515±755 cpm/mg in caveolin-1 KO mice).
Treatment of muscle from WT mice with CCh (0.1 µM) caused a significant increase in ZIP
kinase activity (18,003±2941 cpm/mg protein: 474±17% increase above basal, p<0.001).
Carbachol (0.1 µM) also caused an increase in ZIP kinase activity in muscle from caveolin-1 KO
mice (11,213±1701 cpm/mg protein; 219±16% increase above basal, p<0.001); however, the
increase was significantly attenuated (54±6% inhibition, p<0.01) compared to CCh response in
WT mice (Fig. 20). Y27632 (1 µM) blocked CCh-stimulated Rho kinase activity in both WT and
caveolin-1 KO mice (Fig. 20). These results provide conclusive evidence that caveolin-1
positively regulates G 13 /RhoA-mediated ZIP kinase activity in gastric muscle.

III. 4g. Inhibition of carbachol-stimulated MYPT1 phosphorylation and sustained muscle
contraction by MβCD and caveolin-1 KO.
Previous studies in gastrointestinal muscle have demonstrated that sustained contraction
is mediated by stimulation of Rho-dependent pathways involving phosphorylation of MYPT1
(regulatory subunit of MLC phosphatase) at Thr696 by Rho kinase/ZIP kinase and CPI-17
(endogenous MLC phosphatase inhibitor) at Thr38 by PKC. Phosphorylation of MYPT1 and CPI17 leads to inhibition of MLC phosphatase activity, increase in MLC 20 phosphorylation and
sustained muscle contraction (Murthy, Grider et al. 2000). Since there is decrease in Rho
kinase/ZIP kinase activity by disruption of caveolae with MβCD, we tested the hypothesis that
MYPT1 phosphorylation and sustained muscle contraction are positively regulated by caveolin1. The effect of MβCD (10 mM) on CCh-induced MYPT1 phosphorylation and contraction in
freshly dispersed muscle cells was examined. MYPT1 phosphorylation was measured by in-cell
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western using phospho-specific (Thr696) antibody. Treatment of cells with CCh (0.1 µM) for 10
min significantly increased MYPT1 phosphorylation (314±43% increase, p<0.001). Carbachol
also caused an increase in MYPT1 phosphorylation in cells treated with MβCD (126±15%
increase, p<0.001); however, the increase was significantly attenuated (58±10% inhibition,
p<0.01) compared to CCh response in control cells (Fig. 21).
Treatment of cells with MβCD (10 mM) had no significant effect on basal muscle cell
length (control: 115±4 µm vs. MβCD treated: 111±5 µm). Consistent with the increase in Rho
kinase and ZIP kinase activity and MYPT1 phosphorylation, treatment of freshly dispersed
muscle cell with CCh (0.1µM) induced sustained (measured at 10 min) muscle contraction
(22±3% decrease in muscle cell length). Carbachol also caused muscle contraction in cells
treated with MβCD (11±2% decrease in cell length); however, contraction was significantly
attenuated (49±3% inhibition, p<0.01) compared to CCh response in control cells (Fig. 22).
MβCD-induced decrease in muscle contraction is consistent with its inhibitory effect on CChinduced Rho kinase/ZIP kinase activity and MYPT1 phosphorylation in dispersed muscle cells.
The specific involvement of caveolin-1 in CCh-induced sustained muscle contraction was
examined using caveolin-1 KO mice. Basal lengths of gastric muscle cells isolated from WT
mice were similar to that of caveolin-1 KO mice (WT: 92±5 µm; KO: 98±4 µm). Carbachol
(0.1µM) caused a significant contraction (21±2% decrease in muscle cell length) in gastric
muscle cells isolated from WT mice that was similar to the contraction in isolated rabbit gastric
muscle cells (22±3% decrease in cell length). Carbachol (0.1 µM) also caused muscle
contraction in muscle cells isolated from caveolin-1 KO mice (13±2% decrease in muscle cell
length), however, contraction was significantly attenuated (39±3 inhibition, p<0.01) compared to
CCh response in WT mice, and the attenuation was similar to that obtained in rabbit gastric
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muscle cells treated with MβCD (Fig. 22), suggesting that caveolin-1 positively regulates RhoAdependent sustained contraction in gastric muscle.
In summary, stimulation of Rho kinase and ZIP kinase activity, MYPT1 phosphorylation
and muscle contraction in response to CCh was attenuated in dispersed cells treated with MβCD
or in cultured cells transfected with caveolin-1 siRNA. Similar inhibition of Rho kinase and ZIP
kinase activity and muscle contraction was obtained in gastric muscle cells from caveolin-1 KO
mice compared to gastric muscle cells of WT mice. These results suggest that caveolin-1
positively regulates G 13 -coupled m3 receptor signaling.
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Fig. 15. Inhibition of carbachol-stimulated Rho kinase activity by methyl β-cyclodextrin.
Freshly dispersed gastric smooth muscle cells were divided into control and experimental group.
The control group was incubated with DMSO and the experimental group was incubated with
methyl β-cyclodextrin (MβCD) (10 mM) each for 30 min. After 30 min, cells were treated with
CCh (0.1 µM) for 10 min in the presence or absence of a selective Rho kinase inhibitor Y27632
(1 µM). Rho kinase activity was measured using [γ-32P]ATP by immunokinase assay. Results are
expressed as cpm/mg protein.

Values are means ± S.E of 6 experiments. ## Significant

inhibition of CCh response in MβCD treated cells compared to CCh response in control cells
(P<0.01).
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Fig. 16. Inhibition of carbachol-stimulated Rho kinase activity by caveolin-1 siRNA.
Primary culture of gastric smooth muscle cells were transfected with control pSIREN-DNRDsRed vector and pSIREN-DNR-DsRed vector containing caveolin-1 specific siRNA for 48 h.
After plasmid transfection, cells were treated with CCh (0.1 µM) for 10 min in the presence or
absence of a selective Rho kinase inhibitor, Y27632. Rho kinase activity was measured using [γP]ATP by immunokinase assay. Results are expressed as cpm/mg protein. Values are means ±

32

S.E of 4 experiments. ## Significant inhibition of CCh response in cells transfected with
caveolin-1 siRNA compared to CCh response in cells transfected with control pSIREN-DNRDsRed vector (P<0.01).
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Fig. 17. Inhibition of carbachol-stimulated Rho kinase activity by caveolin-1 KO.
Gastric muscle isolated from wild type and caveolin-1 KO mice were treated with CCh (0.1 µM)
for 10 min in the presence or absence of Y27632 (1 µM). Rho kinase activity was measured
using [γ-32P]ATP by immunokinase assay. Results are expressed as cpm/mg protein. Values are
means ± S.E of 3 experiments. ## Significant inhibition of CCh response in caveolin-1 KO mice
compared to CCh response in wild type mice (P<0.01).

101

102

Fig. 18. Inhibition of carbachol-stimulated zipper interacting protein (ZIP) kinase activity
by methyl β-cyclodextrin.
Freshly dispersed gastric smooth muscle cells were divided into control and experimental group.
The control group was incubated with DMSO and the experimental group was incubated with
methyl β-cyclodextrin (MβCD) (10 mM) each for 30 min. After 30 min, cells were treated with
CCh (0.1 µM) for 10 min in the presence or absence of a selective Rho kinase inhibitor Y27632
(1 µM). ZIP kinase activity was measured using [γ-32P]ATP by immunokinase assay. Results are
expressed as cpm/mg protein. Values are means ± S.E of 6 experiments. ## Significant inhibition
of CCh response in MβCD treated cells compared to CCh response in control cells (P<0.01).
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Fig. 19. Inhibition of carbachol-stimulated zipper interacting protein (ZIP) kinase activity
by caveolin-1 siRNA.
Primary culture of gastric smooth muscle cells were transfected with control pSIREN-DNRDsRed vector and pSIREN-DNR-DsRed vector containing caveolin-1 specific siRNA for 48 h.
After plasmid transfection, cells were treated with CCh (0.1 µM) for 10 min in the presence or
absence of a selective Rho kinase inhibitor, Y27632. ZIP kinase activity was measured using [γP]ATP by immunokinase assay. Results are expressed as cpm/mg protein. Values are means ±

32

S.E of 4 experiments. ## Significant inhibition of CCh response in cells transfected with
caveolin-1 siRNA compared to CCh response in control cells (P<0.01).
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Fig. 20. Inhibition of carbachol-stimulated zipper interacting protein (ZIP) kinase activity
by caveolin-1 KO.
Gastric muscle isolated from wild type and caveolin-1 KO mice were treated with CCh (0.1 µM)
for 10 min in the presence or absence of Y27632 (1 µM). ZIP kinase activity was measured
using [γ-32P]ATP by immunokinase assay. Results are expressed as cpm/mg protein. Values are
means ± S.E of 3 experiments. ## Significant inhibition of CCh response in caveolin-1 KO mice
compared to CCh response in wild type mice (P<0.01).
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Fig. 21. Inhibition of carbachol-stimulated MYPT1 phosphorylation by MβCD
Primary culture of gastric smooth muscle cells was grown on a 96 well plate and divided into
control and experimental group. The control group was incubated with DMSO and the
experimental group was incubated with methyl β-cyclodextrin (MβCD) (10 mM) each for 30
min. After 30 min, wells in each group were treated with CCh (0.1 µM) for 10 min and MYPT1
phosphorylation was measured by in-cell western using phospho-specific (Thr696) antibody.
Results are expressed as percent phosphorylation. Values are means ± S.E of 4 experiments. **
Significant inhibition of CCh response in MβCD treated cells compared to CCh response in
control cells (P<0.01).
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Fig. 22. Inhibition of carbachol-stimulated sustained muscle contraction by MβCD and
caveolin-1 KO.
Left panel: Freshly dispersed smooth muscle cells from rabbit stomach were divided into
control and experimental group. The control group was incubated with DMSO and the
experimental group was incubated with methyl β-cyclodextrin (MβCD) (10 mM) each for 30
min. After 30 min, cells were treated with CCh (0.1 µM) plus methoctramine (0.1 µM) for 10
min. Right panel: Gastric muscle cells were isolated from caveolin-1 KO mice and WT mice
were separately treated with CCh (0.1 µM) plus methoctramine for 10 min.
The mean length of 50 muscle cells was measured by scanning micrometry and compared
with the length of untreated muscle cells. Results were expressed as percent decrease in cell
length from control length (rabbit stomach: control (115±4 µm) and MβCD treated (111±5 µm);
mouse stomach: wild type (92±5 µm) and caveolin-1 KO (98±4 µm)). Values are means ± S.E of
5-6 experiments. ** Significant inhibition of CCh response in MβCD treated cells and in muscle
cells isolated from caveolin-1 KO mice compared to CCh response in DMSO treated cells and
muscle cells from wild type mice (P<0.01).
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III. 5. Regulation of G i -coupled muscarinic m2 receptor signaling by caveolin-1.
Studies from our group and several others have demonstrated that muscarinic m2
receptors are coupled to inhibition of adenylyl cyclase activity (AC) via activation of Gα i
proteins. To examine whether caveolae and caveolin-1 also regulate G i -coupled adenylyl cyclase
activity, inhibition of forskolin-stimulated cAMP formation in response to CCh was measured
using three approaches mentioned above.

III. 5a. Lack of effect on m2-mediated inhibition of adenylyl cyclase activity by methyl βcyclodextrin.
Freshly dispersed gastric smooth muscle cells were divided into control and experimental
group. The control group was incubated with DMSO and the experimental group was incubated
with methyl β-cyclodextrin (MβCD) (10 mM) each for 30 min. After 30 min, cells were treated
with forskolin (10 µM) for 10 min in the presence or absence of CCh (0.1 µM), and adenylyl
cyclase activity was measured as increase in cAMP formation by radioimmunoassay as described
in Methods. The basal levels of cAMP were similar in both groups (3.9±1.2 pmol/mg protein in
control cell vs. 3.8±0.8 pmol/mg protein in cells treated with MβCD). Treatment of cells with
forskolin (10 µM) caused an increase in cAMP formation and the increase was similar in both
groups (531±34% increase above basal in control cells and 479±32% increase above basal in
cells treated with MβCD) (Fig. 23). These results suggest that caveolae has no significant effect
on adenylyl cyclase activity in gastric muscle cells. Carbachol (0.1 µM) caused a significant
inhibition of forskolin-stimulated cAMP formation in control cells (168±20% increase in cAMP
above basal, and 68±5% attenuation compared to response to forskolin alone, p<0.001) and in
cells treated with MβCD (142±16% increase above basal, and 71±6% attenuation compared to
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forskolin alone, p<0.001). The inhibition of forskolin-stimulated cAMP by CCh is similar in
control cells and in cells treated with MβCD (Fig. 23), suggesting that caveolae has no effect on
m2-coupled G i activity in gastric muscle cells.

III. 5b. Lack of effect on m2-mediated inhibition of adenylyl cyclase (AC) activity by
caveolin-1 siRNA.
Primary culture of gastric smooth muscle cells were transfected with control pSIRENDNR-DsRed vector and pSIREN-DNR-DsRed vector containing caveolin-1 specific siRNA for
48 h. Suppression of caveolin-1 expression was verified by western blot analysis and
immunofluorescence. Muscle cells were treated with forskolin (10 µM) for 10 min in the
presence or absence of CCh (0.1 µM), and adenylyl cyclase activity was measured. The basal
levels of cAMP were similar in both groups (2.7±0.8 pmol/mg protein in control cell vs. 2.5±0.6
pmol/mg protein in cells transfected with caveolin-1 siRNA). Treatment of cells with forskolin
(10 µM) caused an increase in cAMP formation and the increase was similar in both groups
(738±42% increase above basal in control cells and 682±54% increase above basal in cells
transfected with caveolin-1 siRNA) (Fig. 24). These results suggest that caveolin-1 has no
significant effect on adenylyl cyclase activity in gastric muscle cells. Carbachol caused a
significant inhibition of forskolin-stimulated cAMP formation in control cells (218±18%
increase in cAMP above basal, and 70±6% attenuation compared to response to forskolin alone,
p<0.001) and in cells transfected with caveolin-1 siRNA (221±19% increase above basal, and
67±6% attenuation compared to forskolin alone, p<0.001). The inhibition of forskolin-stimulated
cAMP by CCh is similar in control cells and in cells transfected with caveolin-1 siRNA (Fig.
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24), also suggesting that caveolin-1 has no effect on m2-coupled G i activity in gastric muscle
cells.
III. 5c. Lack of effect on m2-mediated inhibition of adenylyl cyclase (AC) activity by
caveolin-1 knockout.
Gastric muscle was isolated from wild type and caveolin-1 KO mice and inhibition of
forskolin-stimulated cAMP formation and AC activity in response to CCh (0.1 µM) was
measured. The basal levels of cAMP were similar in both groups (3.7±1.0 pmol/mg protein in
WT mice vs. 3.9±0.6 pmol/mg protein in KO mice). Treatment of cells with forskolin (10 µM)
caused an increase in cAMP formation and the increase was similar in both groups (584±35%
increase above basal in WT mice and 541±27% increase above basal in KO mice). These results
suggest that caveolin-1 has no significant effect on adenylyl cyclase activity in gastric muscle
cells. Carbachol (0.1 µM) caused a significant inhibition of forskolin-stimulated cAMP
formation in gastric cells isolated from caveolin-1 KO mice (154±12% increase in cAMP above
basal, and 73±4% attenuation compared to response to forskolin alone, p<0.001) and in cells
isolated from WT mice (143±13% increase above basal, and 72±9% attenuation compared to
forskolin alone, p<0.001) (Fig. 25). The inhibition of forskolin-stimulated cAMP by CCh is
similar in WT mice and caveolin-1 KO mice (Fig. 25), suggesting that caveolin-1 has no effect
on m2-coupled G i activity in gastric muscle cells.

In summary, activation of AC activity by forskolin or inhibition of forskolin-stimulated AC
activity by CCh was not affected in dispersed cells treated with MβCD or in cultured muscle
cells transfected with caveolin-1 siRNA. Similarly, activation of AC activity or inhibition of
forskolin-stimulated AC activity by CCh was not affected by caveolin-1 KO. These results
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suggest that caveolin-1 has no effect on G i -coupled m2 receptor signaling. This is in contrast to
the positive regulation of G q/13 -coupled m3 receptor signaling by caveolin-1.
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Fig. 23. Lack of effect on m2-mediated inhibition of adenylyl cyclase activity by methyl βcyclodextrin.
Freshly dispersed gastric smooth muscle cells were divided into control and experimental group.
The control group was incubated with DMSO and the experimental group was incubated with
methyl β-cyclodextrin (MβCD) (10 mM) each for 30 min. After 30 min, cells were treated with
forskolin (10 µM) for 10 min in the presence or absence of CCh (0.1 µM) and adenylyl cyclase
activity was measured as increase in cAMP formation by radioimmunoassay. Forskolin caused
an increase in cAMP formation and the increase was similar in both groups. Carbachol caused a
significant inhibition of forskolin-stimulated cAMP formation and the extent of inhibition was
similar in control cells and in cells treated with MβCD. Results are expressed as pmol/mg
protein. Values are means ± S.E of 4 experiments. ** Significant inhibition of forskolinstimulated cAMP formation by CCh in both control and MβCD treated cells (P<0.001).
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Fig. 24. Lack of effect on m2-mediated inhibition of adenylyl cyclase activity by caveolin-1
siRNA.
Primary culture of gastric smooth muscle cells were transfected with control pSIREN-DNRDsRed vector and pSIREN-DNR-DsRed vector containing caveolin-1 specific siRNA for 48 h.
After plasmid transfection, cells were treated with forskolin (10 µM) for 10 min in the presence
or absence of CCh (0.1 µM) and adenylyl cyclase activity was measured as increase in cAMP
formation by radioimmunoassay. Forskolin caused an increase in cAMP formation and the
increase was similar in both groups. Carbachol caused a significant inhibition of forskolinstimulated cAMP formation and the extent of inhibition was similar in control cells and in cells
transfected with caveolin-1 siRNA. Results are expressed as pmol/mg protein. Values are means
± S.E of 4 experiments. ** Significant inhibition of forskolin-stimulated cAMP by CCh in both
control and caveolin-1 siRNA transfected cells (P<0.001).
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Fig. 25. Lack of effect on m2-mediated inhibition of adenylyl cyclase (AC) activity by
caveolin-1 KO.
Gastric muscle isolated from wild type and caveolin-1 KO mice were treated with forskolin (10
µM) for 10 min in the presence or absence of CCh (0.1 µM) and adenylyl cyclase activity was
measured as increase in cAMP formation by radioimmunoassay. Forskolin caused an increase in
cAMP formation and the increase was similar in both groups. Carbachol caused a significant
inhibition of forskolin-stimulated cAMP formation and the extent of inhibition was similar in
wild type and caveolin-1 KO mice. Results are expressed as pmol/mg protein. Values are means
± S.E of 4 experiments. ** Significant inhibition of forskolin-stimulated cAMP formation by
CCh in muscle cells from both wild type and caveolin-1 KO mice (P<0.001).
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III. 6. Regulation of muscarinic m2 and m3 receptor internalization by caveolin-1.
Differential regulation of m2 and m3 receptor signaling raised the possibility that
caveolin-1 is selectively associated with m3 receptors, but not m2 receptors. To examine this
notion, association of m3 and m2 receptors with caveolin-1 was examined by western blot
analysis of muscle homogenates fractionated by sucrose density gradient centrifugation. As
shown previously caveolin-1 was selectively present in low buoyant fractions 4-5. In the unstimulated state both m2 and m3 receptors are present in high-density gradient fractions 9-12 and
absent from the caveolar fractions 4-5. However, treatment of cells with CCh for 10 min caused
translocation of m2, but not m3 receptors to caveolar fractions (Fig 26).
Since internalization of several G protein-coupled receptors utilize both clathrin and
clathrin-independent viz. caveolae-dependent pathways, we tested the hypothesis that m2
receptors are selectively internalized via caveolae-dependent pathway (Fig. 27). Internalization
was measured as decrease in radiolignad ([3H]Scopolamine) binding to surface receptors after
pretreatment of cells with CCh (0.1 µM) for 20 min. Previous studies have shown that 20-min
treatment with ligand causes maximum internalization of G protein coupled receptors such as
VAPC 2 , and CB 1 receptors (Mahavadi S 2004; Murthy, Mahavadi et al. 2008). The role of
caveolae/cavelin-1 in the regulation of internalization was examined using MβCD in freshly
dispersed muscle cells and caveolin-1 siRNA in cultured muscle cells. Limited yield of muscle
cells from control and caveolin-1 KO mice precluded the use of this approach for binding
studies. An essential step in the caveolae-dependent internalization process involves activation of
Src kinase and phosphorylation of caveolar coat proteins at Tyr14 (Fagerholm, Ortegren et al.
2009). A selective Src kinase inhibitor PP2 was used as an additional tool to examine the
caveolae-dependent pathway.
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Specific binding was calculated as the difference between binding in the absence and in
the presence (non-specific binding) of (10 µM) CCh. Binding to m2 receptors was examined in
the presence of m3 receptor antagonist, 4-DAMP (0.1 µM), whereas binding to m3 receptor was
examined in the presence of m2 receptor antagonist methoctramine (0.1 µM). Binding to m2
receptors or m3 receptors was expressed as percent of both total (m2 and m3 receptor) specific
binding.

III. 6a. Inhibition of m2 receptor internalization by methyl β-cyclodextrin.
Freshly dispersed gastric smooth muscle cells were divided into control and
experimental group. The control group was incubated with DMSO and the experimental group
was incubated with MβCD (10 mM) each for 30 min. Each group was further divided into two
sets and one set in each group was incubated with CCh (0.1 µM) for 20 min and after that the
cells are washed and used for radioligand binding studies.
Binding to m2 receptors was 68±5% of total specific binding (1,782±154 cpm/mg
protein) in control cells and 66±5% of total specific binding (1,628±186 cpm/ mg protein) in
cells treated with MβCD. These results suggest that either total binding or binding to m2
receptors was not affected by treatment of cells with MβCD. To examine m2 receptor
internalization, muscle cells were treated with CCh (0.1 µM) for 20 min, washed free of ligand,
and then binding was measured in the presence of m3 receptor antagonist 4-DAMP (0.1 µM).
Treatment of control cells with CCh attenuated binding to m2 receptors to 21±4% of total
binding (69±5% attenuation compared to control m2 receptor binding) reflecting internalization
of m2 receptors. In contract, when cells are pretreated with MβCD, CCh treatment had no
significant effect on binding to m2 receptor (62±7% of total specific binding), which is similar to
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binding to m2 receptors in the absence of CCh treatment (66±5% of total specific binding) (Fig.
28). These results suggest that m2 receptor internalization was mediated via caveolar-dependent
pathway in gastric smooth muscle.

III. 6b. Inhibition of m2 receptor internalization by caveolin-1 siRNA.
Primary culture of gastric smooth muscle cells were transfected with control pSIRENDNR-DsRed vector and pSIREN-DNR-DsRed vector containing caveolin-1 specific siRNA for
48 h. Suppression of caveolin-1 expression was verified by western blot analysis and
immunofluorescence. Each group was further divided into two sets and one set in each group
was incubated with CCh (0.1 µM) for 20 min and after that the cells are washed and used for
radioligand binding studies.
Binding to m2 receptors was 67±6% of total specific binding (1,814±205 cpm/mg
protein) in control cells and 66±3% of total specific binding (1,758±254 cpm/ mg protein) in
cells transfected with caveolin-1 siRNA. These results suggest that either total binding or
binding to m2 receptors was not affected by transfection of cells with caveolin-1 siRNA. To
examine m2 receptor internalization, muscle cells were treated with CCh (0.1 µM) for 20 min,
washed free of ligand, and then binding was measured in the presence of m3 receptor antagonist
4-DAMP (0.1 µM). Treatment of control cells with CCh (0.1 µM) attenuated binding to m2
receptors to 26±5% of total binding (61±6% attenuation compared to control m2 receptor
binding) reflecting internalization of m2 receptors. In contrast, cells transfected with caveolin-1
siRNA, CCh treatment had no significant effect on binding to m2 receptor (64±6% of total
specific binding), which is similar to binding to m2 receptors in the absence of CCh treatment

125

(67±6% of total specific binding) (Fig. 29). These results suggest that m2 receptor internalization
was mediated via caveolin-1-dependent pathway in gastric smooth muscle.

III. 6c. Inhibition of m2 receptor internalization by Src kinase inhibitor, PP2.
To examine the involvement of Src kinase in m2 receptor internalization, a selective
Src kinase inhibitor PP2 (1 µM) was used. Binding to m2 receptors was 67±8% of total specific
binding (1689±225 cpm/mg protein) in control cells and 64±5% of total specific binding
(1567±196 cpm/mg protein) in cells treated with PP2. These results suggest that either total
binding or binding to m2 receptors was not affected by PP2. Treatment of control cells with CCh
(0.1 µM) attenuated binding to m2 receptors to 25±5% of total binding (63±4% attenuation
compared to control m2 receptor binding) reflecting internalization of m2 receptors. In contrast,
cells pretreated with PP2, CCh (0.1 µM) treatment had no significant effect on binding to m2
receptor (59±7% of total specific binding), which is similar to binding to m2 receptors in the
absence of CCh treatment (67±8% of total specific binding) (Fig. 30). These results suggest that
m2 receptor internalization was mediated via caveolin-1-dependent pathway involving Src
kinase in gastric smooth muscle.

III. 6d. Lack of effect on m3 receptor internalization by methyl β-cyclodextrin.
Freshly dispersed gastric smooth muscle cells were divided into control and
experimental group. The control group was incubated with DMSO and the experimental group
was incubated with MβCD (10 mM) each for 30 min. Each group was further divided into two
sets and one set in each group was incubated with CCh (0.1 µM) for 20 min and after that the
cells were washed and used for radioligand binding studies. Binding to m3 receptors was
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examined in the presence of methoctramine (0.1 µM) and expressed as percent of total specific
binding.
Binding to m3 receptors was 30±4% of total specific binding (1,782±154 cpm/mg
protein) in control cells and 28±4% of total specific binding (1,628±186 cpm/ mg protein) in
cells treated with MβCD. These results suggest that binding to m3 receptors was not affected by
treatment of cells with MβCD. Pretreatment of control cells with CCh (0.1 µM) attenuated
binding to m3 receptors to 10±2% of total binding (66±4% attenuation compared to control m3
receptor binding) in control cells and to 11±2% of total binding (61±3% attenuation) in cell
treated with MβCD (Fig. 31). The decrease in binding to m3 receptor reflected internalization of
m3 receptors and this was not affected by MβCD, suggesting that m3 receptor internalization
was mediated via caveolae-independent pathway in gastric smooth muscle.

III. 6e. Lack of effect on m3 receptor internalization by caveolin-1 siRNA.
Primary culture of gastric smooth muscle cells were transfected with control pSIRENDNR-DsRed vector and pSIREN-DNR-DsRed vector containing caveolin-1 specific siRNA for
48 h. Suppression of caveolin-1 expression was verified by western blot analysis and
immunofluorescence. Each group was further divided into two sets and one set in each group
was incubated with CCh (0.1 µM) for 20 min and after that the cells are washed and used for
radioligand binding studies. Binding to m3 receptors was examined in the presence of
methoctramine (0.1 µM) and expressed as percent of total specific binding.
Binding to m3 receptors was 33±4% of total specific binding (1,814±205 cpm/mg
protein) in control cells and 31±2% of total specific binding (1,758±254 cpm/ mg protein) in
cells transfected with caveolin-1 siRNA. These results suggest that binding to m3 receptors were
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not affected by transfection of cells with caveolin-1 siRNA. Pretreatment of control cells with
CCh attenuated binding to m3 receptors to 10±3% of total binding (69±5% attenuation compared
to control m3 receptor binding) in control cells and to 11±3% of total binding (64±4%
attenuation) in cells transfected with caveolin-1 siRNA (Fig. 32). The decrease in binding to m3
receptor reflected internalization of m3 receptors and this was not affected by caveolin-1 siRNA,
suggesting that m3 receptor internalization was mediated via caveolin-1-independent pathway in
gastric muscle.

III. 6f. Lack of effect on m3 receptor internalization by Src inhibitor, PP2.
To examine the involvement of Src kinase in m3 receptor internalization, a selective
Src kinase inhibitor PP2 (1 µM) was used. Binding to m3 receptors was 31±4% of total specific
binding (1689±225 cpm/mg protein) in control cells and 29±4% of total specific binding
(1567±196 cpm/mg protein) in cells treated with PP2. These results suggest that binding to m3
receptors were not affected by treatment of cells with PP2. Pretreatment of control cells with
CCh (0.1 µM) attenuated binding to m3 receptors to 11±2% of total binding (64±5% attenuation
compared to control m3 receptor binding) in control cells and to 16±4% of total binding (45±5%
attenuation) in cells transfected with caveolin-1 siRNA (Fig. 33). The decrease in binding to m3
receptor reflected internalization of m3 receptors and this was minimally, but significantly,
affected by PP2, suggesting that m3 receptor internalization was partly mediated via Src kinaseindependent pathway in gastric smooth muscle.

In summary, pretreatment of muscle cells with CCh caused internalization of both m2
and m3 receptors. Internalization of m2, but not m3 receptors was blocked in dispersed cells
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treated with MβCD or in cultured muscle cells transfected with caveolin-1 siRNA. These results
suggest that caveolin-1 positively regulates m2, but not m3 receptor internalization in gastric
muscle.
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Fig. 26. Localization of muscarinic m2 and m3 receptors in caveolar and non-caveolar
fractions.
Freshly dispersed muscle cells were used for caveolae isolation using sucrose density gradient
centrifugation. After centrifugation, 1 ml fractions were collected from the top. The density of
buoyancy increases with the increase in fraction number. Equal amount of protein were subjected
to electrophoresis. Localization of caveoin-1 and m2 and m3 receptors in different fractions was
examined by western blot analysis using specific antibody. Caveolin-1 is localized in low
buoyant fraction 4-and 5. In the basal state both m2 and m3 receptors are present in high buoyant
fraction 9-12 and upon treatment of cells with CCh for 15 min, m2 but not m3 receptors are
translocated to caveolar fractions. Results shown are representative of 3 different experiments
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Fig. 27. Pathways for receptor internalization.
Internalization of G protein-coupled receptors is mediated by two major pathways: Clathrindependent pathway and clathrin-independent or caveolar-mediated pathway. Clathrin–dependent
pathway involves phosphorylation of receptors by G protein coupled receptor kinases (GRKs)
followed by binding of -arrestin to the phosphorylated receptor, recruitment of clathrin to βarresitn-bound receptors and formation of clathrin-coated pits and fission of clathrin pits with the
help of dynamin. Caveolar-mediated pathway is independent of clathrins. Following receptor
clustering in caveolar microdomains, Src mediated phosphorylation of caveolin-1 at Tyr14 leads
to caveolae-detachment and internalization of receptors.
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Fig. 28. Inhibition of m2 receptor internalization by methyl β cyclodextrin.
Freshly dispersed gastric smooth muscle cells were divided into control and experimental group.
The control group was incubated with DMSO and the experimental group was incubated with
MβCD (10 mM) each for 30 min. Each group was further divided into two sets and one set in
each group was incubated with CCh (0.1 µM) for 20 min in the presence of 4-DAMP (0.1 µM)
to induce m2 receptor internalization. The cells are washed and incubated with [3H]Scopolamine
in the absence of 4-DAMP to measure binding to both m2 and m3 receptors (total) or in the
presence of 4-DAMP to measure binding to m2 receptors. Specific binding was calculated as the
difference between the binding in the absence of CCh and non-specific binding in the presence
of 10 µM CCh. Decrease in specific binding after CCh pretreatment represents receptor
internalization. Results are expressed as percent of total (m2 and m3) specific binding. Values
are means ± S.E of three experiments. ** Significant decrease in binding compared to control
binding in the absence of CCh pretreatment (P<0.001).
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Fig. 29. Inhibition of m2 receptor internalization by caveolin-1 siRNA.
Primary culture of gastric smooth muscle cells were transfected with control pSIREN-DNRDsRed vector and pSIREN-DNR-DsRed vector containing caveolin-1 specific siRNA for 48 h.
Each group was further divided into two sets and one set in each group was incubated with CCh
(0.1 µM) for 20 min in the presence of 4-DAMP (0.1 µM) to induce m2 receptor internalisation.
The cells are washed and incubated with [3H]Scopolamine in the absence of 4-DAMP to
measure binding to both m2 and m3 receptors (total) or in the presence of 4-DAMP to measure
binding to m2 receptors. Specific binding was calculated as the difference between the binding in
the absence of CCh and non-specific binding in the presence of 10 µM CCh. Decrease in specific
binding after CCh pretreatment represents receptor internalization. Results are expressed as
percent of total (m2 and m3) specific binding. Values are means ± S.E of three experiments. **
Significant decrease in binding compared to control binding in the absence of CCh pretreatment
(P<0.001).
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Fig. 30. Inhibition of m2 receptor internalization by Src kinase inhibitor, PP2.
Freshly dispersed gastric smooth muscle cells were divided into control and experimental group.
The control group was incubated with DMSO and the experimental group was incubated with a
selective Src kinase inhibitor PP2 (1 µM). Each group was further divided into two sets and one
set in each group was incubated with CCh (0.1 µM) for 20 min in the presence of 4-DAMP (0.1
µM) to induce m2 receptor internalisation. The cells are washed and incubated with
[3H]scopolamine in the absence of 4-DAMP to measure binding to both m2 and m3 receptors
(total) or in the presence of 4-DAMP to measure binding to m2 receptors. Specific binding was
calculated as the difference between the binding in the absence of CCh and non-specific binding
in the presence of 10 µM CCh. Decrease in specific binding after CCh pretreatment represents
receptor internalization. Results are expressed as percent of total (m2 and m3) specific binding.
Values are means ± S.E of three experiments. ** Significant decrease in binding compared to
control binding in the absence of CCh pretreatment (P<0.001).

138

139

Fig. 31. Lack of effect on m3 receptor internalization by methyl β cyclodextrin.
Freshly dispersed gastric smooth muscle cells were divided into control and experimental group.
The control group was incubated with DMSO and the experimental group was incubated with
MβCD (10 mM) each for 30 min. Each group was further divided into two sets and one set in
each group was incubated with CCh (0.1 µM) for 20 min in the presence of methoctramine (0.1
µM) to induce m3 receptor internalisation. The cells are washed and incubated with
[3H]Scopolamine in the absence of methoctramine to measure binding to both m2 and m3
receptors (total) or in the presence of methoctramine to measure binding to m3 receptors.
Specific binding was calculated as the difference between the binding in the absence of CCh and
non-specific binding in the presence of 10 µM CCh. Decrease in specific binding after CCh
pretreatment represents receptor internalization. Results are expressed as percent of total (m2 and
m3) specific binding. Values are means ± S.E of three experiments. ** Significant decrease in
binding compared to control binding in the absence of CCh pretreatment (P<0.001).
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Fig. 32. Lack of effect on m3 receptor internalization by caveolin-1 siRNA.
Primary culture of gastric smooth muscle cells were transfected with control pSIREN-DNRDsRed vector and pSIREN-DNR-DsRed vector containing caveolin-1 specific siRNA for 48 h.
Each group was further divided into two sets and one set in each group was incubated with CCh
(0.1 µM) for 20 min in the presence of methoctramine (0.1 µM) to induce m3 receptor
internalisation. The cells are washed and incubated with [3H]Scopolamine in the absence of
methoctramine to measure binding to both m2 and m3 receptors (total) or in the presence of
methoctramine to measure binding to m3 receptors. Specific binding was calculated as the
difference between the binding in the absence of CCh and non-specific binding in the presence
of 10 µM CCh. Decrease in specific binding after CCh pretreatment represents receptor
internalization. Results are expressed as percent of total (m2 and m3) specific binding. Values
are means ± S.E of three experiments. ** Significant decrease in binding compared to control
binding in the absence of CCh pretreatment (P<0.001).
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Fig. 33. Lack of effect on m3 receptor internalization by Src inhibitor, PP2.
Freshly dispersed gastric smooth muscle cells were divided into control and experimental group.
The control group was incubated with DMSO and the experimental group was incubated with a
selective Src kinase inhibitor PP2 (1 µM). Each group was further divided into two sets and one
set in each group was incubated with CCh (0.1 µM) for 20 min in the presence of methoctramine
(0.1 µM) to induce m3 receptor internalisation. The cells are washed and incubated with
[3H]Scopolamine in the absence of methoctramine to measure binding to both m2 and m3
receptors (total) or in the presence of methoctramine to measure binding to m3 receptors.
Specific binding was calculated as the difference between the binding in the absence of CCh and
non-specific binding in the presence of 10 µM CCh. Decrease in specific binding after CCh
pretreatment represents receptor internalization. Results are expressed as percent of total (m2 and
m3) specific binding. Values are means ± S.E of three experiments. ** Significant decrease in
binding compared to control binding in the absence of CCh pretreatment (P<0.001).

144

145

III. 7. Regulation of excitation-transcription coupling by caveolin-1.
Modulation of smooth muscle phenotype occurs as results of modulation of signaling
pathways that regulate smooth muscle contractile proteins such as smooth muscle γ-actin (SM-γ
actin), SM-myosin heavy chain (SM-MHC), calponin, and caldesmon. Expression of contractile
proteins is regulated by the key transcriptional factors such as serum response factor (SRF) and
transcriptional co-activators such as myocardin (Pipes, Creemers et al. 2006). The Ca2+ and
RhoA/Rho kinase pathways have been associated with the regulation of SRF/myocardin activity.
Recent studies have revealed that the number of caveolae, and their marker protein caveolin-1 is
greatly increased as smooth muscle cells acquire a contractile phenotype (Gosens, Stelmack et al.
2011) (Fig. 34). Since there is decrease in RhoA/Rho kinase pathway with caveolin-1
suppression, we tested the hypothesis that caveolin-1 positively regulates contractile protein
expression in smooth muscle. Expression of SRF, myocardin, γ-actin and caldesmon was
measured by real time RT-PCR and western blot in cultured muscle cells transfected with control
siRNA or caveolin-1 siRNA. mRNA expression of contractile proteins such as γ-actin and
caldesmon (Fig. 36) and the transcription factors SRF (% inhibition) and myocardin (%
inhibition) (Fig. 35) are significantly inhibited in cells transfected with caveolin-1 siRNA
compared to cells transfected with control siRNA. This inhibition of mRNA expression
paralleled inhibition of protein expression of γ-actin, caldesmon, SRF and myocardin in cells
transfected with caveolin-1 siRNA compared to cells transfected with control siRNA. These
results suggest that a positive regulation of contractile proteins expression and the transcription
factors that regulate contractile protein expression is exerted by caveolin-1 in gastric smooth
muscle. The decrease in the expression of contractile proteins by caveolin-1 suppression is
accompanied by an increase in proliferative signals such as epidermal growth factor receptor
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phosphorylation and ERK1/2 activity. Basal level of EGF receptor phosphorylation was
significantly higher (65±13% increase) in cells transfected with caveolin-1 siRNA. Treatment
with EGF caused a significant increase (138±18% increase above basal levels, p<0.01) in EGF
receptor phosphorylation in control cells. The effect of EGF was significantly augmented in cells
transfected with caveolin-1 siRNA (218±21% increase above basal, 58±6% augmentation
compared to EGF response in control cells) (Fig. 37). Consistent with increase in EGF receptor
phosphorylation, basal ERK1/2 activity was significantly higher in cells transfected with
caveolin-1 siRNA (control cells 1430±138 cpm/mg protein; 2336±351 cpm/mg protein; 62±4%
increase, p<0.01). Treatment with EGF caused a significant increase (151±13% increase above
basal levels, p<0.01) in ERK1/2 activity in control cells. The effect of EGF was significantly
augmented in cells transfected with caveolin-1 siRNA (235±21 increase above basal, 57±4%
augmentation compared to EGF response in control cells) (Fig. 38).

In summary, expression of contractile proteins, γ-actin and caldesmon and the
transcription factors SRF and myocardin that regulate the expression of contractile proteins are
down regulated in cells transfected with caveolin-1 siRNA. This is accompanied by an increase
in basal and EGF-stimulated EGF receptor phosphorylation and ERK1/2 activity in cells
transfected with caveolin-1siRNA. These results suggest that caveolin-1 negatively regulates
proliferative phenotype and positively regulates contractile phenotype in gastric muscle.
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Fig. 34. Excitation-contraction coupling in smooth muscle.
Expression of smooth muscle specific genes is essential for maintaining its contractile
phenotype. Ca2+ and RhoA-dependent signaling pathways positively regulate the expression of
smooth muscle specific genes through transcription factors such as serum response factor (SRF)
and myocardin that selectively binds to CArG elements on promoter region. In contrast,
signaling through growth factors promotes smooth muscle proliferation by suppressing SRF and
myocardin activity.
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Fig. 35. Inhibition of serum response factor (SRF) and myocardin expression by caveolin-1
siRNA.
Total RNA was isolated from smooth muscle cells transfected with control pSIREN-DNRDsRed vector and pSIREN-DNR-DsRed vector containing caveolin-1 specific siRNA
transfected cells using RNAqueous prep kits (Ambion, Austin, Tx) and reverse transcribed using
2 µg of total RNA using qScript cDNA prep kits (Quanta, Gaithersburg, MD). The cDNA was
amplified with specific primers for serum responsive factor (SRF) and myocardin. Quantitative
real-time polymerase chain reaction (qRT-PCR) was used to measure RNA levels of SRF and
myocardin. For each cDNA sample, real-time PCR was conducted in a 20-μl-reaction volume
TM

containing Quantitect

SYBRgreen PCR Mastermix (Qiagen, Mississauga, ON). Real-time

PCR reactions were performed in triplicate. Results are expressed as fold differences in gene
expression in caveolin-1 siRNA transfected cells relative to that in control cells transfected with
the vector alone. Values represent the means ±SE of 3 separate experiments. Inset: Culture
muscle cell lysates containing equal amounts of total proteins were separated with SDS-PAGE
and expression of SRF and myocardin was analyzed using selective antibody. Results are
expressed as fold differences in SRF or myocardin protein expression in caveolin-1 siRNA
transfected cells relative to that in vector-transfected cells. Values represent the means ±SE of 3
separate experiments. *Significant inhibition of expression in caveolin-1 siRNA transfected cells
compared to expression in control cells (p<0.05).
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Fig. 36. Inhibition of γ-actin and caldesmon expression by caveolin-1 siRNA.
Total RNA was isolated from smooth muscle cells transfected with control pSIREN-DNRDsRed vector and pSIREN-DNR-DsRed vector containing caveolin-1 specific siRNA
transfected cells using RNAqueous prep kits (Ambion, Austin, Tx) and reverse transcribed using
2 µg of total RNA using qScript cDNA prep kits (Quanta, Gaithersburg, MD). The cDNA was
amplified with specific primers for γ-actin and caldesmon. Quantitative real-time polymerase
chain reaction (qRT-PCR) was used to measure RNA levels of SRF and myocardin. For each
TM

cDNA sample, real-time PCR was conducted in a 20-μl-reaction volume containing Quantitect
SYBRgreen PCR Mastermix (Qiagen, Mississauga, ON). Real-time PCR reactions were
performed in triplicate. Results are expressed as fold differences in gene expression in caveolin-1
siRNA transfected cells relative to that in control cells transfected with the vector alone. Values
represent the means ±S.E of 3 separate experiments. Inset: Culture muscle cell lysates
containing equal amounts of total proteins were separated with SDS-PAGE and expression of γactin and caldesmon was analyzed using selective antibody. Results are expressed as fold
differences in SRF or myocardin protein expression in caveolin-1 siRNA transfected cells
relative to that in control vector-transfected cells. Values represent the means ±S.E of 3 separate
experiments. * Significant inhibition of expression in caveolin-1 siRNA transfected cells
compared to expression in control cells (p<0.05).
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Fig. 37. Augmentation of EGF receptor phosphorylation by caveolin-1 siRNA.
Primary culture of gastric smooth muscle cells were transfected with control pSIREN-DNRDsRed vector and pSIREN-DNR-DsRed vector containing caveolin-1 specific siRNA for 48 h.
Following transfection cells were treated with EGF (1 ng/ml) for 5 min. Cell lysates containing
equal amounts of total proteins were separated on SDS-PAGE and the phosphorylation of EGF
receptor was analysed using phospho-specific (Tyr1068) antibody. Blots shown are representative
of 3 different experiments. The bar graphs show quantification of the EFG receptor
phosphorylation by densitometry. Values represent the means ±S.E of 3 separate experiments. *
Significant increase in EGF receptor phosphorylation compared to basal phosphorylation
(p<0.01). ** Significant increase in EGF receptor phosphorylation in response to EGF in cells
transfected with caveolin-1 siRNA compared to response in control cells transfected with the
vector alone (p<0.05).
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Fig. 38. Augmentation of ERK1/2 activity by caveolin-1 siRNA.
Primary culture of gastric smooth muscle cells were transfected with control pSIREN-DNRDsRed vector and pSIREN-DNR-DsRed vector containing caveolin-1 specific siRNA for 48 h.
Following transfection cells were treated with EGF (1ng/ml) for 5 min and ERK1/2 activity was
measured using [γ-32P]ATP by immunokinase assay. Results are expressed as cpm/mg protein.
Values represent the means ±S.E of 3 separate experiments. ** Significant increase in ERK1/2
activity compared to basal activity (p<0.01). * Significant increase in ERK1/2 activity in
response to EGF in cells transfected with caveolin-1 siRNA compared to response to EGF in
control cells (p<0.05).
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CHAPTER IV: DISCUSSION
IV. DISCUSSION

The fundamental phenomenon of contraction in smooth muscle cells of the
gastrointestinal tract is critical for propelling the intraluminal content from the orad to the caudad
direction. Contraction is initiated by the release of contractile transmitters that mainly constitutes
acetylcholine and tachykinins that are derived from enteric excitatory motor neurons. The
signaling pathways activated by the contractile agonists also play an important role in the
regulation of smooth muscle contractile phenotype by transcriptional and translational regulation
of contractile protein expression. Both excitation-contraction and excitation-transcription
coupling are, in turn, regulated by cell-extrinsic (extracellular matrix) and cell-intrinsic proteins.
Caveolae are integral parts of the smooth muscle membrane and several studies have
demonstrated that caveolae act as signaling platforms or scaffolds that regulate cellular signaling
through direct and indirect interaction with signaling proteins. All three main components of G
protein coupled receptor system (receptor, G proteins and effector enzymes) are localized at the
plasma membrane and their co-localization with caveolae is well suited for efficient transduction
of signaling events. Caveolae contain the protein caveolins, and all three gene products of the
caveolin proteins (caveolin-1, caveolin-2 and caveolin-3) are expressed in smooth muscle
(Taggart 2001). Previous studies in both visceral and airway smooth muscle have shown that the
relative mRNA expression levels were 15:1:1 for caveolin-1, caveolin-2 and cavelolin-3,
respectively (Shakirova, Bonnevier et al. 2006). Caveolin-1 is the predominant isoform in the
smooth muscle and drives the formation of caveolae. However, little is known about the role of
caveolin-1 in the regulation of excitation-contraction and excitation-transcription coupling in
gastrointestinal smooth muscle. In the present study we initially characterized m2 and m3

158

receptor signaling in gastric smooth muscle and then examined the role of caveolin-1 in the
regulation of signaling pathways mediated by muscarinic receptors. Since selective receptorspecific ligands are not available, m2 receptor-selective antagonist, methoctramine and m3
receptor-selective antagonist 4-DAMP were used to analyze the receptor-specific signaling.
Previous studies in intestinal muscle have demonstrated that m3 are coupled to stimulation of
PLC-β (PI hydrolysis) via G q and RhoA-dependent activation of Rho kinase/ZIP kinase via G 13 ,
whereas m2 receptors are coupled to inhibition of adenylyl cyclase via G i (Murthy, Zhou et al.
2003; Uchiyama and Chess-Williams 2004). Similarly, m3-mediated stimulation of PI
hydrolysis, and Rho kinase and ZIP kinase activity, and m2-mediated inhibition of AC activity
was obtained in gastric muscle cells. Hence, these enzyme activities were used as readouts of
G q/13 -coupled m3 receptor activity and G i -coupled m2 receptor activity to examine the role of
caveolae/caveolin-1 on receptor-effectors coupling. Increase in MLC 20 phosphorylation, a
biochemical correlate, and decrease in muscle cell length were used as readouts of muscle
function. Expression of key transcription factors such as SRF and myocardin and contractile
proteins such as γ-actin, and caldesmon, and proliferative signals such as phosphorylation of
EGF receptor and stimulation of ERK1/2 activity were measured as readouts to examine the role
of caveolin-1 in the regulation of contractile phenotype. The role of caveolae/caveolin-1 was
examined using three complimentary approaches: a) methyl β-cyclodextrin (MβCD) to deplete
cholesterol in freshly dispersed muscle cells, b) caveolin-1 siRNA to suppress caveolin-1
expression in cultured muscle cells, and c) caveolin-1 knockout (KO) mice.
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IV. 1. Signaling transduction by muscarinic receptors
Five distinct muscarinic receptors (m1-m5), derived from distinct gene products, have
been characterized in mammalian tissues. Our initial studies characterized the expression of
muscarinic receptors and the receptor-specific signaling pathways activated by CCh in rabbit
gastric smooth muscle cells. Gastric smooth muscle expresses selectively m2 and m3 receptors
and this was confirmed by RT-PCR, western blot and radioligand binding studies. Expression of
m2 receptors is much greater (~70%) than m3 receptors (~30%). Although vascular, visceral and
airway smooth muscle cells express mostly m2 and m3 receptors, the relative expression of m2
and m3 receptors varies depending on the tissue. In general, the expression of m2 receptors is
more abundant than m3 receptors (Eglen, Reddy et al. 1994; Niihashi, Esumi et al. 2000; Wang,
Han et al. 2001; Murthy, Zhou et al. 2003). Although the expression of m2 receptors is abundant
than m3 receptors, contraction is exclusively mediated by m3 receptors in gastric muscle cells
(Kitazawa, Hirama et al. 2008). Similar selective involvement of m3 receptors in contraction was
demonstrated in vascular and other visceral smooth muscle cells. The contribution of m2
receptors to mediate muscle contraction varies depending on the smooth muscle tissue. Using
receptor selective antagonists and transgenic mice, it was demonstrated that more than 90% of
the contraction in response to CCh was mediated via m3 receptors in intestinal and bladder
muscle, whereas only 50% contraction was mediated via m3 receptors in airway muscle and the
remaining contraction was mediated via m2 receptors (Boulanger, Morrison et al. 1994; ChessWilliams, Chapple et al. 2001; Stengel, Yamada et al. 2002).
In the present study, we have demonstrated that CCh-stimulated PI hydrolysis and Rho
Kinase and ZIP kinase activity were blocked by the selective m3 receptor antagonist, 4-DAMP,
whereas CCh-induced inhibition of AC activity was blocked by the selective m2 receptor
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antagonist, methoctramine and pertussis toxin. These results are consistent with the muscarinic
receptor signaling in other visceral and vascular smooth muscle (Singer, Vang et al. 2002;
Gerthoffer 2005; Unno, Matsuyama et al. 2006). Receptor-specific coupling to G proteins and
activation of signaling pathways are not unique to muscarinic m2 and m3 receptors. Previous
studies in smooth muscle have shown that similar receptor-specific coupling to distinct G
proteins and signaling with 5-HT (5-HT 2 and 5-HT 4 ) receptors, adenosine (A 2 and A 1 )
receptors, shingosine-1-phosphate (S1P 1 and S1P 2 ) receptors, neuropeptide (NPY 1 and NPY 2 )
receptors, and endothelin (ET A and ET B ) receptors (Kuemmerle, Murthy et al. 1995; Murthy and
Makhlouf 1995; Murthy and Makhlouf 1998; Hersch, Huang et al. 2004; Misra, Murthy et al.
2004; Zhou and Murthy 2004).
Excitatory neurotransmitters such as acetylcholine and tachykinins mobilize intracellular
Ca2+ via Gα q -dependent stimulation of PLC-β1. Activation of PLC-β1 hydrolyzes
phosphatidylinositol 4,5 bisphosphate (PIP 2 ) to generate two messengers: IP 3 , which releases
Ca2+ from intracellular stores via binding to specific receptors, and diacylglycerol (DAG), which
activates various PKC isoforms. Increase in cytosolic Ca2+ results in activation of
Ca2+/calmodulin-dependent MLC kinase and subsequent phosphorylation of MLC 20 , an essential
step in smooth muscle contraction (Murthy 2006; Deng, Ding et al. 2011). The selective m3
receptor antagonist, 4-DAMP, blocks acetylcholine-induced PI hydrolysis and initial muscle
contraction.
Contractile agonists that activate G q also activate G 13 : both G proteins activate RhoA via
distinct guanine nucleotide exchange factors (GEFs), and their involvement in smooth muscle is
receptor-specific. Muscarinic m3 and CCK-A receptors activate RhoA via Gα 13 only, whereas
S1P 2 and motilin receptors activate RhoA via both Gαq and Gα 13 (Murthy, Zhou et al. 2001; Le
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Page, Bi et al. 2003; Murthy, Zhou et al. 2003; Suzuki, Hajicek et al. 2009; Sabbatini, Bi et al.
2010) . Activated RhoA, in turn stimulates Rho kinase, a serine/threonine protein kinase that
belongs to family of enzymes including myotonic dystrophy protein kinase (DMP kinase),
Cdc42-binding kinase, and citron kinase (Riento and Ridley 2003; Wansink, van Herpen et al.
2003). Rho kinase phosphorylates the regulatory subunit of MLC phosphatase, MYPT1, at Thr696
and inhibits catalytic activity resulting in increase in MLC 20 phosphorylation and sustained
contraction (Fukata, Amano et al. 2001). ZIP kinase, a member of death-associated protein
kinase family, was also shown to phosphorylate MYPT1 at Thr696, albeit with a greater potency,
and also MLC 20 in vitro in a Ca2+-independent mechanism (Borman, MacDonald et al. 2002;
Endo, Surks et al. 2004). However, the physiological significance of ZIP kinase in vivo is
unclear. Stimulation of ZIP kinase activity by CCh and inhibition by the selective Rho kinase
inhibitor, Y27632 provide evidence that the contractile agonist activate ZIP kinase and its
activity is dependent on Rho kinase suggesting that Rho kinase is an upstream kinase. However,
Rho kinase does not phosphorylate ZIP kinase in vitro suggesting that activation of ZIP kinase
by Rho kinase may be indirect via one or more kinases (Graves, Winkfield et al. 2005).
Carbachol-induced stimulation of Rho kinase and ZIP kinase activity and sustained contraction
were also inhibited by 4-DAMP and Y27632, suggesting that sustained contraction was also
exclusively mediated by m3 receptors. The results with Y27632 imply the involvement of Rho
kinase pathway, but the relative roles of Rho kinase vs. ZIP kinase, in direct phosphorylation of
MYPT1 to mediate contraction is unknown and awaits further studies with specific ZIP kinase
inhibitors.
Muscarinic m2 receptors are coupled to inhibition of AC activity and this is consistent
with the expression of AC V and VI isoforms in gastric smooth muscle cells. G i proteins inhibit
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AC V/VI isoforms and this is in contrast with the activation of AC II/IV forms that are not
inhibited by G i proteins (Murthy and Makhlouf 1997; Murthy and Makhlouf 1998; Wansink, van
Herpen et al. 2003). Although m2 receptors are not directly coupled to muscle contraction,
activation of these receptors is shown to augment m3 receptor-mediated contraction. This is
partly due to inhibition of RGS4, an activator of Gα q -GTPase, and activation of G αq -dependent
PLC-β1 activity by m2-mediated stimulation of PI3-kinase activity (Hu, Li et al. 2009). The
augmentation is attributed to inhibition of cAMP formation by m2 receptor activation. The
physiological significance of decrease in cAMP formation was viewed as functional antagonism
of on-going relaxation mediated by cAMP-dependent protein kinase (PKA) and facilitation of
contraction via G q /G 13 -coupled pathways.

In conclusion, m3 receptors are coupled to stimulation of PI hydrolysis, and Rho
kinase and ZIP kinase activity, and muscle contraction, whereas m2 receptors are coupled to
inhibition of AC activity in gastric smooth muscle.

IV. 2. Regulation of m2 and m3 receptor signaling by caveolae and caveolin-1.
Caveolae and their main membrane proteins, caveolins, concentrate receptors, G proteins,
effector enzymes, and associated signaling molecules so as to facilitate coordinated generation and
degradation of second messengers. Caveolins contain a caveolin-scaffolding domain that binds
signaling molecules via a characteristic caveolin-binding domain in these molecules. Caveolae
contain abundant cholesterol and sphingolipids and the cholesterol is necessary for caveolae
structure and function. Depletion of cholesterol with pharmacological treatments alters signaling by
both tyrosine kinase- and G protein-coupled receptors (GPCRs) (Chini and Parenti 2004; Matthews,
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Taggart et al. 2005; Patel, Murray et al. 2008). The effect of caveolae and caveolins on smooth
muscle contraction appears to be receptor- and ligand-specific. In general caveolae and caveolins
appear to facilitate vascular smooth muscle contraction via G protein coupled receptors, and inhibit
proliferation via tyrosine kinase-coupled receptors (Insel, Head et al. 2005; de Laurentiis, Donovan
et al. 2007). The effect of caveolae and caveolins on muscarinic m3 and m2 receptor-mediated
signaling is not clear.
In the present study, the role of caveolae/caveolin-1 in the regulation of m2 and m3 receptor
signaling was analyzed using pharmacological (MβCD), molecular (caveolin-1 siRNA) and genetic
(caveolin-1 knockout) approaches. A novel aspect of these studies is that similarity of results
obtained with all three approaches. MβCD, a water-soluble heptasaccharide, binds cholesterol with
high specificity and has been used extensively as cholesterol depleting pharmacological agent.
Depletion of cholesterol by MβCD results in disruption of caveolae and affects plasma membrane
signaling pathways. The exact mechanism by which cholesterol removal affects signaling pathways
is not clear, however, cholesterol replenishment restores the plasma membrane signaling (Ostrom
and Insel 2006). The efficiency and specificity of MβCD treatment was confirmed in vascular and
airway smooth muscle by the significant decrease in caveolae and lack of effect of MβCD on other
cellular structures (Gosens, Stelmack et al. 2007). The intact depolarization-induced response of
MβCD treated cells to KCl also excluded the non-selective damage of the plasma membrane (Dreja,
Voldstedlund et al. 2002). Although use of MβCD and other cholesterol chelating drugs remains a
mainstay to study the function of caveolae, the effects of MβCD could be non-specific than
molecular approaches. Disruption of caveolae by MβCD can affect signaling by redistribution of
proteins, and thus changing their relative local concentrations or by changing the chemical
environment of the membrane. To more precisely understand the role of caveolin-1, the most
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abundant isoform of caveolin in smooth muscle, we used the caveolin-1 siRNA approach to
suppress caveolin-1 expression and to examine the specific role of caveolin-1 in muscarinic
signaling. Transfection of siRNA was analyzed by immunocytochemistry and suppression of
caveolin-1 expression was analyzed by western blot. We also took the advantage of using caveolin1 KO mice as they became available commercially. Cavelolin-1 KO mice have provided excellent
animal models to examine the physiological significance of caveolae. These mice have been used
in previous studies to examine the role of caveolin-1 in the regulation of vascular and visceral
muscle function (Zhao, Liu et al. 2002; Schwencke, Schmeisser et al. 2005; Insel and Patel 2007;
Sathish, Yang et al. 2011). Despite the importance of caveolin-1 in the formation of caveolae and
signal transduction, caveoin-1 KO mice are viable raising the possibility of compensatory
mechanisms.
Our studies indicate that the effect of caveolae and caveolin-1 on muscarinic receptor
signaling appears to be receptor-and signaling-specific. Caveolae and caveolin-1 facilitate
G q /G 13 -coupled m3 receptor signaling, but not G i -coupled m2 receptor signaling. In contrast,
caveolae and caveolin-1 facilitate m2 receptor, but not m3 receptor internalization.

IV. 2a. Regulation of G q -coupled m3 receptor signaling by caveolin-1.
Carbachol-induced stimulation of PI hydrolysis in the presence of methoctramine was
measured as readout of G q -coupled m3 receptor signaling. Carbachol-induced PI hydrolysis was
significantly inhibited by the disruption of caveolae in freshly dispersed cells and by the
suppression of caveolin-1 in cultured muscle cells. Similar decrease in PI hydrolysis was
obtained in gastric muscle from caveolin-1 KO mice. These results suggest that caveolin-1
positively regulates G q -coupled m3 receptor signaling. This could lead to decrease in IP 3
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formation, IP 3 -induced Ca2+ release, and Ca2+/calmodulin-dependent MLC kinase activity,
MLC 20 phosphorylaiton and muscle contraction in response to CCh. Consistent with this notion,
CCh-induced MLC 20 phosphorylation and contraction was significantly reduced in cells treated
with MβCD. Similar decrease in contraction was also observed in muscle cells obtained from
caveolin-1 KO mice. These results are similar to recent data from studies with vascular and
airway smooth muscle cells, where disruption of caveolae with MβCD leads to reduced
contraction in response to contractile agonists such as endothelin-1, serotonin, α1 adrenergic
receptor agonist, and acetylcholine (Cristofaro, Peters et al. 2007; Gosens, Stelmack et al. 2007).
However, studies by Shakirova et al. showed that the effect of caveolin-1 was agonist- and
tissue-specific. Response of ileum longitudinal muscle to endothelin-1, but not to carbachol or
serotonin was reduced in caveolin-1 KO mice, whereas the response of femoral arterial muscle to
α1-adrenergic agonist was increased (Okamoto, Schlegel et al. 1998; Shakirova, Bonnevier et al.
2006).
Collectively, our results provide conclusive evidence that caveolin-1 facilitates G q coupled m3 receptor signaling and muscle contraction in response to contractile agonists such as
CCh. Although, it is not clear whether caveolin-1 targets m3 receptor, or Gα q or PLC-β1 isoform
to facilitate the effect. Analysis of m3 receptor expression in sucrose density gradient fractions
showed that m3 receptors are not associated with caveolin-1. This suggests that distal
components of m3 receptor may be spatially associated with caveolin-1. Previous studies have
shown that Gα q protein contain caveolin binding motif and directly interacts with caveolin-1
proteins (Sengupta, Philip et al. 2008; Allen, Yu et al. 2009; Guo, Golebiewska et al. 2011).
Thus, it is possible that the interaction of Gα q with caveolin-1 augments PI hydrolysis. In support
to this notion, PI hydrolysis in response to substance P, which interacts with G q -coupled
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neurokinin receptor, was also inhibited by MβCD. It is also important to note that in smooth
muscle caveolae contains proteins that are not only important for GPCR signaling, but also ion
channel and pumps involved in Ca2+ homeostasis. Recent studies demonstrated that KCl-induced
contraction was similar in wild type and caveolin-1 KO mice suggesting that caveolin-1 KO does
not affect the membrane-depolarization process (Shakirova, Bonnevier et al. 2006).
In conclusion, the results described here indicate a significant role for caveolin-1 in
regulation of G q -coupled PLC-β1 activity and muscle function. Further work examining the
localization of Gα q proteins and PLC-β1 isoforms in caveolae and their interaction with
caveolin-1 may reveal more precise understanding of the mechanism regulating PI hydrolysis
and contraction.

IV. 2b. Regulation of G 13 -coupled m3 receptor signaling by caveolin-1.
Stimulation of Rho kinase and ZIP kinase activity in response to CCh was measured as
readouts of G 13 -coupled m3 receptor signaling. Previous studies in intestinal smooth muscle
have shown that acetylcholine-stimulated Rho kinase activity is downstream of G 13 /RhoA
signaling (Buyukafsar and Levent 2003; Murthy, Zhou et al. 2003; Rattan, Puri et al. 2003). Our
studies provide evidence that contractile agonists such as carbachol also stimulate ZIP kinase
activity and its activation is downstream of Rho kinase.
Carbachol-stimulated Rho kinase and ZIP kinase activity was significantly inhibited by
the disruption of caveolae in freshly dispersed cells and by the suppression of caveolin-1 in
cultured muscle cells. Similar decrease in Rho kinase and ZIP kinase activity was obtained in
gastric muscle from caveolin-1 KO mice. One of the downstream targets of Rho kinase and ZIP
kinase is MYPT1. Both kinases phosphorylate MYPT1 at Thr696 leading to inhibition of MLC
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phosphatase, increase in MLC 20 phosphorylation and muscle contraction. Thus, inhibition of
Rho kinase and ZIP kinase activity could lead to decrease in MYPT1 phosphorylation and
muscle contraction in response to CCh. Consistent with this notion, CCh-induced MYPT1
phosphorylation at Thr696 and contraction were significantly reduced in cells treated with MβCD.
Similar decrease in contraction was also observed in muscle cells obtained from caveolin-1 KO
mice. Thus, our results suggest that caveolin-1 is necessary for optimal G 13 /RhoA-dependent
signaling in gastric smooth muscle. It is not clear, however, whether caveolin-1 targets RhoA or
Rho kinase to facilitate the effect. Lack of m3 receptors in the caveolar fractions suggests that
distal components of m3 receptor such as RhoA may be spatially associated with caveolin-1.
RhoA is small GTP binding proteins and exists in active GTP-bound and inactive GDP-bound
states. The inactive cytosolic pool is associated with Rho-dissociation inhibitor and the active
plasma membrane pool is associated with caveolae. Previous studies by confocal microscopy in
mesenteric arteries showed activation-induced colocalization of RhoA with caveolin-1, and
MβCD treatment significantly decreased the colocalization and contraction (Dubroca, Loyer et
al. 2007). Similar inhibition of agonist-induced RhoA translocation and contraction was obtained
by blocking caveolin-1 scaffolding domain with a synthetic peptide in ferret aorta (Taggart,
Leavis et al. 2000). In addition, sites of monoglycosylation and ADP ribosylation of RhoA,
which inhibits RhoA translocation and muscle contraction, are located within the caveolin-1
binding motif of RhoA (Dubroca, Loyer et al. 2007). Although, caveolin-1 is generally
considered as negative regulator of signaling molecules, our studies using several complimentary
approaches suggested that caveolin-1 positively regulates G 13 /RhoA-mediated signaling by m3
receptors. The mechanisms governing the facilitation of RhoA activation by caveolin-1 are
unknown. Activation of RhoA is dependent on the Rho guanine exchange factors (RhoGEFs).
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There are several members in the RhoGEF family of proteins that include p115RhoGEF, PDZRhoGEF, and LARG (leukemia associated RhoGEF). All the RhoGEF proteins harbor a
common signature motif including RGS (regulator of G protein signaling), Db1 homology (DH),
and pleckstrin homology (PH) domains that are responsible for the exchange of GDP for GTP
after binding to inactivated G α subunits. The role of RhoGEFs can be described that of a
molecular link between heterotrimeric G proteins and monomeric G proteins. Further
experiments are needed to identify the localization of RhoA and specific Rho GEFs involved in
the activation of Rho kinase and ZIP kinase and muscle contraction in gastric muscle.
It is important to note that downstream of m3 receptor activation, PKC, in addition to
Rho kinase and ZIP kinase, play an important role in the inhibition of MLC phosphatase and
regulation of muscle contraction. In the active GTP-bound conformation, RhoA physically
interact with downstream effectors such as Rho Kinase and phospholipase D (PLD) and
stimulates their activity. Phosphatidic acid formed as a hydrolytic product of phosphatidylcholine
by PLD activity, leads to sustained activation of several PKC isozymes (Murthy, Grider et al.
2000; Preininger, Henage et al. 2006). PKC, in turn, phosphorylates an endogenous MLC
phosphatase inhibitor known as CPI-17 and phosphorylation greatly accelerates the ability of
CPI-17 to inhibit MLC phosphatase and augment MLC 20 phosphorylation (Li, Eto et al. 1998;
Woodsome, Eto et al. 2001; Tazzeo, Bates et al. 2012). We did not examine the effect of
caveolin-1 on this PKC/CPI-17 pathway in gastric muscle. Previous studies in vascular muscle
have identified caveolae as regulators of PKC signaling. Studies by Je et al (Je, Gallant et al.
2004) showed that chemical loading of caveolin-1 peptide that inhibits caveolin-1 function
caused significant inhibition of contraction in response to phorbol esters. Understanding agonistinduced, isoform(s)-specific translocation of PKC could lead to assess the singular contribution
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of Rho kinase and ZIP kinase pathway to the decrease in muscle contraction in cells treated with
MβCD or caveolin-1 siRNA or in cells isolated from caveolin-1 KO mice.
In conclusion, the results described here indicate a significant role for caveolin-1 in
regulation of G 13 -coupled RhoA-dependent pathway and muscle function. Further work
examining the localization of RhoA and PKC isoforms in caveolae and their interaction with
caveolin-1 may reveal more precise understanding of the mechanism regulating Rho kinase/ZIP
kinase and sustained muscle contraction.

IV. 2c. Regulation of G i -coupled muscarinic m2 receptor signaling by caveolin-1.
Since m2 receptors are coupled to PTx-sensitive G i proteins, inhibition of forskolinstimulated cAMP formation, reflecting inhibition of AC activity was measured as readout of G i coupled m2 receptor signaling. The effect of caveolae and caveolin-1 was analyzed using all
three approaches described above. In contrast to the effect of caveolae and caveolin-1 on the
G q /G 13 -coupled m3 receptor signaling, disruption of caveolae with MβCD in freshly dispersed
muscle cells or suppression of caveolin-1 in cultured muscle cells with caveolin-1 siRNA did not
affect the inhibition of AC activity in response to CCh. Similar results were obtained using
caveolin-1 KO mice. CCh-induced inhibition of AC activity was similar in gastric muscle cells
from WT mice and caveolin-1 KO mice. The similarity of results with three distinct approaches
strongly suggests that caveolin-1 has no effect on G i -coupled m2 receptor signaling in gastric
muscle cells.
Taken together, our studies provide evidence that caveolin-1 differentially regulate m3
and m2 receptor signaling in gastric muscle: m3-coupled Gα q and Gα 13 signaling is facilitated,
whereas m2-coupled Gα i signaling is not affected.
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Our studies also demonstrated that the increase in AC activity in response to direct
activator forskolin was similar in control cells and in cells treated with MβCD or caveolin-1
siRNA. Stimulation of AC activity by forskolin was also similar in gastric muscle from WT mice
and caveolin-1 KO mice. These results suggest that caveolin-1 had no effect on AC activity. Our
results differ with previous studies showing suppression of caveolin-1 in C6 glioma cells or lack
of caveolin-1 in the brain of caveolin-1 KO mice significantly augmented forskolin-stimulated
AC activity (Allen, Yu et al. 2009; Head, Hu et al. 2011). These studies suggest that the effect of
caveolin-1 on AC activity varies within different tissues and/or with the expression of specific
AC isoforms. There are nine different isoforms of AC’s and their localization in caveolae seems
to be isoforms-specific. AC3, AC5, AC6 and AC8 are expressed in lipid rafts while the other
isoforms of AC are not (Ostrom, Liu et al. 2002). Localization of the AC isoforms in membrane
microdomains play an important role in the coupling of G protein coupled receptors to discrete
AC isoforms and differential regulation of AC isoforms by signaling molecules such as Ca2+ and
PKC. Further experiments are sought to characterize the localization of AC isoforms in the
caveolae to define the regulation of their activity by signaling molecules. In addition, given that
cAMP signaling is compartmentalized by the expression of phosphodiesterases, we speculate
that such intermolecular association with other signaling partners in caveolar microdomains is
also relevant to understand the role of caveolin-1 in cAMP signaling.
In conclusion, the results described here indicate that m2 receptor signaling via G i is
not regulated by caveolae and caveolin-1 and this is in contrast to the positive regulation of m3
receptor signaling via G q/13 . Further work examining the localization of AC isoforms and cAMPspecific phosphodiesterases, and their regulation by signaling molecules may reveal more precise
understanding of the mechanisms involved in cAMP signaling in gastric smooth muscle.
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IV. 3. Regulation of m2 and m3 receptor internalization by caveolae and caveolin-1.
Compelling evidences showing selective regulation of m3 receptor signaling by caveolin1 necessitated the importance to look into the probability of occurrence of muscarinic receptors
in caveolar microdomains. Western blot analysis of m2 and m3 receptors in different fraction of
sucrose density centrifugation showed that in basal state both m2 and m3 receptors are absent in
caveolar fraction. However, upon treatment with CCh, there was translocation of m2 but not m3
receptors to caveolar fractions raising the possibility that caveolae could facilitate m2, but not
m3 receptor internalization.
Multiple “turn off” signals operate in the cell to fine-tune the intensity of G protein
coupled receptor signaling. The most important mechanism involved regulating the density of
surface receptors through the process of receptor desensitization and subsequent internalization.
Receptor desensitization can be broadly classified into two major categories: homologous
desensitization that strictly target the agonist-bound receptors leaving the unbound non-activated
receptor population to function, and heterologous desensitization that target ligand-free
receptors. Homologous desensitization of agonist-occupied receptors is initiated by GRK (G
protein coupled receptor kinase)-mediated phosphorylation of the receptor and binding of the
scaffolding protein β-arrestin to the phosphorylated receptor, which uncouples the receptor from
the G protein as a prelude to receptor internalization (Delom and Fessart 2011).
The molecular events that drive the receptor internalization process can be either clathrindependent or clathrin-independent, caveolae-dependent. Internalization via the clathrindependent pathway triggers activation of signaling pathways (e.g., ERK1/2 and Src kinase) from
early endosomes, whereas internalization via caveolae results in accelerated receptor
degradation. Although the importance of clathrin-dependnet internalization in receptor
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trafficking and activation of signaling pathways for several GPCRs is well established, the
contribution of the caveolar-dependent pathway has been little explored. In clathrin-dependent
model, binding of β-arrestins provides a scaffold for associating the receptor to clathrin and
facilitates the formation of clathrin-coated pits. As the clathrin pits gets matured, they are
invaginated and pinch off from the cell surface by the GTPase activity of dynamin and
progressively released into the cytoplasm as free clathrin coated vesicles and the clathrin coat is
removed (Bunemann, Lee et al. 1999). In the clathrin-independent, caveolar-dependent model,
internalization of specific receptors through caveolae is strictly dependent on tyrosine kinase
signaling. Ligand binding triggers receptor clustering in caveolar microdomains and activation of
phosphorylation events. The essential step in the internalization process via caveolae involves
activation of Src kinase following receptor clustering. Activation of Src causes phosphorylation
of caveolar coat proteins such as caveolin-1 at Tyr14 (Sverdlov, Shajahan et al. 2007). The
primary function of Src mediated phosphorylation of caveolar proteins is to regulate and stabilize
the assembly of multi-protein complexes that finally leads to caveolae fission and internalization.
Ectopic expression of phosphorylation-deficient caveolin-1 (Y14F) inhibits agonist-induced
internalization of GPCRs via caveolae-dependent pathways (Shajahan, Timblin et al. 2003).

IV. 3a. Regulation of m2 receptor internalization by caveolae and caveolin-1.
Internalization was measured as decrease in radioligand ([3H]Scopolamine) binding to
surface receptors after treatment of cells with CCh for 20 min. Treatment of cells with CCh for
20 min significantly inhibited the binding of [3H]Scopolamine, measured in the presence of 4DAMP, suggesting internalization of m2 receptors. Previous studies with radioligand binding
studies showed that 20-min treatment is sufficient to cause maximum internalization of various
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GPCRs. The role of caveolin-1 in the regulation of m2 and m3 receptor internalization was
examined using MβCD in freshly dispersed muscle cells and in cultured muscle cells transfected
with caveolin-1 siRNA Limited yield of muscle cells from mice precluded the use of caveolin-1
KO mice for binding studies. Disruption of caveolae or suppression of caveolin-1 had no effect
on the maximal binding of m2 receptors, but significantly attenuated m2 receptor internalization.
Internalization of m2 receptors was also attenuated by the blockade of Src kinase. These results
suggest that m2 receptor internalization was facilitated by caveolae or caveolin-1 and consistent
with the translocation of m2 receptors to caveolar fractions. This is in contrast to the lack of
effect of caveolin-1 on the rapid responses to m2 receptor activation such as inhibition of AC
activity. In our experiments, role of caveolin-1 in m2 receptor recycling or endocytosis remains
to be clarified. Future studies will also be necessary to identify signaling molecules involved in
the activation of Src kinase by m2 receptors and regulation of m2 receptor internalization via the
caveolar pathways. Previous studies demonstrated that activation of Src kinase via G βγ is critical
for internalization via caveolar pathways (Murthy, Mahavadi et al. 2008). These studies linked
G βγ signaling to the regulation of caveolae-mediated internalization and demonstrated that Src
kinase is the downstream effector of the G βγ heterodimer. Stimulation of G i -coupled m2
receptors is shown to activate Src kinase in gastrointestinal muscle (Murthy 2008), however,
further studies are sought to understand the role of G βγ in the activation of Src kinase and m2
receptor internalization via caveolae-dependent pathways in gastric muscle.
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IV. 3b. Regulation of m3 receptor internalization by caveolae and caveolin-1.
Treatment of cells with CCh for 20 min significantly inhibited the binding of
[3H]Scopolamine, measured in the presence of methoctramine, suggesting internalization of m3
receptors. The extent (~ 70%) of internalization of m3 receptors is similar to the m2 receptor
internalization. Disruption of caveolae or suppression of caveolin-1 had no effect on the maximal
binding of [3H]Scopolamine to m3 receptors and did not affect m3 receptor internalization.
These results suggest that m3 receptor internalization is caveolae-independent and probably
involves clathrin-dependent pathways. This is contrast to the positive effect of caveolin-1 on the
rapid responses of m3 receptor signaling such as stimulation of PI hydrolysis, Rho kinase and
ZIP kinase activity. These results also suggest that caveolae-dependent internalization is
receptor-specific. Similar, caveolae-dependent pathway for internalization of vasoactive

.

intestinal peptide receptor, VPAC 2 was obtained in gastric muscle (Muthy, unpublished)

Caveolin-binding motifs are present in many G protein coupled receptors (GPCRs) such
as β-adrenergic receptor, endothelin receptors, muscarinic receptors, opioid receptors, and mGlu
receptor 1α (Chini and Parenti 2004; BM 2012). Desensitization in response to angiotensin II in
rat aorta was inhibited by MβCD suggesting that AT 1 receptor internalization occurs via
caveolae-dependent pathways. Caveolin-1 was coimmunoprecipitated with AT 1 receptor after
agonist stimulation, and this interaction was inhibited by MβCD (Linder, Thakali et al. 2007).
Consensus caveolin binding motifs are also present in GRKs (G-protein receptor kinases) and
interaction of GRKs with caveolin play an important role in agonist-induced internalization of
GPCRs (Carman, Lisanti et al. 1999). In addition to GPCR internalization, tyrosine kinasecoupled receptors are internalized via caveolae-dependent pathway (Mukherjee, Tessema et al.
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2006). Caveolin-1 is a target of insulin-like growth factor I (IGF-I) receptor and plays a role in
IGF-I receptor internalization and signaling. IGF stimulates caveolin-1 tyrosine phosphorylation
and the IGF-I receptors co-localize with the caveolin-1 in the plasma membrane (Salani,
Passalacqua et al. 2010).
In conclusion, our studies provide evidence that caveolin-1 positively regulates m2,
but not m3 receptor internalization in gastric muscle. This is in contrast to the regulation by
caveolin-1 of m2 and m3 receptor mediated rapid signaling pathways.

VI. 4. Regulation of Excitation-transcription coupling by caveolin-1
Unlike other cell types, such as cardiac and skeleton muscle cells smooth muscle (SM)
cells do not undergo terminal differentiation, rather they switch between proliferative and
differentiated phenotypes in response to various intrinsic and extrinsic signals. SM cells derive
their characteristic contractile and physiological phenotype through the transcriptional activation
of a distinct subset of SM-specific genes encoding for proteins such as SM-myosin heavy chain,
SM-α actin, γ-actin, SM-myosin light chain kinase, calponin, and caldesmon (Wang and Olson
2004).
Serum response factor (SRF) a member of the MADS (MCM1, Agamous, Deficiens,
SRF) family of transcription factors plays an important role in the regulation of SM gene
expression and differentiation (Shore and Sharrocks 1995). SRF recognizes a consensus
sequence of CC(A/T) 6 GG, also known as the CArG box or serum response element on the target
genes to drive their transcription (Kim, Ip et al. 1997; Manabe and Owens 2001). SRF associate
with other transcription factors aptly termed as co-factors to control and regulate the expression
of SRF target genes. Myocardin constitute one of the most intimate coactivators of SRF that was
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originally identified in a bioinformatics screen of cardiac gene expression profiling, and its
expression is specific for cardiac myocytes and SM cells (Wang, Chang et al. 2001). Myocardin
binds and activate promoters containing multiple CArG elements along with stimulated SRF.
The myocardin family of proteins contains two additional members and shares homology with
myocardin-related transcription factor A (MRTF-A) and factor B (MRTF-B) (Wang, Li et al.
2002). The critical role of myocardin and its family in SMC differentiation comes from the
finding that showed that the differentiation process is severely compromised when dominant
mutant form of myocardin and MRTFs or small interfering RNA targeted to myocardin was used
to suppress its activity (Yoshida, Sinha et al. 2003).
SRF/myocardin-mediated transcription of SM marker genes is regulated by actin
dynamics and a decrease in G actin pool is critical for SRF-dependent activation of SM-specific
genes (Copeland and Treisman 2002). Recently, Ca2+ and Rho family of small GTPases
including RhoA has been shown to facilitate F-actin to G-actin ratio through multiple pathways
that finally stimulate SRF activity (Wamhoff, Bowles et al. 2004). Overexpression of
constitutively active RhoA stimulates transcription of SRF/myocardin-mediated genes such as
SM-α actin, SM-MHC and the stimulation is dependent on Rho kinase activity. In addition,
increase in cytosolic Ca2+ upregulates the expression of myocardin (Mack, Somlyo et al. 2001).
These results suggest that the factors that regulate Ca2+ and RhoA-dependent pathways could
modulate SM marker genes (excitation-transcription) long-term, in addition to modulating
muscle contraction (excitation-contraction) short-term as shown above. Positive regulation of
Ca2+ and RhoA signaling by caveolae and caveolin-1 prompted us to examine the role of
caveolin-1 in the regulation of smooth muscle contractile phenotype. The present study
significantly extends understanding the role of caveolin-1 in the regulation of smooth muscle
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marker genes because our results demonstrate that caveolin-1 suppresses the proliferative signals
and facilitates differentiated contractile phenotype in gastric smooth muscle. Our data reveal that
caveolin-1 represses EGF receptor and ERK1/2 activity and promotes the expression of
contractile proteins and their transcription factors. Suppression of caveolin-1 attenuated
expression of SRF and myocardin and SM contractile proteins such as γ-actin and caldesmon,
and augmented basal and agonist-induced EGF receptor phosphorylation and ERK1/2 activity.
Mitogen-activated protein kinases such as ERK1/2 are recognized as important signaling
molecules in cell proliferation.
Our results are in line with previous studies indicating that vascular muscle cells,
fibroblasts and epithelial cells isolated from caveolin-1 KO mice exhibit hyperproliferative
phenotype (Cohen, Park et al. 2003). Studies in airway and vascular muscle demonstrated that
expression of caveolin-1 was more than two fold higher in quiescent contractile muscle cells
compared to proliferating muscle cells in culture (Gosens, Stelmack et al. 2011). Overexpression
of caveloin-1 causes antiproliferative effects. Consistent with the antiproliferative role of
caveolins, expression of receptors for growth factors such as EGF and PDGF, and constituent of
growth factor signaling such as Src, Shc, Grb 2 and Ras are localized in caveolae (Gosens,
Stelmack et al. 2006). Interaction of these signaling proteins with caveolins suppresses their
activity. Transactivation of growth factor signals by GPCRs is also associated with the decrease
in the binding of growth factor receptors with caveolin-1 (Olivares-Reyes, Shah et al. 2005),
however, the molecular mechanisms that causes disassociation of caveolin-1 from growth factor
signal are not clear. In addition, it was demonstrated that non-phosphorylated, but not
phosphorylated (activated) EGF receptor is associated with caveolin-1 (Matveev and Smart
2002). Caveolin-1 KO mice do not develop tumors spontaneously, but are more susceptible to
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tumor formation in response to carcinogens (Torres, Tapia et al. 2006). Thus, there is clear
association between caveolae and growth factor signal. Our current findings in gastric muscle are
highly reminiscent of these observations, and reveal the importance of caveolin-1 in regulating
proliferative and contractile phenotype in gastrointestinal smooth muscle. It is interesting to note
that the smooth muscle differentiation is not affected in caveolin-1 KO mice, suggesting
functional compensation for the lack of caveolin-1.
Although, our studies suggest a link between decrease in Ca2+ and RhoA signaling in the
absence of caveolin-1 to decrease in contractile protein expression, they do not exclude the
existence of additional, transcriptional and post-translational mechanisms downstream of
caveolin-1 that control contractile proteins expression. Preliminary studies from our laboratory,
using microarray analysis, compared of microRNA levels from gastric muscle expressing or not
expressing caveolin-1. One of the striking changes detected in response to absence of caveolin-1
expression was upregulation of microRNA133a. MicroRNAs play an important role in the
regulation of gene expression by pairing to the mRNA targets. Searching for conserved targets of
microRNA-133a by RNA hybrid analysis, we identified the transcription factor SRF, which
regulates expression of contractile proteins. SRF expression is negatively regulated by
microRNA-133a. In vascular smooth muscle, overexpression of microRNA-133a reduced SRF
expression, whereas the effects were opposite when microRNA-133a was inhibited by antimicroRNA-133a. Future studies are important to examine the mechanisms involved in the
regulation of contractile protein expression by caveolin-1 in gastric smooth muscle involving
mcroRNA-133a. It is also important to examine the expression profile of caveolins in
gastrointestinal disorders with smooth muscle hyperproliferation. If caveolin-1 expression is
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decreased, this could contribute to the smooth muscle proliferation and stricture formation in
inflammatory diseases.
In conclusion, our results provide evidence that caveolin-1 negatively regulates
proliferative phenotype and positively regulates contractile phenotype in gastric muscle. Further
studies examining the molecular mechanisms involved in the regulation of contractile protein
expression by caveolin-1 may reveal more precise understanding of the mechanism regulating
SM contractile phenotype.

In summary, our studies demonstrated that CCh, acting via m3 receptors caused
stimulation of PI hydrolysis and RhoA-dependent signaling (Rho kinase and ZIP kinase) and
induced muscle contraction, and acting via m2 receptors caused inhibition of AC activity.
Stimulation of PI hydrolysis, RhoA-dependent signaling and muscle contraction were attenuated
in dispersed cells by the disruption of caveolae with MβCD, or by the suppression of caveolin-1
in cultured muscle cells transfected with caveolin-1 siRNA. Similar inhibition of PI hydrolysis
and RhoA-dependent signaling was obtained in gastric muscle from caveolin-1 KO mice
compared to control mice. Inhibition of cAMP formation via m2 receptors, in contrast, was not
affected in dispersed cells treated with MβCD or in cultured muscle cells transfected with
caveolin-1 siRNA. Similarly, inhibition of AC activity was not affected in gastric muscle from
caveolin-1 KO mice. In the basal state both m2 and m3 receptors are present in non-caveolar
fractions and upon treatment with CCh, m2, but not m3 receptors are translocated to caveolar
fractions. Pretreatment of muscle cells with CCh caused internalization of both m2 and m3
receptors: internalization of m2, but not m3 receptors was blocked in dispersed cells treated with
MβCD or in cultured muscle cells transfected with caveolin-1 siRNA. The possible physiological
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significance of this regulation of m2 receptor internalization is not clear. However, there exists
the potential for regulation of m3 receptor signaling by m2 receptors; this should be investigated
more rigorously. Thus, caveolin-1 selectively regulates m3/G q -mediated PI hydrolysis, m3/G 13 mediated RhoA signaling and contraction, and m2 receptor internalization. Since, there was no
change in the binding of [3H]Scopolamine to m2 and m3 receptors by caveolae and caveolin-1,
we propose that caveolae and caveolin-1 promote m3 receptor signaling via enhanced receptoreffector coupling rather than enhanced receptor affinity. Furthermore, expression of contractile
proteins, γ-actin and caldesmon and the transcription factors SRF and myocardin that mediate the
expression of contractile proteins are down regulated in cells transfected with caveolin-1 siRNA
suggesting that caveolin-1 expression is also important for the maintenance of smooth muscle
contractile phenotype. The study also suggests that caveolin-1 could be a marker of the mature,
contractile smooth muscle cell phenotype, and is a determinant of functional characteristics of
gastric muscle. In parallel, caveolin-1 suppresses the activity of proliferative signals.
In conclusion our studies using pharmacological, molecular and genetic approaches,
provide conclusive evidence that caveolae and caveolin-1 play an important role in orchestrating
G protein coupled receptor signaling to have dual pro-excitation-contraction and excitationtranscription coupling, and anti-proliferative role in gastric smooth muscle.
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